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Medicine is magical
Magical is art
We’ve got the boy in the bubble
And the baby with the baboon heart
~ Paul Simon
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1.1 “Living causes death”
The Dutch proverbial wisdom “Van leven ga je dood” signifies that indeed, almost anything can 
be harmful to the living cell. Environmental factors and pathogens, as well as non-infectious 
diseases and aging, can cause cells and tissues to become damaged. Even though cellular 
repair mechanisms act to mend the damage, severe injury will induce cell death. It is estimated 
that in the human body 1010 cells die every day; inflammatory cells will remove these dead or 
dying cells from the tissue. However, severe damage may be irreversible and lead to reduced 
tissue function, or even organ dysfunction. Insight into the mechanisms of various forms of cell 
damage enables us to find new therapies to reduce or prevent tissue injury.
There appears to be one common trait underlying all things harmful to the human cell. Having 
evolved into aerobic life-forms, humans and most [1] other metazoans are now dependent on 
the fickle substance which killed many early organisms: oxygen. In fact, it has been postulated 
that failure of oxygen and energy metabolism underlies all complex diseases in humans. One of 
these conditions is the main topic of this thesis: ischemia-reperfusion injury (IRI).
1.2 Ischemia-reperfusion injury
IRI is the damage that occurs when an organ or tissue is temporarily occluded from the 
bloodstream. This may take place spontaneously, such as in stroke or myocardial infarction, or 
artificially, such as in transplantation and various other types of surgery. In the ischemic phase 
of this condition, cells become deprived of oxygen. As a result, their metabolism switches from 
aerobic to anaerobic glycolysis, which leads to the formation of pyruvic acid and hydrogen (H+). 
Normally, these hydrogen ions are scavenged by nicotinamide adenine dinucleotide (NAD+) 
and converted to H
2
O in the mitochondrion. However, under anaerobic circumstances there 
is insufficient oxygen to complete the mitochondrial respiration chain, and a build-up of both 
NADH and H+ occurs. As a consequence, pyruvic acid acts as an H+-acceptor, and is thereby 
converted to lactic acid. The combined build-up of H+ and lactic acid lowers the intracellular 
pH. As adenosine triphosphate (ATP) becomes depleted, active transporters which control 
the intracellular ion homeostasis become deregulated. The sodium-potassium exchanger is 
inhibited, while the activity of the pH-dependent sodium-hydrogen exchanger is increased due 
to the cellular acidosis. As a result, sodium enters the cell, leading to cell swelling and tissue 
oedema. In response to the elevated intracellular sodium level, the activity of the calcium-
sodium exchanger is reversed and calcium is pumped into the cell. This, in combination 
with inhibited active transport of calcium into the endoplasmatic reticulum (especially the 
sarcoplasmatic reticulum in heart and muscle cells), leads to a calcium overload. 
Thus, ongoing ischemia renders the cell swollen, acidic, ATP-depleted, overloaded with Na+ and 
Ca2+, and with its mitochondrial respiration chain strongly inhibited. This will lead to cell death 
in a matter of minutes to hours, depending on the cell type [2–4].
Therefore, restoration of blood flow after ischemia is essential for cell survival. Unfortunately, 
reperfusion of ischemic tissue is accompanied with many paradoxical effects which are 
detrimental to the cell, rather than beneficial. This especially holds true for 1) the restoration 
of oxygen, 2) the normalisation of pH, 3) the normalisation of calcium and 4) the inflammatory 
response. 
Firstly, replenishing the cells with oxygen allows them to resume aerobic metabolism and 
restore ATP-dependent processes. However, oxygen is a highly reactive molecule which can 
react with by-products and enzymes upregulated during anaerobic metabolism (e.g. xanthine 
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oxidase/xanthine dehydrogenase, phospholipase A2, NADPH oxidase and electrons leaking 
from the mitochondrial respiratory chain). Reactive oxygen species (ROS), such as superoxide 
and the hydroxyl radical, are formed, which cause oxidative stress, lipid peroxidation and 
damage to the membranes of cells and cell organelles [5,2,6].  
Next to oxygen, restoration of the pH is essential to normalize many pH-dependent processes 
in the cell. However, upon reperfusion, excess H+ in the intracellular space is first washed 
out, creating an outward gradient for H+ over the cell membrane. This will cause the sodium-
hydrogen exchanger to increase transport of sodium into the cell, thereby aggravating the 
sodium overload. Secondly, cellular acidosis inhibits a number of processes which induce cell 
death, such as the opening of the pH-dependent mitochondrial permeability transition pore 
(MPTP), which plays a pivotal role in IRI. Sudden normalization of the pH relieves this inhibition 
and causes the cell to go into apoptosis rather than to recover [7,8,4]. 
Restoration of the calcium balance has paradoxical effects especially in cardiomyocytes, where 
the calcium homeostasis controls cell contractibility. Upon reperfusion, the cardiac muscle cell 
becomes re-energized and will start to contract. However, at the onset of reperfusion, the 
cytosolic calcium level is still high, and will remain high until the sodium balance is restored and 
the sodium-calcium exchanger restart its normal function. Under these conditions, myofibrillar 
activation leads to uncontrolled hypercontraction of the cell, which can cause irreversible 
damage to the cytoskeleton. The detrimental effects of high cytosolic calcium in combination 
with sudden re-energization may also occur in other cell-types, where ATP-dependent 
processes are continued under a deregulated ion balance. Furthermore, calcium has been 
shown to aggravate oxidative stress and may therefore cause cell death upon reperfusion in 
cells which had been minimally compromised during the ischemic period [9,6,2].
The final paradoxical event after reperfusion is the inflammatory response (Figure 1). IRI causes 
endothelial activation and triggers the complement cascade, leading to a proinflammatory and 
procoagulant state of the blood vessel lining. Adhering leukocytes, as well as other cell-types 
such as kidney cells, release cytokines which attract neutrophils, macrophages, lymphocytes 
and/or dendritic cells to the site. While inflammatory cells are important in the long-term 
process of tissue repair, their acute responses after IRI appear to cause additional tissue 
damage. Inflammatory cells are a primary source of ROS, and release over twenty different 
proteolytic enzymes. Moreover, extensive adhesion and migration of inflammatory cells to 
the endothelium may cause capillary obstruction, although the severity of this effect may be 
organ-specific [10](see also Figure 1).
Furthermore, IRI causes vasoconstriction in small arterioles, due to an increased release of e.g. 
endothelin-1 and adenosine, and decreased release of vasodilatory agents such as bradykinin 
and nitric oxide. This combination of vasoconstriction, complement activation and endothelial 
swelling may cause microvascular dysfunction and the ‘no-reflow’ phenomenon, i.e. parts of 
the microcirculation become permanently occluded and suffer additional ischemic damage. 
Consequently, depletion or inhibition of inflammatory cells has been shown to reduce IRI in 
animal models and humans [4,11]. 
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Figure 1|Detrimental effects of the inflammatory response. Under normal haemostasis, blood 
flow in large and small capillaries is unobstructed (A), however, ischemia-reperfusion injury (IRI) 
triggers adhesion and migration of leukocytes to and across the vessel wall (B). Reactive oxygen 
species (ROS) released by these cells cause damage to the vascular cells and parenchyma. In 
small capillaries, or in vessels suffering from vasoconstriction and/ or endothelial swelling due 
to the IRI, adhering leukocytes may cause capillary obstruction, which leads to no-reflow in 
parts of the injured organ (C).
1.3 The kidney and renal IRI
The mouse kidney is built up out of ~11.000 nephrons, while the human kidney contains 
300.000 to one million of these filtration units. Blood is filtered by the glomerulus, after which 
the pro-urine passes through several specialized sections of the nephron, such as the proximal 
tubule, the loop of Henle and the distal tubule, where water and solutes are reabsorbed and 
waste products are excreted. The final urine is gathered in the collecting duct.
The kidneys filter on average 125 ml of blood per minute (or 180 litres per day), over 90% of 
which has to be reabsorbed to prevent excessive water and salt loss. Many unwanted and 
toxic molecules are excreted into the urine via active transport in the cells of the proximal 
General introduction and outline of this thesis|15
tubule, which contributes to the kidneys high energy demand. Furthermore, the kidney has 
a unique blood supply: its microvascular structure of coiled capillaries receives up to 20% of 
the cardiac output. Unfortunately, these two properties render the kidney highly sensitive to 
IRI: its transport processes rapidly suffer from the lack of oxygen, and the adhesion of immune 
cells easily occludes the microcirculation, which may result in the no-reflow phenomenon. 
The detrimental effects of IRI are often most pronounced in the outer medulla, where the 
microvasculature is most complex and blood flow is reduced disproportionately compared to 
the total kidney.
Renal IRI occurs in many clinical conditions, such as sepsis, shock, renal artery stenosis, contrast 
administration, cardiac and aortic surgery and transplantation. It is a common cause of acute 
kidney injury (AKI), a condition characterized by a sudden deterioration in renal function, 
which affects 3-10% of hospitalized patients. The occurrence of AKI is highly correlated with 
impairment of renal function, requirement of renal replacement therapy and in-hospital 
mortality. A proportion of patients do not recover from AKI and in some it may progress into 
or reveal underlying chronic kidney disease (CKD), whilst others even develop end-stage renal 
failure. In both cases, patients will require lifelong hemodialysis or a kidney transplant [12]. 
Renal transplantation, in turn, causes IRI to the graft which may lead to delayed graft function 
(DGF) after transplantation. As such, renal IRI during transplantation is detrimental to long-
term graft survival [13]. 
Current methods to reduce IRI are inadequate and novel therapies are needed, not only for 
the kidney, but also for the heart and other vital organs. This thesis sheds light on a number 
of promising approaches: ischemic preconditioning, modulation of adenosine and opiate 
metabolism and modulation of the immune response with Diannexin.
1.4 Cytoprotective strategies and substances
1.4.1  Ischemic PreConditioning 
In 1986, Charles Murry and colleagues performed an experiment in which they compared a 
control group of dogs undergoing 40 minutes of coronary artery occlusion, to dogs pre-treated 
with four cycles of 5 minutes of coronary artery occlusion and 5 minutes of intermittent 
reperfusion prior to the sustained ischemia. The preconditioned dogs were found to have 
significantly less myocardial damage: the first report of ischemic preconditioning (IPC). IPC is 
a protective strategy in which exposure to short, nonlethal episodes of ischemia results in 
attenuated tissue injury during subsequent ischemia and reperfusion. Since then, this protective 
effect has been observed for many vital organs, such as liver, kidney and brain. In 1993, Karin 
Przyklenk and colleges were the first to demonstrate that preconditioning is also effective when 
the stimulus is applied to a remote organ or tissue (remote ischemic preconditioning; RIPC; 
Figure 2). In their dog model of myocardial infarction, preconditioning of one vascular territory 
conferred protection to another vascular bed in the heart [14]. Since then, many studies have 
shown protective effects of brief ischemic insults in various remote organs on IRI in different 
target organs [15,16]. 
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What is the mechanism underlying the protective effect mediated by IPC and RIPC? This question 
has received much attention in recent years, since more detailed knowledge of IPC signalling 
may allow us to design therapies which enhance IPC, and adjust our therapeutic approach to 
fit specific patient groups. A number of endogenous molecules have been implicated in IPC 
signalling, most of which are known to have cytoprotective effects. Two of these substances, 
adenosine and opioid peptides, are of special importance to this thesis (see § “Adenosine” and 
boxed text “Endogenous opioid peptides”). Downstream, the ultimate protective step in IPC 
signalling appears to be inhibition of MPTP-opening, which prevents cell death. RIPC appears 
to resemble IPC in that it finally results in MPTP inhibition, and that many signalling molecules 
seem similar to those implicated in IPC signalling. However, RIPC requires transduction of the 
protective signal from the remote to the target organ. The mechanism of transfer appears to 
differ depending on the remote and target organ, but is thought to reside in a humoral factor, 
neurogenic transduction, alteration of immune cells, or a combination of these pathways 
(Figure 2).
1.4.2 Diannexin shielding
As described above, reduction of the inflammatory response could be an effective method 
to limit IRI. Interventions which aim to inhibit leukocyte adhesion and infiltration would 
simultaneously reduce capillary obstruction, ROS production and cytokine and chemokine 
release. One approach is to target a major trigger for adhesion of inflammatory cells to 
the injured site: the exposition of phosphatidylserines (PS) on damaged (endothelial) cells 
(Figure 3). Exposition of PS on the outer leaflet of the cell membrane is a very early signal 
of cell stress or death. Passing leukocytes which carry a putative PS-receptor and/or bridging 
molecules, sense and bind to PS exposing cells. This process can be influenced by annexin 
A5 (ANXA5), a 37kD protein which binds PS with high affinity and specificity [17]. As such, 
ANXA5 molecules show little affinity for viable cells, but self-assemble as trimers upon 
binding to PS exposing membranes [18,19]. Next, ANXA5 trimers undergo extended two-
dimensional crystallisation, forming a sheet which covers the PS-positive membrane patches 
[20]. The ‘shield’ formed by ANXA5 has many effects on the stressed cell: it inhibits membrane 
vesiculation, thereby preventing apoptotic body formation, and shields the exposed PS from 
leukocytes and phospholipase A2, which reduces both inflammation and coagulation. Thus, 
endogenous ANXA5 seems to be an important secondary factor in the progress of pathological 
cell conditions and would have therapeutic potential, if not for its extremely short half-life (>30 
minutes in humans). A promising alternative are the recombinant ANXA5 dimers, which share 
the therapeutic shielding properties of ANXA5, but are not excreted by renal clearance due to 
their larger size, and thus have an increased half-life in vivo.
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Figure 3|Phosphatidylserine (PS) shielding by annexin A5 or Diannexin can reduce 
inflammation and no-reflow after ischemia-reperfusion injury (IRI). Upon IRI, PS (black 
spheres) are exposed on the outer leaflet of the cell membrane, where they serve as an 
attachment site for passing leukocytes. Binding and crystallization of annexin A5 or its 
homodimer Diannexin (blue discs) shields PS from the extracellular environment, thereby 
reducing leukocyte adhesion and subsequent capillary obstruction. EC = endothelial cells, Th = 
thrombocyte, RBC = red blood cell.
1.4.3 Adenosine
Since 1929, the purine nucleoside adenosine has been recognized as an extracellular signalling 
molecule with important effects on blood flow, heart rate and blood pressure. By stimulating 
G-coupled receptors on the cell membrane, adenosine lowers the heart rate, causes 
vasodilatation in most vascular beds, modulates sympathetic nervous system activity and 
enhances tolerance to ischemia. More recently, this molecule has also been shown to be involved 
in inflammation, platelet aggregation and tissue protection and repair [21]. The regulation of the 
extracellular adenosine concentration is the major determinant of the interaction of adenosine 
with its receptors A1, A2a, A2b and A3. Low concentrations of adenosine are normally present 
in the extracellular space, but these levels are rapidly increased under metabolically stressful 
conditions, such as ischemia and inflammation [22–24]. Under these circumstances, the 
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precursor molecules ATP, ADP and AMP are released from e.g. platelets, macrophages and 
injured cells [25], and changes in adenosine metabolism cause increased conversion of these 
molecules into adenosine. The half-life of adenosine is short (<30 seconds), as it is rapidly taken 
up by cells via the equilibrative nucleoside transporter (ENT), and intracellularly converted into 
inosine by adenosine deaminase (ADA) or rephosphorylated to ATP by adenosine kinase (AK) 
[26]. There are several drugs which increase the extracellular adenosine concentration and 
therefore promote its cytoprotective actions: the ENT can be pharmacologically inhibited by 
dipyridamole, leading to an increase in extracellular adenosine. Furthermore, statins, which are 
known for their low-density lipoprotein cholesterol-lowering effects, also cause upregulation 
of ecto-5’-nucleotidase (NT5E), thereby improving extracellular formation of adenosine. Thus, 
modulation of the adenosine metabolism is a promising strategy to reduce cell damage not 
only in IRI, but also in other diseases which endanger kidney function, e.g. sepsis (see boxed 
text “Sepsis”).
1.5 Thesis outline
After presenting a general introduction to this thesis in chapter 1, chapter 2 provides a detailed 
overview of our knowledge of IPC in renal IRI, in the form of a systematic review and meta-
analysis of all animal experiments published on this topic to date. Contributions to this body 
of literature by our own research group are presented in chapter 3, where we investigate the 
effect of RIPC by brief hind limb ischemia on renal IRI and the involvement of adenosine, and 
chapter 4, which further investigates the mediator molecules involved in renal RIPC by brief 
limb ischemia and reveals a role for the endorphins in RIPC signalling. In chapter 5, we present 
a different approach to reduce damage after renal IRI, namely pharmacological inhibition of 
the inflammatory response by DA5. The pharmacokinetics and biodistribution of ANXA5 and 
DA5 are studied and compared. After investigating renal IRI in animal models, chapter 6 turns 
to the study of IRI in skeletal muscle in humans in vivo, for which results may be translatable 
to the myocardium. We used a model of IRI in the forearm of healthy volunteers, in which 
the effect of statin treatment on mild IRI can be measured in a safe and minimally invasive 
manner. Chapter 7 further extends our knowledge of adenosine as a cytoprotective molecule 
by investigating the adenosine metabolism in sepsis, a condition often accompanied by renal 
failure. Finally, the results presented herein are discussed and placed in perspective in chapter 
8, and summarized in chapter 9. 
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Ischemic preconditioning (IPC) is a potent renoprotective strategy which has not yet been translated successfully into clinical practice, in spite of promising results in animal studies. We performed a unique systematic review and meta-analysis of animal studies to identify 
factors modifying IPC efficacy in renal IRI, in order to enhance the design of future (clinical) 
studies. 
An electronic literature search for animal studies on IPC in renal IRI yielded fifty-eight studies 
which met our inclusion criteria. We extracted data for serum creatinine, blood urea nitrogen 
(BUN) and histological renal damage, as well as study quality indicators. 
Meta-analysis showed that IPC reduces serum creatinine (SMD 1.54 [95%CI 1.16, 1.93]), BUN 
(SMD 1.42 [95% CI 0.97, 1.87]) and histological renal damage (SMD 1.12 [95% CI 0.89, 1.35]) 
after IRI as compared to controls. Factors influencing IPC efficacy were the window of protection 
(<24h = early versus ≥24h = late) and animal species (rat versus mouse). No difference in efficacy 
between local and remote IPC was observed. 
In conclusion, our findings show that IPC effectively reduces renal damage after IRI, with higher 
efficacy in the late window of protection. However, there is a large gap in study data concerning 
the optimal window of protection, and IPC efficacy may differ per animal species. Moreover, 
current clinical trials on RIPC may not be optimally designed, and our findings identify a need 
for further standardization of animal experiments.
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Introduction
IPC is a potent protective strategy in which application of a brief episode of ischemia and 
reperfusion (I/R) results in tolerance to subsequent IRI [27,16,28]. The conditioning stimulus 
has been shown to be effective when applied either to the target organ itself (local IPC; 
LIPC [29]) or to a remote organ or tissue (remote IPC; RIPC [14]). LIPC and RIPC were both 
originally discovered in the dog heart, and have been successfully reproduced in a variety of 
animal species, using various organs, e.g. heart, intestine, brain, liver and kidney. There is a 
large variety in the IPC protocols used: the preconditioning stimulus may be one continuous 
ischemic period, or it may be comprised of two or more cycles of brief ischemia. Moreover, the 
interval between the preconditioning stimulus and the index ischemia may vary, and positive 
results in animals have been found for both short intervals of a few minutes or hours (the 
so-called early window of protection), as well as for long intervals of days or even weeks (late 
window of protection).
Thus, IPC poses a promising alternative to existing treatments for IRI in humans, since current 
strategies to reduce this important and common clinical problem are inadequate. Next to the 
heart, the kidney is one of the major organs of interest for clinical application of IPC. Its high 
energy demand and intricate microvascular network render the kidney especially sensitive 
to IRI, which is a major cause of kidney injury in e.g. renal artery stenosis and renal surgery 
[30,31]. Furthermore, renal IRI is a major cause of cardiovascular morbidity and mortality, and 
is associated with delayed graft function after transplantation, renal damage in cardiac and 
aortic surgery, and shock [32–35]. In animal models, both LIPC and RIPC have been shown to 
be effective tools to protect the kidney (e.g. [36,37]). 
Where do we stand in terms of the translation of IPC to beneficial treatment for patients? LIPC 
has not been studied in the human kidney, but several clinical studies have been conducted 
in the heart: a number of studies have investigated LIPC in patients undergoing coronary 
artery bypass grafting (CABG) surgery, which collectively show that LIPC reduces inotrope 
requirements, ventricular arrhythmias, and shortens intensive care unit stay [38]. For RIPC, 
several clinical trials have been performed for cardiac as well as renal IRI, but their outcome 
is not clear-cut: many studies report protective effects of RIPC after CABG surgery, heart 
valve surgery, or abdominal aortic aneurysm repair, but not all findings have been positive 
([39,41,40,42] and recently reviewed in [43]). 
Thus, even though the protective effect of LIPC and RIPC on renal IRI has been shown in many 
animal studies, translation of IPC to the clinic has, as yet, not been successful. The variety of 
IPC protocols used in clinical trials may be one of the reasons for this ambiguity, i.e. in some 
studies, the stimulus could have been suboptimal or incorrectly applied. There is no consensus 
on how many ischemic stimuli should be applied and what the duration of these ischemic and 
intermediate reperfusion periods should be. It is unclear whether the early or late window of 
protection is most effective. Furthermore, it is unknown which patient-related factors such as 
age, gender or co-morbidities play a role. 
Meta-analysis and systematic review of preclinical (animal) studies have previously been used 
to optimize conditions in animal models and to improve the design of clinical trials [44–46]. In 
the case of IPC, meta-analysis of animal study data may provide valuable indicators to optimize 
the IPC protocol, as well as the window of protection in humans. It has been shown that proper 
analysis of animal experiments can also improve the decision making in whether or not to 
start a clinical trial. Moreover, this approach can be used to perform a quality assessment 
of the current literature, including measures to avoid bias (e.g. randomization, concealment 
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of allocation and blinded outcome assessment). As such, meta-analysis of existing literature 
on animal models may improve future animal research in the field, thereby contributing to 
the Refinement and Reduction of animal experiments, as proposed by the Animal Research: 
Reporting In Vivo Experiments [47] and Gold Standard Publication Checklist [48] guidelines. 
This report presents innovative methods in reviewing animal studies, i.e. a systematic review 
and meta-analysis of the efficacy of IPC in experimental models of renal IRI. We set out to 1) 
provide a complete and systematic overview of all literature available on the effects of IPC 
(both local and remote) on renal IRI; 2) report summary estimates of efficacy based on meta-
analysis; 3) identify factors modifying the efficacy of IPC in renal IRI, to inform the design of 
future clinical trials; and 4) provide insight in the quality of literature in the field of IPC and 
renal IRI in animal models.
Approach for meta-analysis
Literature search strategy, inclusion and exclusion criteria
The present review was based on published results of animal studies on the effects of IPC on 
renal IRI, which were identified via a systematic computerized search in PubMed and Embase. 
The inclusion criteria and method of analysis were specified in advance and documented in 
a protocol. The databases were searched for published articles up to October 19th 2011. The 
full search strategies are included in Appendix 1 (Pubmed) and 2 (Embase), and involved the 
following search components: “animal” [49,50], “kidney”, “ischemia-reperfusion injury” and 
“preconditioning”. Studies were included in the systematic review if they fulfilled all of the 
following criteria: 1) the study assessed the effect of remote or local IPC on renal IRI; 2) the 
study was performed in animals in vivo; 3) the study was an original full paper which presented 
unique data. Studies were excluded if 1) the renal IRI model involved cold storage of the 
kidney, or 2) the study was performed only in genetically modified animals. Study selection 
was performed independently by two reviewers (TM and KW) on the basis of title and abstract. 
In case of doubt, the whole publication was evaluated. Differences were clarified by discussion 
with a third investigator (MW). No language restrictions were applied. If necessary, papers in 
languages other than English were translated by scientists (native speakers for that particular 
language) within the Radboud University Nijmegen Medical Centre. 
Study characteristics and data extraction
The following study characteristics and data items were extracted from the studies included: 
animal species, strain, sex, number of animals in treatment and control groups, measures 
of randomization, measures of blinding, number of animals excluded for statistical analysis, 
reason for exclusion of animals, reported outcome measures and results. Bibliographic details 
such as author, journal, and year of publication were also registered.  Three outcome measures 
were assessed: serum creatinine, blood urea nitrogen (BUN) and histological renal damage. For 
histology, data could be extracted if the authors used the Jablonski [51] score for renal damage, 
or an adapted version of this scoring system. 
Data were extracted if raw data or group averages, standard deviation (SD) or standard error of 
the mean (SEM) and number of animals per group (n) were reported, or could be recalculated. 
For 30 articles, relevant outcome measures or study details were not reported. We therefore 
contacted these authors via e-mail and received response from eight authors, six of which 
provided additional data. For two papers, authors reported using 6-8 animals per group and we 
included these data using n=6 animals [52,53]. If the number of animals was stated less specific 
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(e.g. >3 animals or 4-8 animals) and the exact numbers could not be retrieved by contacting 
the authors, data were not included. If SEM was reported, these were converted to SD for 
meta-analysis. If a study contained separate groups for each gender, or several preconditioning 
protocols, these groups were analyzed as if they were separate studies. If two or more identical 
groups existed, the data were pooled for these groups. If outcomes were measured at several 
time points, we chose the time point at which efficacy was greatest. In 8 out of 11 cases, 
this was 24h post ischemia, which was also the most common time of measurement overall 
(see Table 1). When data were presented only graphically, we contacted authors to obtain the 
numerical values. If these were not available, data were measured using digital image analysis 
software (ImageJ; http://rsbweb.nih.gov/ij/). 
Assessment of methodological quality
We designed a 16-point rating system to assess the methodological quality of the included 
publications (see Table 2 and legend for details). Concerning the number of excluded animals, 
we assumed that there had been no exclusion if the number of animals per group mentioned 
in the materials and methods section was identical to the number stated in the figure legends 
or results section.
Data synthesis and statistical analyses
Data were analyzed using Review Manager Version 5.1 (Copenhagen, The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2011). Meta-analysis was performed for the outcome 
measures serum creatinine, BUN and histology score, by computing the standardized mean 
difference (SMD; the mean of the experimental group minus the mean of the control group 
divided by the pooled SD of the two groups). To account for anticipated heterogeneity, we 
used random effect models in which some heterogeneity is allowed. Subgroup analyses were 
pre-defined and performed for all outcome measures, and were used to assess the influence 
of variables on IPC efficacy, as well as to explore possible causes for heterogeneity. The five 
subgrouping variables were: timing of index ischemia (late or early window of protection), 
preconditioning protocol (fractionated or continuous), site of preconditioning (LIPC, RIPC or 
both), animal species (rat or mouse) and gender (male, female or both). Differences between 
subgroups were determined by calculating the difference between the respective SMDs (ΔSMD) 
and confidence interval (CI) of the difference. Furthermore, subgroup interaction analysis was 
performed in an attempt to further explain the expected study heterogeneity: we compared 
smaller sets of experiments by combining two subgrouping variables, e.g. early-RIPC versus 
early-LIPC. Unless indicate otherwise, data are presented as SMD and 95% CIs. 
For each outcome measure, we assessed the possibility of publication bias by visually evaluating 
the possible asymmetry in funnel plots. Finally, we investigated whether study methodology 
influenced the results of our meta-analysis. Pre-specified sensitivity analysis was performed to 
assess whether the chosen cut-off point for early versus late window of protection influenced 
the outcome of this subgroup analysis. 
Results
Study selection and characteristics
The electronic search strategy retrieved 253 records from PubMed and 270 articles from 
EMBASE, 310 of which were unique. Seventy-seven papers met our inclusion criteria. On the 
basis of predefined criteria, 19 reports were excluded and the remaining 58 articles were 
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retrieved in full (see Figure 1). 
Literature search
Databases: PubMed and EMBASE
No language restrictions
Combined search results (523) Remove duplicates (213)
Articles screened on basis of title 
and abstract, application of 
inclusion criteria (310)
Included (77)
Excluded (total = 233)
‐ Target organ other than kidney (61)
‐ Pharmacological preconditioning (59) 
‐ No preconditioning performed (43) 
‐ Review article, letter or commentary (37) 
‐ Preconditioning by hypoxia, hyperoxia, heat,                
fasting or radiation (respectively 4, 1, 3, 1 and 1)
‐ Postconditioning (8) 
‐ In vitro or ex vivo model (6) 
‐ Preconditioning by pneumoperitoneum (4) 
‐ Patient study (5)
Manuscript review and 
application of exclusion criteria
Inclusion in quality 
assessment(58)
Excluded (total = 19)
‐ Cold storage of the kidney (18)  
‐ Knock‐out animals only (1)
In
cl
ud
ed
El
ig
ib
ili
ty
Sc
re
en
in
g
Id
en
tif
ic
at
io
n
Inclusion in meta‐analysis 
creatinine(33)
Inclusion in meta‐analysis 
blood urea nitrogen (17)
Inclusion in meta‐analysis 
histology (15)
 
Figure 1|Flow chart of study selection. The number of studies in each phase is indicated 
between brackets.
The characteristics of the included studies are summarized in Table 1. There was a large 
variation in study characteristics. In 76% of the 58 included studies, the delay between the 
preconditioning stimulus and the index ischemia was <24h, which we considered to be the 
early window of protection. Eleven studies (19%) assessed protection in the late window of 
protection (timing of index ischemia ≥ 24h after IPC), and three studies (5%) reported data 
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for both late and early window(s) of protection. For the early window of protection, the delay 
between IPC and index ischemia was 4 to 40 min (average 9±7 min). For the late window 
of protection, this was 24 h up to 12 wk (average 17±23 d). In 28 of the 58 studies (48%), 
the IPC protocol consisted of one continuous stimulus. Twenty-two studies (38%) used only 
fractionated protocol(s), i.e. two to five cycles of brief ischemia and reperfusion, whereas eight 
studies employed both fractionated and continuous stimuli. 
The majority of studies focussed on the protective effects of LIPC on renal IRI. However, five 
studies assessed the effects of RIPC, using hind limb, intestine, liver or subphrenic aortic 
occlusion as remote stimuli. In four studies, both LIPC and RIPC of one kidney to its contralateral 
counterpart were performed (either intentionally, or as a result of a bilateral preconditioning 
stimulus and a unilateral index ischemia). 
Out of all 58 included studies, 14 were conducted in mice (24%), 34 in rat (59%), and 10 in 
other species, namely rabbit (7%), dog (5%) and pig (5%). Eight out of 58 studies (14%) were 
performed in female animals, 37 in males (64%), and 4 studies used animals of both genders 
(7%). Nine studies did not report the gender of the animals. 
Methodological quality of studies
The results of the quality assessment of the 58 studies included in this systematic review 
are shown in Table 2 and Figure 2. On average, studies reported 9 out of 16 characteristics 
(59±10%). The lowest score was 5 out of 15 items (33%) and the highest scoring studies 
reported 12 items out of 14 (80%). In the quality assessment of clinical trials, randomization, 
blinding, and description of withdrawals are key quality measures. However, only 40% of the 
animal studies included in this systematic review reported randomization of the animals across 
treatment groups. Out of the 39 studies in which renal histology was an outcome measure, 
74% reported blinding of the outcome assessment. No study reported blinding for any other 
outcome measure. Only 29% of the studies reported the number of animals excluded, 64% of 
which did not state the reason for exclusion. Although the strong influence of body temperature 
on renal damage has been shown in both large and small animal models, 36% of the studies did 
not report whether the body temperature of the animals was controlled.
    
  
    
      
     
     
    
    
     
   
    
   
  
    
   
    


 
Figure 2|Quality assessment score, averaged per item. Many studies scored poorly on key 
characteristics of scientific practice and measures to avoid bias, such as characteristics of the 
subject population, randomization, blinding and exclusion criteria.
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Meta analysis of outcome measures 
Results for the outcome measure serum creatinine are summarized in Table 3 and Figure 3. 
Thirty-two articles studied the effect of one or more IPC protocols on serum creatinine after 
renal IRI.  The analysis contained 62 experiments, including data for 512 control animals which 
underwent renal IRI only and 492 animals that underwent IPC + renal IRI. In 36 experiments, 
the SMD and 95%CI indicated that IPC significantly reduced the IRI-induced rise in serum 
creatinine. One study reported a negative effect of IPC on serum creatinine [85]. Overall 
analysis showed that IPC reduced serum creatinine after IRI (1.54 [1.16, 1.93], p<0.00001). 
Overall study heterogeneity was high (83%).
Subgroup analysis showed a beneficial effect of IPC for all subgroups, except for female (notably, 
this subgroup contained only two experiments and was therefore excluded from further 
statistical analysis). We also found a subgroup effect of the variable ‘window of protection’ 
(Table 2, filled squares). The ΔSMD and CI of the difference between early versus late was 2.43 
[1.29, 3.57], indicating that the late window of protection of IPC was more effective in reducing 
serum creatinine than the early window. 
Subgroup analysis indicated a higher IPC efficacy in studies conducted in mouse versus rat 
(Table 2, triangles; ΔSMD 1.7 [1.5, 1.90]). For other species (dog, pig, rabbit) subgroups were 
too small to perform reliable subgroup analysis. No difference in IPC efficacy was observed 
between continuous versus fractionated; ΔSMD 0.46 [-0.30, 1.22]), or males only versus groups 
of mixed gender (ΔSMD 0.38 [-0.60, 1.36]). For site of preconditioning, no differences were 
found when comparing the subgroups LIPC versus RIPC (ΔSMD 0.06 [-0.98, 1.10]), LIPC versus 
LIPC +RIPC (ΔSMD 1.01 [-0.44, 2.46]) or RIPC versus LIPC + RIPC (ΔSMD 0.95 [-0.73, 2.63]). 
Results for the outcome measure BUN are summarized in Table 4 and Figure 4. Seventeen 
articles studied the effect of one or more IPC protocols on BUN after renal IRI. In 20 out of 29 
experiments, the IRI-induced rise in BUN was significantly reduced in animals undergoing IPC, 
when compared to a control group that underwent IRI only (overall effect size 1.42 [0.97, 1.87]; 
p<0.00001). Overall study heterogeneity was high (76%).
Subgroup analysis showed that the beneficial effect of IPC on BUN was present in all subgroups. 
Between-subgroup analysis revealed a higher IPC efficacy in mouse versus rat (Table 3, triangles; 
ΔSMD 2.12 [0.48, 3.76). No effect was found for the window of protection (early versus late; 
ΔSMD 1.25 [-0.05, 2.55]) or the IPC protocol (continuous versus fractionated; ΔSMD 0.96 [-0.03, 
1.95]). Furthermore, the site of preconditioning did not influence IPC efficacy: LIPC versus RIPC, 
LIPC versus LIPC +RIPC and RIPC versus LIPC + RIPC, respectively ΔSMD 0.2 [-0.69, 1.09]), ΔSMD 
0 [-1.03, 1.03] and ΔSMD 0.2 [-0.82, 1.22]. Subgroup analysis could not be performed for the 
variable ‘gender’, because of insufficient data. 
Results for the outcome measure renal histology are summarized in Table 5 and Figure 5. Twenty-
six experiments from 15 studies reported the effect of IPC on the Jablonski score for renal 
histology. Eight studies using a histology score not comparable with Jablonski’s were excluded 
from analysis. Data included contained 205 control and 191 IPC-treated animals. Overall, IPC 
had a significant renal protective effect of 1.12 [0.89, 1.35]. Overall study heterogeneity was 
63%.
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Figure 3|Effect of IPC on serum creatinine after renal IRI. Left side favours control (renal 
IRI only), right side favours IPC. An overall beneficial effect of IPC on serum creatinine was 
observed (1.54 [1.16, 1.93]). Data presented as SMD and 95% CI.
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Figure 4|Effect of IPC on BUN after renal IRI. Left side favours control (renal IRI only), right side 
favours IPC. An overall beneficial effect of IPC on BUN was observed (1.42 [0.97, 1.87]). Data 
presented as SMD and 95% CI.
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
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5|Effect of IPC on renal histology after renal IRI. Left side favours control (renal IRI 
only), right side favours IPC. An overall beneficial effect of IPC on renal histology was observed 
(1.22 [0.89, 1.35]). Data presented as SMD and 95% CI.
Subgroup analysis showed that the beneficial effect of IPC on histology was present in all 
subgroups. Between-subgroup analysis could only be performed for the variables window 
of protection, IPC protocol, gender and animal species, because of insufficient numbers of 
experiments in the other subgroups. No significant differences between subgroups were found 
(early versus late, ΔSMD 1.8 [-0.07, 3.67]; continuous versus fractionated, ΔSMD 0.3 [-0.50, 
1.10]; males versus mixed gender, ΔSMD 0.25 [-0.58, 1.08]; rat versus mice, ΔSMD 0.55 [-0.14, 
1.24]).
Subgroup interaction analysis
In an attempt to further explain the expected study heterogeneity, subgroup interaction analysis 
was performed for all subgroup interactions which contained three or more experiments. 
Study heterogeneity was not notably reduced by combining subgroup variables and remained 
on average 80±6% for serum creatinine, 62±23% for BUN and 47±30% for renal histology. The 
analyses revealed no significant differences in the interaction between subgroups and did 
therefore not alter the results of the subgroups analysis. Interestingly, for serum creatinine, 
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the subgroup interactions early-RIPC and continuous-RIPC did not show an overall effect of 
IPC, whereas early-LIPC and continuous-LIPC did show the protective effect. This may indicate 
that the positive effect of an early window of protection, or the benefits of a continuous IPC 
protocol are less pronounced for RIPC than for LIPC. However, because of the small number of 
experiments in these subgroups interactions (six and three experiments, respectively), these 
results must be interpreted with care. 
Publication bias
The presence of publication bias was assessed for all outcome measures. Visual analysis of 
funnel plots revealed that small, negative studies appeared to be underrepresented (data not 
shown). This was especially true for serum creatinine and BUN, and to a lesser extent for renal 
histology data. 
Sensitivity analysis
To assess the robustness of our findings, we undertook a sensitivity analysis by redefining the 
cut off-point for the early window of protection at a later time point (<48h) or an earlier time 
point (<6h). This did not significantly alter the outcome of any of the outcome measures (data 
not shown). 
Discussion
Here we report a unique systematic review and meta-analysis of current literature reporting 
experimental animal models of IPC in renal IRI. Three important outcome measures were 
assessed, namely serum creatinine, BUN and histological renal damage quantified by Jablonski 
score. For all three, protective effects of IPC were observed, i.e. IPC reduced serum creatinine 
(1.54 [1.16, 1.93]), BUN (1.42 [0.97, 1.87]) and histological damage (1.12 [0.89, 1.35]) after IRI, 
when compared to control animals undergoing renal IRI only. Importantly, in the clinical setting, 
serum creatinine currently remains the gold standard to assess renal function. In rodents 
however, questions have been raised regarding the reliability of creatinine for measuring renal 
function, since the impact of tubular creatinine excretion on creatinine clearance is even larger 
in mice than in humans [107]. We therefore put forward that other outcome measures, such as 
BUN and/or renal histology may also be of great value when translating animal study results to 
the human setting. Furthermore, other renal damage markers such as Kidney Injury Molecule-1 
(KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) are gaining ground in clinical 
practice [108]. Reporting these markers in both animal and human studies may provide further 
information for the translation of animal study data to the human setting. 
We performed subgroup analysis to investigate several pre-defined factors which we 
hypothesized to modify the efficacy of IPC in renal IRI, namely: window of protection (early 
or late), IPC protocol (continuous or fractionated), site of preconditioning (RIPC, LIPC or both), 
species (mouse or rat) and gender (male, female or mixed). The protective effects of IPC were 
persistent in all subgroups, for all outcome measures, except for female (only 2 experiments). 
Based on the latter observation, we propose the need for future studies in females, since it has 
been shown that there is a significant difference between males and females for cardiac IPC 
efficacy (e.g. [109]).
For serum creatinine, the window of protection influenced the efficacy of IPC: IPC was more 
effective when conducted >24h before index ischemia (late window of protection), as compared 
to an early widow of protection (<24h before index ischemia). We observed the same trend 
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towards higher efficacy in the late window of protection for BUN and renal histology. The cut-
off point of the window of protection could be redefined at 6h or 48h without significantly 
influencing the result, since the vast majority of experiments (93%) investigated either a time 
window of <40 minutes, or >4 days. The remaining 7% of the experiments concerned a time 
window of 6-24h between IPC and IRI. In other words, there is a large gap in these data which 
makes it difficult to assess the optimal window of protection for IPC. Nevertheless, our data 
strongly indicate that the late window of protection might be more effective to reduce renal IRI 
as compared to the early window. This finding is particularly interesting since almost all clinical 
trials currently registered at Clinicaltrials.gov investigating the effects of LIPC and RIPC use only 
the early window of protection. To our knowledge, data on the efficacy of combined activation 
of the early and late window in humans is lacking.
The second variable which influenced IPC efficacy was animal species: for serum creatinine and 
BUN data, IPC was more effective when performed in mice versus rats. This suggests that mouse 
models of renal IPC may be more sensitive when compared to rat, and are thus the preferable 
models for future animal studies. Furthermore, this finding implicates that IPC efficacy is 
species-specific, and therefore the protective effect may be greater, or less pronounced in large 
animals and humans. This illustrates the difficulty in directly translating animal study results to 
the human settings, and further studies in large animals and humans are necessary to clarify 
this issue. 
No significant differences were observed for the variables IPC protocol (continuous versus 
fractionated), or site of preconditioning (LIPC, RIPC or both). The latter finding is interesting, 
since the use of LIPC in clinical practice is limited because of the risk of damage to major 
vascular structures, and the fact that even brief ischemia may damage the target organ in 
vulnerable patients. RIPC therefore has more potential for clinical application, since the IPC 
stimulus can be applied to e.g. a limb, which is easy to handle and relatively resistant to IRI. 
Our finding that RIPC and LIPC are equally effective indicates that RIPC has an at least equal 
potential for translation to the clinic, although it must be noted that only two studies used the 
limb as remote organ. Subgroup analysis of the serum creatinine levels in animals undergoing 
simultaneous LIPC of one kidney and RIPC of the contralateral kidney show a trend towards 
higher efficacy (Table 2, filled circles), indicating that a combination of LIPC and RIPC may have 
an additive effect. However, this result must be interpreted with care, because of the low 
number of experiments included.
Methodological quality of studies
Our assessment reveals that there is much to gain in terms of the methodological quality of 
animal studies in this field. Key characteristics of scientific practice and measures to avoid 
bias, such as characteristics of the subject population, randomization, blinding and exclusion 
criteria, were infrequently reported. A number of recent systematic reviews show that this 
is the case in many fields of animal research. For scientific and ethical reasons, it is urgent 
that the standards routinely applied in human research become standard of practice in animal 
research as well. While it is possible that some authors merely failed to report these details, 
there is reason for concern, since it is unclear whether there is a significant difference between 
the reported study quality and the actual study quality. For this reason better reporting of 
animal studies is crucial. Regrettably, there appears to be an inverse correlation between the 
impact factor of the journal in which the study is published and the required detail of the 
materials and methods description [48]. The high heterogeneity of the data presented in this 
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systematic review may be explained in part by the differences in study quality, as well as the 
lack of consensus and general standards of practice in animal studies. It has proven difficult to 
obtain missing data by contacting authors directly, which further emphasizes the importance 
of adequately reporting animal studies. However, in spite of insufficient reporting, systematic 
review and meta-analysis of current publications aid in making possible bias transparent, and 
can provide us with valuable new insights, which will support the translation of animal data to 
the clinic.
Strengths and limitations
The major strength of our study is that as far as we are aware, we are the first performing a 
systematic review and meta-analysis on renal protection by IPC in animal studies. We were able 
to include a large number of studies per outcome measure, which enabled us to investigate the 
effect of several subgroup variables. 
Some potential limitations should be discussed. Firstly, the extracted data are highly 
heterogeneous, which is most likely due to a large variety in experimental designs used and the 
variation in study quality. The fact that our subgroup interaction analysis did not notably reduce 
heterogeneity supports this notion. Although we have tried to account for this heterogeneity 
by using a random effects model and performing subgroup and sensitivity analysis, pooling of 
the results may not be appropriate for all subgroups. Therefore, differences between (small) 
subgroups should be interpreted with caution and be used to generate new hypotheses, rather 
than for drawing final conclusions. However, all included studies provide information on the 
association between IPC and IRI in the animal kidney and are thus valuable for this systematic 
review. 
Secondly, the included studies may be subject to publication bias. Visual analysis of funnel 
plots revealed that only small, negative studies appeared to be underrepresented in current 
literature on IPC in renal IRI. Asymmetry was most notable in serum creatinine and BUN data. 
This may indicate that publication bias is present, which could cause overestimation of the 
effect sizes. Importantly, funnel plot asymmetry can result from non-publication of negative 
results, but may also be caused by other factors, such as true study heterogeneity, or differences 
in study quality [110]. Our finding that the study quality is rather heterogeneous may therefore 
explain part of the funnel plot asymmetry. 
Clinical implications
Both LIPC and RIPC (and also the combination of the two), appear to have the potential to 
reduce IRI, and since RIPC by brief limb ischemia has the advantage of being safe and easy to 
perform, the latter has the greatest potential for clinical practice. In contrast to the variety 
of IPC protocols used in animal studies, current clinical trials on RIPC in renal IRI are using 
similar preconditioning protocols, namely fractionated IPC stimuli, and a short delay between 
IPC and index ischemia (early window of protection). The current review indicates that even 
though this approach might be effective, efficacy could be even higher in the late window of 
protection. Future studies should be designed to investigate the optimal window of protection 
in patients, taking into account the possible difference between acute and delayed IPC. 
Whether a combination of the two is additive or even synergistic requires further testing in 
animal and human models as well.
It is important to realize that, to date, no studies (animal or human) have investigated the 
effect of co-medication and co-morbidities such as diabetes, hypertension or obesity, on IPC 
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in renal IRI. For the heart, it has been shown that medication and co-morbidities influence IPC 
efficacy (reviewed e.g. in [111]). Similarly, differences in IPC efficacy between genders may 
indicate that the optimal IPC stimulus is different in males versus females. We propose that 
future clinical studies should be designed to optimize IPC efficacy for certain patient groups, 
and that animal studies in this area can inform the design of such clinical trials. Furthermore, 
a better mechanistic insight is needed in the cause of the observed interspecies difference. 
These data will give us a clue whether translation to humans is feasible.
Conclusion
The currently applied approach of systematic review and meta-analysis indicates that, in animal 
studies, IPC has an overall protective effect on the kidney, since it reduces serum creatinine, 
BUN and renal damage as assessed by histology after IRI. We found that IPC is more effective 
in reducing serum creatinine when the IPC stimulus is applied >24h before index ischemia 
(late window of protection), a trend which was also observed for BUN and renal histology 
data. Furthermore, serum creatinine and BUN data showed an effect of animal species on IPC 
efficacy: IPC was more effective when performed in mice versus rats. No significant differences 
were observed for the variables site of preconditioning (local, remote or both) or IPC protocol 
(continuous versus fractionated). Our review indicates that current clinical trials on RIPC may 
not be optimally designed, and further optimization may be necessary for successful translation 
to the clinic.
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Appendix 1|Search strategy
PubMed Kidney “kidney”[MeSH Terms] OR “acute kidney injury”[MeSH Terms] 
OR “kidney”[Tiab] OR “kidneys”[Tiab] OR “renal”[Tiab] OR 
“kidney transplantation”[MeSH Terms] OR “nephrology”[MeSH 
Terms] OR “nephrology”[Tiab]
Preconditioning “ischemic preconditioning”[MeSH Terms] OR “IPC”[tiab] OR 
“RIPC”[tiab] OR “brief ischemia”[tiab] OR “brief ischaemia”[tiab] 
OR “preconditioning”[tiab] OR “pre conditioning”[tiab] OR 
“pre-conditioning”[tiab] OR “transient ischaemia”[tiab] OR 
“transient ischemia”[tiab] OR “intermittent ischaemia”[tiab]OR 
“intermittent ischemia”[tiab] OR “continuous ischemia”[tiab] 
OR “continuous ischaemia”[tiab]
Ischemia-
reperfusion injury
“warm ischemia”[Mesh Terms] OR “warm Ischemia”[Tiab] 
OR “warm Ischaemia”[Tiab] OR “cold ischemia”[Mesh Terms] 
OR “cold ischemia”[Tiab] OR “cold ischaemia”[Tiab] OR 
“primary graft dysfunction”[Mesh Terms] OR “primary graft 
dysfunction”[Tiab] OR “I/R”[Tiab] OR “IRI”[Tiab] OR “ischemic 
reperfusion”[Tiab] OR “ischaemic reperfusion”[Tiab] OR 
“ischemia reperfusion”[Tiab] OR “ischaemia reperfusion”[Tiab] 
OR “kidney ischemia”[Tiab] OR “kidney ischaemia”[Tiab] 
OR “renal ischaemia”[tiab] OR “renal ischemia”[tiab] OR 
“reperfusion injury”[Mesh Terms] OR “reperfusion injury”[tiab] 
OR “reperfusion injuries”[tiab] OR “ischemia reperfusion”[tiab] 
OR “ischaemia reperfusion”[tiab] OR “renal injury”[tiab] OR 
“renal injuries”[tiab]
Animals Laboratory animal search filter [49]
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Embase Kidney exp kidney/ OR exp acute kidney failure/ OR exp kidney 
transplantation/ OR exp kidney allograft rejection/ OR (renal OR 
kidney OR kidneys OR nephrology).ti,ab.
Preconditioning exp ischemic preconditioning/ OR (IPC OR RIPC OR brief ischemia 
OR brief ischaemia OR preconditioning OR pre conditioning  OR 
pre-conditioning OR transient ischaemia OR transient ischemia 
OR intermittent ischaemia OR intermittent ischemia OR 
continuous ischemia OR continuous ischaemia).ti,ab.
Ischemia-
reperfusion injury
exp reperfusion injury/ OR exp cold ischemia/ OR exp primary 
graft dysfunction/ OR (warm ischemia OR warm ischaemia 
OR cold ischemia OR cold ischaemia OR reperfusion injury OR 
primary graft dysfunction OR I/R OR IRI OR ischemic reperfusion 
OR ischaemic reperfusion OR kidney ischemia OR kidney 
ischaemia OR renal ischaemia OR renal ischemia OR reperfusion 
injury OR reperfusion injuries OR ischemia reperfusion OR 
ischaemia reperfusion OR renal injury OR renal injuries).ti,ab. 
OR (cold ischemia OR cold ischemia time OR cold ischemia 
times OR cold ischemic time OR cold ischemic times OR cold 
ischaemia OR cold ischaemia time OR cold ischaemia times OR 
cold ischaemic time OR cold ischaemic times).ti,ab. OR (warm 
ischemia OR warm ischaemia).ti,ab.
Animals Laboratory animal search filter [50] 
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Remote ischemic preconditioning by brief hind limb ischemia protects against renal ischemia-
reperfusion injury: the role of adenosine.
Kimberley E. Wever1 
Michiel C. Warlé2
Frank A. Wagener1,3
José W. Van der Hoorn5
Rosalinde Masereeuw1
J. Adam van der Vliet2 
and Gerard A. Rongen1,4  
Departments of 1Pharmacology and Toxicology, 2Surgery, 3Orthodontics and Oral Biology and 
4General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands. 5Netherlands Organization for Applied Scientific Research-Quality of Life, Gaubius 
Laboratory, Leiden, The Netherlands.
Nephrology Dialysis Transplantation 2011; 26(10):3108-17.
Remote ischemic preconditioning against renal IRI: the role of adenosine|51
Remote ischemic preconditioning (RIPC) is a strategy to protect a target organ against ischemia-reperfusion injury (IRI) by inducing short-term ischemia/reperfusion (I/R) in a remote organ. RIPC of the kidney by temporary limb occlusion would be a safe, 
inexpensive and non-invasive method to prevent renal damage in e.g. transplantation and 
aortic surgery. We investigated whether brief hind limb occlusion can protect against renal IRI 
and whether this protection is adenosine-dependent. 
Rats underwent either no RIPC, unilateral RIPC or bilateral RIPC. The preconditioning stimulus 
was either continuous (12’/12’ I/R), or fractionated (three times 4’/4’ I/R). After the last 
reperfusion period, we induced 25’ of ischemia in the right kidney. 
After 24h of reperfusion, renal function was improved by 30-60% in both bilateral RIPC groups 
and in the fractionated unilateral group. Renal tubule damage and Kidney Injury Molecule-1 
expression were reduced in three out of four RIPC groups. Treatment with the adenosine 
receptor blocker 8-(p-sulphofenyl)theophilline had no effect on fractionated or continuous 
RIPC. 
Brief hind limb ischemia induces protection against renal IRI, which makes this a promising 
strategy to prevent renal IRI in a clinical setting. Bilateral RIPC was more effective than unilateral 
RIPC, and this protection occurs via an adenosine-independent mechanism. 
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Introduction
Due to its high energy demand and intricate microvascular network, the kidney is highly 
sensitive to IRI, which is a major cause of AKI in e.g. renal artery stenosis and renal surgery 
[30,31]. Furthermore, renal IRI is associated with delayed graft function after transplantation, 
complicates shock, cardiac and aortic surgery and is a major cause of cardiovascular morbidity 
and mortality [32–35]. Although renal IRI is an important and common clinical problem, current 
strategies to reduce IRI are inadequate and novel therapies are needed.
In 1993, the phenomenon of RIPC was first demonstrated in a dog model of myocardial 
infarction, where preconditioning of one vascular territory conferred protection to another 
vascular bed in the heart [14]. Since then, many studies have shown protective effects of brief 
ischemic insults in various remote organs on IRI in different target organs [16,15]. 
Protection of the kidney by RIPC has only been sparsely studied. One rat study showed 
protection against renal IRI by brief hepatic occlusion, using renal function as endpoint [54].  In 
rats, hind limb ischemia by brief clamping of the infrarenal aorta reduced oxidative stress after 
45’ of renal ischemia [79]. Only one study human has been conducted, where renal function 
was measured as a secondary endpoint in patients undergoing elective abdominal aortic 
aneurysm repair. The results indicated that two cycles of 10’/10’ ischemia/reperfusion (I/R) of 
the common iliac artery significantly lowered serum creatinine [39]. 
RIPC by brief ischemia of a limb (which is effective for the heart and skeletal muscle) has great 
clinical advantages, since the limb is easy to handle and relatively resistant to IRI. To date, most 
studies used infrarenal aortic or iliac artery occlusion to induce hind limb ischemia. However, 
limb occlusion by tourniquet or blood pressure (BP) cuff is especially relevant for clinical 
application, because it is a safer, non-invasive and comparatively inexpensive procedure. 
For the kidney as well as for other organs, some studies have been performed using a single 
continuous ischemic stimulus, while others used a fractionated stimulus, i.e. brief I/R cycles. For 
the heart, there is conflicting data on whether continuous and fractionated protocols RIPC are 
equally effective, although very few studies have directly compared these protocols [112,113]. 
For the kidney and the hind limb, no such study has been performed to date. Secondly, there 
is hardly any data on whether the tissue mass or area of the remote organ plays a role in the 
effectiveness of RIPC.
The mechanism underlying RIPC and its signalling pathways remain largely unclear. Both 
neurogenic pathways [114,115], and the release of biochemical messengers in the circulation 
[16,15] have been implicated and may differ depending on the stimulus protocol and the 
organs involved. One candidate signalling molecule is adenosine, which was shown to be 
involved in RIPC of the heart by brief renal ischemia and brief mesenteric artery occlusion 
(MAO; [116,117,112]). Interestingly, adenosine is implicated in both the humoral [116] and 
the neurogenic pathway [118,112]. The involvement of adenosine in RIPC by brief hind limb 
ischemia of the kidney has not been studied to date.
The present study is the first to explore whether brief hind limb ischemia induced by BP cuff 
occlusion is effective in protecting the kidney after IRI. We first conducted a proof-of-principle 
study, in which we investigated whether brief hind limb ischemia is effective in preconditioning 
the kidney. Concurrently, we determined whether the efficacy of this RIPC stimulus depends on 
the protocol of limb ischemia and/or limb tissue mass. In a second study, we investigated the 
involvement of adenosine in RIPC of the kidney for two protocols of brief hind limb ischemia, 
by testing the effect of the non-specific adenosine receptor antagonist 8-(p-sulphofenyl)
theophilline (8-SPT).
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Subjects and Methods
Animals
All procedures involving animals were approved by the Committee for Animal Experiments of 
the Radboud University Nijmegen. Male Sprague-Dawley rats (Harlan Laboratories, Eystrup, 
Germany) weighing 306 ± 30 grams (study I and II) or 262 ± 10 grams (8-SPT dosage test) were 
housed under standard specific pathogen free housing conditions at the Central Animal Facility 
Nijmegen. 
Surgical procedures
All surgical procedures were performed using standard aseptic surgical techniques. Anaesthesia 
was induced with 5% isoflurane in O
2
/N
2
O and maintained at 2.5-3%. Body temperature was 
monitored at 37.5°C. For studies I and II, analgesic (carprofen, 5mg/kg b.w.) was administered 
subcutaneously (s.c.) 30’ prior to surgery. 
RIPC by brief hind limb ischemia was induced by applying a BP cuff around the proximal thigh. 
In case of sham operation or renal ischemia only, there was a waiting period of 24’ before renal 
IRI induction. During the last 12’ of the RIPC protocol, rats underwent laparotomy and the renal 
vein and artery of the right kidney were clamped for 25’. The left kidney was nephrectomised.
One day post-op, analgesic (carprofen, 5mg/kg b.w.) in 5ml saline was administered s.c. and rats 
were housed in metabolic cages to collect 24h urine. On day 2 post-op, rats were anesthetized 
with 5% isoflurane in O
2
/N
2
O and sacrificed by exsanguination.
To verify the efficacy of 8-SPT to block adenosine receptors at the dosage used (‘8-SPT dose 
test’), the femoral artery was catheterized, the catheter was flushed with Ringers solution 
containing 4 units/ml heparin and connected to a BP monitor. The tail vein was canulated 
to allow bolus injections of 8-SPT (Sigma-Aldrich, Zwijndrecht, The Netherlands) or vehicle 
(physiological salt solution) and i.v. infusion of adenosine. 
Drug dosage
8-SPT (12mg/ml) was dissolved in saline and the pH was adjusted to 7.7 using NaOH. Rats 
were given 2.5ml/kg b.w. of this solution divided over 2 bolus injections, thus receiving a dose 
of 30mg/kg b.w.. Adenosine (7.5mg/ml; Sigma-Aldrich) was dissolved in saline and infused at 
a speed of 0.016ml/kg/min. Thus, a dose of 1.2mg/kg/min was acquired (also employed in 
[119]).
Study Design
Study I. Fifty-six rats were randomized into 6 experimental groups (Figure 1). Six rats were 
sham-operated. Fifty rats underwent 25’ of renal ischemia and were either not preconditioned 
(no RIPC, n=10) or underwent one of the following RIPC protocols: 12’/12’ of hind limb I/R in 
one (12’/12’ unilat, n=9) or both hind limbs (12’/12’ bilat, n=11), or 3 cycles of 4’/4’ I/R in one 
(3x 4’/4’ unilat, n=9) or both hind limbs (3x 4’/4’ bilat, n=11).
8-SPT dose test. Twelve rats were randomized into 2 groups. Throughout the experiment, BP 
and heart rate (HR) were recorded at 1’ and 3’ intervals, respectively. After a 5’ stabilisation 
period, animals were pre-treated with a bolus injection of either 8-SPT (n=6) or vehicle 
(n=6). Three minutes later (t=0), adenosine was infused i.v. for 5’. BP and HR recordings were 
continued for another 5’ after adenosine infusion, after which the animals were sacrificed by 
cervical dislocation.
Study II. We investigated the involvement of adenosine in the two most effective RIPC protocols. 
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All RIPC stimuli were applied to both hind limbs. Fifty rats were randomized in 5 experimental 
groups (Figure 1) and underwent 25’ of renal ischemia. They underwent either no RIPC and 
were treated with vehicle (no RIPC, n=10), or received one of the following treatments: RIPC by 
12’/12’ hind limb I/R in the presence (n=10) or absence (n=9) of 8-SPT, or 3x 4’/4’ hind limb I/R 
in the presence (n=11) or absence (n=10) of 8-SPT.
Figure 1|Schematic overview of studies I and II. Number of animals per group is indicated 
between brackets. See text for further details and abbreviations.
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Tissue handling
Blood samples were collected in EDTA tubes and centrifuged for 5’ at 14000 g to obtain plasma. 
Plasma, urine and renal tissue samples were snap frozen in liquid nitrogen and stored at -80 
°C until further use. For RNA and protein isolation, tissue frozen tissue was pulverized using 
a micro-dismembrator (Sartorius BBI Systems GmbH, Melsungen, Germany), as described 
previously [120]. 
Histology
Fresh tissue was fixed in Bouin’s fixative for at least 24h. For light microscopy, ½ of the lower 
pole of each kidney was dehydrated and embedded in paraffin. For damage scoring, sections of 
5 μm were stained with periodic acid-Schiff (PAS). For each kidney, 4 sections taken at different 
latitudes were scored for damage and cast formation in the renal cortex and averaged. Damage 
scoring was performed on a scale from 0 to 5, with 0 signifying no proximal tubule damage, and 
5 indicating that all tubules were damaged (Figure 3A-F and legend). All scores were performed 
by the same investigator (LtR) while blinded for treatment allocation.
Quantitative PCR
Total RNA was isolated with Trizol reagent (Invitrogen, Breda, The Netherlands), pelleted 
by centrifugation (10’ x 12000 g, 4 oC) and resuspended in DEPC-treated water. Reverse 
transcription with Mo-MLV reverse transcriptase (Invitrogen) was performed on 1 µg RNA.
RTQ-PCR was performed in duplo on approximately 1 ng cDNA, using the ABI/PRISM 7900HT 
Gene Expression Micro Fluidic Card (Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s instructions. cDNA amplification was performed in Taqman® Universal 
PCR Master Mix, supplemented with 20x solution of primer probe sets for the renal injury 
markers KIM-1 and NGAL and the housekeeping gene β-actin (respectively Rn00667669_m1, 
Rn00590612_m1 and Rn00597703_m1; all from Applied Biosystems). PCR reactions were 
analyzed using 700 System Sequence Detection Software (version 1.2.3, Applied Biosystems).
Protein isolation and Western blotting
Pulverized tissue samples were transferred to ice-cold TS buffer (10 mM Tris-HCl, 250 mM 
sucrose) including protease inhibitors (complete Mini, Roche, Mannhein, Germany). Total 
protein fraction was prepared through centrifugation (30’ x 12000 g, 4 °C). Protein concentrations 
were determined with a standard protein assay (Biorad, Veenendaal, The Netherlands).
For Western blot analysis, samples were corrected for protein amount, separated on a 10% 
polyacrylamide gel and transferred to a nitrocellulose membrane using the Iblot system 
(Invitrogen). The membrane was incubated overnight at 4 °C with the primary antibodies GaR 
KIM-1 (R&D Systems, Abingdon, UK) diluted 1:500 and MaM β-actin (Sigma-Aldrich) diluted 
1:100.000. Subsequently, the membrane was incubated at room temperature for 60 with 
the secondary antibodies alexa680-DaM and alexa800-DaG, diluted 1:5000. Proteins were 
visualized using the Odyssey Infrared Imaging Scanner (LI-COR®, Lincoln, NE). 
Data analysis
Data are given as means ± SEM Software used for statistical analysis was Graphpad Prism® 
(version 5.02 for Windows; Graphpad Software, San Diego, CA). Data were tested for normality 
using the Kolmogorov-Smirnov normality test. For renal function and renal damage data, 
mean values were considered to be significant when p<0.05 by use of a one-way ANOVA with 
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Bonferroni’s multiple comparison post-test. For data on the effect of 8-SPT on BP and HR, mean 
values were considered to be significant when p<0.05 by use of a two-way ANOVA (factors time 
and treatment) with Bonferroni’s post-test. For KIM-1 protein expression, semi-quantitative 
analysis was performed by correcting for ß-actin fluorescence and subsequently averaging and 
comparing the relative fluorescence between treatment groups.
Results
Mortality, HR and BP measurements
In total, 106 rats entered the renal IRI study, all of which survived until sacrifice on day 2. The 
average weight loss of the animals from baseline (prior to surgery, day 0) to sacrifice was 3.1 ± 
1.4 % for sham-operated animals, and 7.0 ± 2.4% for all other groups (p<0.01 versus sham). HR 
and BP were obtained from 43 animals in study II, every 3’ during the 60’ operating procedure 
(data not shown). Mean systolic blood pressure (SBP) during surgery was comparable in 
vehicle- and 8-SPT-treated groups (98 ± 6 versus 105 ± 8 mmHg), although a slight increase 
in BP was observed in the 8-SPT-treated group directly after administration of the compound. 
This difference disappeared over the following 3’. Mean HR did not differ between vehicle- and 
8-SPT-treated groups (354 ± 20 versus 361 ± 21 beats/min, NS). 
Study I: effects of stimulus protocol and tissue mass of brief hind limb ischemia on renal IRI
Renal damage - Renal IRI was assessed by analyzing post-op renal function, expression of the 
renal injury markers KIM-1 and NGAL in renal tissue, and proximal tubule damage. When 
compared to sham-operated animals, the 25’ renal ischemia applied in the No RIPC group 
caused a marked  decrease in creatinine clearance rate (Ccr), as well as an increase in plasma 
creatinine, plasma urea, fractional excretion of sodium (FENa) and urine glucose (Figure 2A-E; 
all parameters p<0.001 versus sham). Urine flow in the No RIPC group was also increased when 
compared to sham (Figure 2F, p<0.05). 
Furthermore, renal IRI caused extensive proximal tubule destruction and cast formation in the 
renal cortex, reflected by a significant increase in damage score from 0 ± 0.03 for sham to 4 
± 0.4 in the No RIPC group (Figure 3A-F and 3G). Furthermore, renal I/R significantly induced 
mRNA expression for both KIM-1 (2 ± 5 for sham versus 687 ± 197 for No RIPC) and NGAL (1 ± 
1 versus 16 ± 4; Figure 3H-I; p<0.001). For KIM-1, the increase in expression was confirmed at 
protein level (Figure 3J).
Protective effects of RIPC - The 12’/12’ bilateral, 3x 4’/4’ unilateral and 3x 4’/4’ bilateral 
protocols were effective in ameliorating renal function after IRI (Figure 2A-F). The effects were 
most pronounced for the two bilateral hind limb ischemia protocols: when compared to the No 
RIPC group, these protocols reduced plasma creatinine by 32-44%, plasma urea by 31-53% and 
FENa up to 59%. The Ccr was improved by respectively 49% and 62%, by the 12’/12’ bilateral 
and 3x 4’/4’ bilateral protocol. Urine glucose (corrected for creatinine) was reduced by 40% in 
the 12’/12’ bilateral group. The unilateral 3x 4’/4’ protocol reduced plasma urea by 29%. The 
3x 4’/4’ bilateral protocol and both unilateral protocols prevented the increase in urine flow 
observed in the No RIPC group. On average, bilateral RIPC improved 5 out of 6 renal function 
parameters, while for unilateral protocols this was 1.5 out of 6 parameters. Furthermore, 
the continuous 12’/12’ protocols improved 3 out of 6 parameters of renal function, while 
fractionated 3x 4’/4’ protocols had a positive effect on 3.5 out of 6 parameters (see also Table 
1).
Remote ischemic preconditioning against renal IRI: the role of adenosine|57
Renal proximal tubule damage was assessed by blinded scoring of the renal cortex, which 
revealed that the 12’/12’ unilateral, 3x 4’/4’ unilateral and 3x 4’/4’ bilateral protocols reduced 
the damage score by 39%, 18% and 47%, respectively (Figure 3G). Interestingly, the 12’/12’ 
bilateral protocol had no effect on proximal tubule damage, in spite of its beneficial effects on 
renal function.
The expression of renal injury markers KIM-1 and NGAL was first determined at mRNA level 
(Figure 3H-I). Relative KIM-1 expression was induced over 600-fold in the No RIPC group, which 
was reduced by 25% for the 12’/12’ unilateral protocol, and by 40% for the 3x 4’/4’ bilateral 
protocol. No changes in NGAL mRNA expression were observed after RIPC when compared 
to the No RIPC group. KIM-1 induction was confirmed at protein level: the 12’/12’ unilateral 
and both 3x 4’/4’ protocols reduced KIM-1 protein levels by 25-33% compared to No RIPC 
(Figure 3J). Similar to the proximal tubule damage score, the 12’/12’ bilateral protocol was 
without effect. Since no changes in NGAL mRNA were observed, NGAL protein expression was 
not measured.
An overview of the parameters for renal damage which improved after RIPC is given in Table 
1. We confer that bilateral protocols were more effective than unilateral protocols, whilst the 
fractionated protocol appeared to be slightly more effective than the continuous one.
Table 1|The effectiveness of 4 RIPC protocols in reducing renal IRI. Rats underwent RIPC 
by either 12’/12’ of hind limb ischemia/reperfusion (I/R), or 3 cycles of 4’/4’ I/R. The RIPC 
stimulus was applied to either one (unilateral) or both (bilateral) hind limbs. Renal IRI was 
determined using five parameters of renal function (plasma creatinine, plasma urea, Ccr, 
FENa, urine glucose) and two parameters of renal damage, namely KIM-1 expression (mRNA 
and/or protein) and renal damage score by histology.
# improved parameters 
renal function
# improved parameters 
renal damage
Total
Unilateral 12’/12’ I/R 1 2 33x 4’/4’ I/R 2 1 3
Bilateral 12’/12’ I/R 5 1 63x 4’/4’ I/R 5 2 7
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Figure 2|Various protocols of RIPC by brief hind limb ischemia improve renal function after 
IRI.  Rats underwent sham operation, or 25’ of renal ischemia and 48h reperfusion. Prior 
to renal ischemia, rats received either No RIPC, a continuous stimulus of 12’/12’ ischemia/
reperfusion (I/R) or a fractionated stimulus of 3 cycles of 4’/4’ I/R. The stimulus was applied to 
either 1 (unilat) or 2 (bilat) hind limbs. Renal ischemia significantly impaired renal function, as 
assessed by plasma creatinine, plasma urea, creatinine clearance rate (Ccr), fractional sodium 
excretion (FENa), urine glucose and urine flow. RIPC significantly ameliorated renal IRI and the 
affected parameters were dependent on the stimulus protocol. Bilaterally applied hind limb 
ischemia was more effective in improving renal function parameters than unilateral hind limb 
ischemia. Fractionated RIPC was slightly more effective than continuous RIPC. N=6-11 rats per 
group. ap<0.001 versus sham; *p<0.05, **p<0.01 versus No RIPC.
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Figure 3A-F|RIPC by brief hind limb ischemia reduces tubular damage and renal injury 
markers after IRI. See Figure 1 or text for experimental design. (A-F) Representative images of 
PAS stained kidney sections, showing 6 levels of proximal tubule damage after I/R. Subsequent 
images represent damage scores 0 to 5, as defined by respectively 0%, 1-10%, 11-30%, 31-60%, 
61-80% and 81-100% of the tubules showing damage and cast formation.
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Figure 3G-J|RIPC by brief hind limb ischemia reduces tubular damage and renal injury 
markers after IRI. See Figure 1 or text for experimental design. (G) the proximal tubule damage 
score as assessed by histology of the renal cortex indicated a marked increase in damage score 
after IRI. The proximal tubule damage was reduced by 3 out of 4 RIPC protocols. (H-J) twenty-
five minutes of renal ischemia led to a significant induction of the renal injury markers KIM-1 
and NGAL. RIPC by brief hind limb ischemia reduced mRNA levels of KIM-1 for 2 out of 4 RIPC 
protocols (I). No changes in NGAL mRNA levels were observed after RIPC (J). KIM-1 protein 
levels were reduced by 3 out of 4 RIPC protocols (H).N=6-11 rats per group. All groups p<0.001 
versus sham; *p<0.05, **p<0.01 versus No RIPC.
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Effects of adenosine receptor antagonist 8-SPT on BP and HR
In order to assess whether a dose of 30mg/kg 8-SPT is effective in inhibiting adenosine-
mediated effects, we administered adenosine via i.v. infusion in the presence or absence of 
8-SPT and monitored SBP and HR. Adenosine infusion induced a 50% decrease in SBP, which 
was significantly reduced by pre-treatment with 8-SPT (figure 4A). Similarly, pre-treatment 
with 8-SPT prevented the adenosine-induced 16% drop in HR seen in vehicle-treated animals 
(Figure 4B).
Figure 4|Effects of adenosine and 8-SPT on systolic blood pressure (SBP) and heart rate (HR). 
(A) Rats treated with adenosine (t=0-5) show a decline in SBP, which could be inhibited by pre-
treatment (t=-3) with the adenosine receptor blocker 8-SPT. 8-SPT-treated rats showed a slight 
increase in SBP after 8’, when compared to baseline. (B) Rats treated with adenosine (t=0-5) 
show a decline in HR, which could be prevented by pre-treatment with 8-SPT. Note that vehicle 
treated rats show a decrease in heart rate, in spite of the fact that their baseline HR appeared 
to be higher than in the 8-SPT group, although this was not significant. N=6 rats per group. 
#p<0.05 versus baseline; *p<0.05 versus vehicle. 
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Study II: no involvement of adenosine in two protocols of RIPC by brief hind limb ischemia
To test the involvement of adenosine in RIPC of the kidney by brief hind limb ischemia, rats 
were pre-treated with vehicle or 8-SPT and preconditioned with either 12/’12’ or 4’/4’ of hind 
limb I/R, before undergoing 25’ of renal ischemia. Since study I indicated that bilateral RIPC 
protocols are most effective in reducing renal IRI, all RIPC stimuli were applied to both hind 
limbs. As in study I, 25’ of renal ischemia caused a significant reduction in renal function, as 
assessed by plasma creatinine, plasma urea, Ccr and FENa (Figure 5A-D). No effects on urine flow 
were observed. Renal function was ameliorated by both the fractionated and the continuous 
RIPC protocol. Treatment with 8-SPT had no influence on the RIPC-induced improvement of 
renal function.
Figure 5|Adenosine is not involved in two protocols of RIPC by brief hind limb ischemia. 
Rats underwent sham operation, or 25’ of renal ischemia and 48h reperfusion. Prior to renal 
ischemia, rats received either no hind limb ischemia (No RIPC), a continuous stimulus of 12’/12’ 
ischemia/reperfusion (I/R) or a fractionated stimulus of 3 cycles of 4’/4’ I/R (always bilateral). 
Renal ischemia significantly impaired renal function, as assessed by plasma creatinine (A), 
plasma urea (B), creatinine clearance (Ccr; C) and fractional sodium excretion (FENa; D). 
Both continuous and fractionated RIPC protocols significantly ameliorated renal IRI. For both 
protocols, pre-treatment with 8-SPT had no effect on the RIPC induced renal protection. N=6-
11 rats per group. All groups p<0.001 versus sham; *p<0.05, **p<0.01 versus No RIPC.
Remote ischemic preconditioning against renal IRI: the role of adenosine|63
Discussion
The present study is the first to show protective effects of brief limb ischemia by BP cuff 
occlusion on the kidney after IRI. In line with literature, our data demonstrate that transient 
hind limb ischemia is a promising technique for clinical application. The first clinical trials 
of RIPC in cardiovascular surgery have shown promising results (18; 19). The present study, 
however, extends the possibilities for clinical application of RIPC by limb ischemia to the field 
of renal disease and transplantation. 
The optimization of RIPC protocols, including brief hind limb ischemia, has received only 
very limited attention. For the first time, we report that occlusion of two hind limbs is more 
effective than one, indicating that there may be a certain threshold for protection depending 
on the mass of the remote tissue/organ. Furthermore, we have compared fractionated and 
continuous stimulus protocols for the organ combination hind limb-kidney. In two previous 
studies that compared fractionated and continuous MAO, the continuous protocol was more 
effective in reducing myocardial infarct size than the fractionated protocol. Our present 
findings, however, indicate the fractionated protocol to be slightly more effective in reducing 
renal IRI. We hypothesize that the effect of fractionation may depend on the remote and/or 
target organ, and on the precise duration of the I/R cycles. 
Remarkably, we observed that renal damage, as assessed by morphology and injury marker 
expression, was not always in line with renal function. There are several explanations for 
this difference in correlation, e.g. residual tubules are capable of increasing function, or the 
observed tubular lesions may not represent all aspects of morphological damage.
Much effort is being invested to elucidate the mechanism underlying RIPC, especially the 
signalling pathways that transfer protection from the remote to the target organ. Most studies 
focus on RIPC of the heart (in combination with several remote organs), and both humoral 
and neurogenic pathways have been proposed. Although damage can be reduced markedly, 
RIPC rarely elicits 100% protection against IRI. This emphasizes the importance of detailed 
knowledge of RIPC signalling routes, as this may enable us to pharmacologically enhance 
or mimic its protective effects. Adenosine would be a possible target for pharmacological 
enhancement by statins and dipyridamole, which respectively enhance adenosine formation 
and reduce extracellular adenosine clearance. 
Because of its rapid cellular uptake and conversion into inosine and adenosine-monophosphate, 
adenosine has a very short half-life and low bioavailability in vivo. Therefore, it is difficult to 
measure levels of free adenosine in plasma. In a study by Dickson et al. [123], adenosine levels 
in the coronary effluent from preconditioned rabbit hearts were not increased, although it 
is unclear whether adenosine breakdown was sufficiently inhibited during sample collection. 
Several groups tried to identify the nature of humoral RIPC signalling molecule(s) by dialysis 
or purification of serum from preconditioned organs. Effluent from preconditioned rat hearts 
protected other isolated rat hearts from IRI, even after dialysis over a 3500 Da filter [124]. 
Furthermore, C18 column eluate of serum from preconditioned organs confers protection, 
indicating the presence of a low-weight, hydrophobic protective substance (21, 20, 22). As 
adenosine is rapidly metabolized, its presence in such processed samples is unlikely. 
Due to the difficulties in measuring adenosine directly, most studies on its role in RIPC employ 
adenosine receptor antagonists (Table 2). Effects of 8-SPT on RIPC were found at doses of 7.5 to 
50 mg/kg; the dose of 30 mg/kg 8-SPT used in the present study is therefore in the dose range 
commonly used in literature. Our adenosine-8-SPT interaction study confirmed full antagonism 
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of the A1 receptor as reflected by the lack of HR response in the presence of 8-SPT. The BP drop 
was significantly inhibited indicating at least partial A2 receptor blockade. This partial effect 
might also be attributed to the dose of adenosine used, which conceivably was higher and more 
long-lasting than adenosine release under physiological conditions. Furthermore, it should 
be noted that the degree to which 8-SPT antagonizes the different adenosine receptors may 
possibly be different for exogenously administered versus endogenously released adenosine. 
This is due to adenosine’s short half-life, as well as the fact that exogenous adenosine is 
unlikely to reach the interstitial space, as the endothelium acts as an active metabolic barrier 
for adenosine.
Four studies, using either the kidney or the intestine as remote organ, reported that adenosine 
receptor antagonists abolished RIPC of the heart. Especially A1 and A3 receptors were 
implicated in a study by Liem et al. [112]. In contrast, a study on RIPC by hind limb ischemia 
on muscle flap IRI reported no effect of either non-selective or A3-specific antagonists [126]. 
The latter observation is in line with our finding that hind limb ischemia induces RIPC via an 
adenosine independent mechanism.
 
Table 2|Overview of studies on the involvement of adenosine in RIPC.
Target 
organ
Remote 
organ
I/R 
protocol
Read-out Findings
Adenosine 
involved?
Ref.
Heart Heart 3x 5’/10’
ADO levels in 
coronary effluent 
No 
elevated 
ADO 
levels
No
Dickson et 
al.[123]
Heart Kidney 10’/20’
8-SPT treatment 
(10 mg/kg)
RIPC 
abolished
Yes
Takaoka 
et al.[116]
Heart Intestine 15’/10’
8-SPT treatment 
(10 or 50 mg/kg)
MRS1191 
treatment (3.3 
mg/kg)
RIPC 
abolished
Yes (AR1 
and AR3)
Liem et 
al.[112]
Muscle 
flap
Hind 
limb
3x 
10’/10’
8-SPT treatment 
(10 mg/kg) 
DPCPX 
(3 mg/muscle 
flap)
No effect 
on RIPC
No (AR1 
and AR3)
Addison 
et al.[126]
Heart Kidney 10’/10’
8-SPT treatment 
(7.5 mg/kg)
RIPC 
abolished
Yes
Pell et 
al.[117]
Heart Kidney 10’/10’
8-SPT treatment 
(10mg/kg)
Renal 
afferent 
firing 
abolished
Yes 
(neuronal)
Ding et 
al.[127]
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The distribution of the four known adenosine receptor subtypes A1, A2a, A2b and A3 differs 
among tissues [128,129]: the rat kidney expresses low levels of all four receptor subtypes, 
while the heart expresses low levels of A1, A2b and A3, and moderate levels of A2a. Skeletal 
muscle contains high levels of A2a and moderate levels of A2b, but lacks any expression of A1 
and A3. Lastly, the intestine expresses low levels of A3, while the other sub-types are expressed 
at barely detectable levels (A1, A2b) or not at all (A2a). Two studies reported that adenosine 
contributes to a neurogenic pathway initiated in the remote organ and leading to RIPC of the 
heart, although the receptor subtype involved has not been identified [127,112]. However, 
these studies used the intestine and kidney as remote organs, both of which express A3 and 
A1, while the present study and that of Addison et al. [126] used the hind limb, which lacks 
these receptor sub-types. We hypothesize that, upon brief ischemia of the intestine or kidney, 
adenosine activates a neurogenic pathway via A1 and/or A3 receptors which induces RIPC, 
and that this pathway is not present in the hind limb, or interstitial adenosine formation may 
be insufficient to stimulate afferents during the RIPC protocols in resting muscle. Secondly, 
differences in adenosine receptor expression in the target organ may contribute to the 
difference in signalling pathways. 
Finally, we cannot exclude that residual A2 receptor stimulation was sufficient to mediate 
full RIPC protection of the kidney. In order to investigate the specific involvement of all three 
adenosine receptor subtypes, specific antagonists such as MRS-1191 or BW-1433 should be 
employed. More likely however, adenosine is not (solely) responsible for the renal protection 
induced by hind limb I/R, and alternative substances are released from the hind limb or renal 
autonomic nerve terminals, which mediate RIPC. 
If not adenosine, then which substance could be responsible for RIPC by hind limb ischemia? The 
number of substances found to be involved in RIPC is ever-increasing and now includes opiates, 
endocannabinoids, nitric oxide, heme oxygenase and many others [15]. We hypothesize that 
an assembly of substances is released from the remote organ, and that its composition differs 
between organs. The relative importance of a compound can be large, so that RIPC is abolished 
upon blocking this compound, or small, in which case RIPC will remain detectable. As such, 
testing individual compounds by administrating specific antagonists may prove ineffective, as 
none of the compounds may abolish RIPC by itself. An alternative approach would be to test the 
effect of sets of antagonists, and attempt to rank the signalling compounds according to their 
relative contribution to RIPC. However, adverse drug-drug interactions could be a disadvantage 
of this approach. 
We conclude that, similar to the heart, the kidney is an important target organ for the clinical 
application of RIPC, e.g. post-transplantation. We have shown that RIPC by brief BP cuff 
occlusion of a hind limb is an effective, non-invasive and low-cost tool to reduce renal damage 
after IRI. The effectiveness of RIPC depends on the mass of remote tissue and the protection 
appears to be independent of adenosine. Future studies on the signalling pathway of RIPC by 
brief limb occlusion will facilitate and optimize its clinical implementation. 
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Humoral signalling compounds in renal RIPC: a role for the opioid receptor|69
Renal ischemia-reperfusion injury (IRI) is a common clinical problem associated with significant mortality and morbidity. One strategy to reduce this damage is remote ischemic preconditioning (RIPC), in which brief ischemia of a limb protects the kidney 
against a prolonged ischemic insult. The mechanism of renal RIPC has not yet been elucidated. 
Here, we address the gap in our understanding of renal RIPC signalling, using a rat model of 
renal IRI and RIPC by brief hind limb ischemia.
Rats were treated with either no RIPC, RIPC + vehicle, or RIPC + an inhibitor or antagonist of one 
of the following candidate signalling molecules: noradrenalin, cannabinoids, glucocorticoids, 
inducible nitric oxide synthase, calcitonin gene-related peptide, ganglion-mediated signalling, 
heme oxygenase and free radicals. Subsequently, animals underwent 25’ of renal ischemia and 
two days of reperfusion, after which renal function and damage were assessed.
RIPC by three 4’ cycles of hind limb ischemia effectively reduced renal IRI. Pre-treatment 
with the opioid receptor antagonist naloxone completely blocked this protective effect, 
when compared to animals treated with RIPC + vehicle; serum creatinine and urea increased 
(respectively 307.8±43.7 versus 169.5±16.7 µmol/l and 42.2±4.9 versus 27.6±2.2 mmol/l), 
as did the renal histological damage (score 4.2±0.7 versus 2.8±0.5) and expression of Kidney 
Injury Molecule-1 (relative fold increase in mRNA expression 164±18 versus 304±33). All other 
antagonists were without effect.
Renal RIPC by brief hind limb ischemia may be the result of endorphin release from the hind 
limb. The importance of opioid signalling in renal RIPC provides vital clues for its successful 
translation to the clinical setting. 
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Introduction
Renal IRI is a common complication following e.g. renal artery stenosis, renal surgery, shock, 
transplantation, and cardiac and aortic surgery [34,31,30,35]. Renal IRI is a common cause of 
acute kidney injury, a condition results in significant mortality and morbidity [130–132]. Current 
strategies to reduce this clinical problem are inadequate and novel therapies are needed.
One strategy to reduce renal IRI is RIPC, in which a brief ischemic stimulus to a remote organ 
confers protection against a prolonged ischemic insult in another organ. This phenomenon was 
discovered in the dog heart [14] and has since been reproduced using a variety of remote and 
target organs [15]. For the kidney, we have recently shown that brief ischemia of the hind limb 
in rats improves renal function and reduces renal damage after IRI [37]. This finding is in line 
with a study in patients undergoing elective abdominal aortic aneurysm repair, in which brief 
common iliac artery occlusion significantly lowered serum creatinine [39]. Thus, RIPC is also a 
promising tool to reduce renal IRI in a clinical setting.
The signalling mechanism underlying RIPC has been studied almost exclusively in the heart 
and has been attributed to both neurogenic pathways [114,115], as well as the release 
of biochemical messengers into the circulation [16,15]. However, transmission may differ 
depending on the stimulus protocol, target organ and remote organ. In studies on (mainly) 
cardiac RIPC, bradykinin, opioid, calcitonin gene-related peptide (CGRP), noradrenalin, nitric 
oxide synthase (NOS) and corticosteroids were reported to be key signalling compounds [15], 
and one study in liver has shown a role for heme-oxygenase-1 (HO-1) [133]. For the kidney, 
studies on RIPC signalling are sparse. We have recently demonstrated that the adenosine 
receptor antagonist 8-(p-sulphofenyl)theophilline (8-SPT), which has been effective in blocking 
RIPC in the heart, has no effect on renal RIPC by hind limb ischemia [37]. 
In the current study, we address some of the gaps in understanding of renal RIPC signalling. 
We tested the involvement of a number of signalling molecules in renal RIPC, based on the 
hypothesis that compounds previously identified in cardiac and other models of RIPC are good 
candidates for renal RIPC signalling. Therefore, we selected a set of receptor antagonists and 
inhibitors to block these candidate compounds in a rat model of brief hind limb ischemia and 
renal IRI. 
Materials and Methods
Animals
All procedures involving animals were approved by the Committee for Animal Experiments 
of the Radboud University Nijmegen. Adult male Sprague-Dawley rats (Harlan Laboratories, 
Eystrup, Germany), weighing 327 ± 18 grams on the day of surgery, were housed under 
standard specific pathogen free housing conditions at the Central Animal Facility Nijmegen. 
Animals used in this study were tested and found to be free of Hantavirus, Sendai virus, Kilham 
rat virus, Toolan’s H-1 virus, RCV/SDA, mouse pneumonia virus, mouse adenovirus FL, mouse 
adenovirus K87, reovirus type 3, rat parvovirus (rNS-1), Clostridium piliforme, Mycoplasma 
pulmonis, Bordetella bronchiseptica, Corynebacterium kutscheri, Pasteurellaceae, Salmonella 
spp., Streptobacil moniliformis, ß-haemolytic Streptococci, Streptococcus pneumonia, 
Klebsiella oxytoca, Klebsiella pneumonia, Pseudomonas aeruginosa, Staphylococcus aureus, 
Pneumocystis carinii, Helicobacter spp., Helicobacter bilis, dermatophytes, ectoparasites, 
pathogenic protozoa, non-pathogenic protozoa and helminthes.
Rats were housed in pairs in Macrolon cages (Techniplast-Gazzada, Buguggiatta, Italy), supplied 
with woody bedding, nesting material and shelters. They had ad libitum access to drinking water 
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and standard chow (RMH-TM, Hope Farms, Woerden, The Netherlands). The environmental 
temperature was regulated at 22 °C, with a relative humidity of ± 45% and a 12/12 h day/night 
cycle in artificial lighting with white lights on at 06:00 h. Radio sound was played during the day 
period. Air was refreshed at the rate of approximately six times per hour. Rats were allowed to 
acclimatize for at least one week before surgery.
Study Design
An overview of the study design and all experimental groups is given in Figure 1. For ethical 
reasons, the study was performed in two phases: a screening phase, in which we selected 
the most promising compounds out of the initial nine, and an confirmation phase. Only those 
interventions that showed a predefined minimal effect size in the screening phase entered the 
confirmation phase.
Part 1: screening. Fifty-six rats were randomized into twelve experimental groups. Four rats 
were sham-operated. Fifty-two rats underwent 25’ of renal ischemia and were either not 
preconditioned (no RIPC, n=9) or underwent three cycles of 4’/4’ I/R in both hind limbs. Of 
the preconditioned animals, seven were treated with vehicle (RIPC + vehicle) and 36 animals 
were treated with one of the nine selected possible inhibitors or antagonists of RIPC signalling 
molecules (n=4 per group).
Part 2: confirmation. Four interventions passed the first screening. In part 2, forty-two rats 
were randomized over the following groups: the selected experimental groups were expanded 
with six animals each, leading to a total of ten animals per group. A second control group 
was added to assess the effect of dimethyl sulfoxide (DMSO) and peanut oil (vehicle for the 
AM251+ AM630 and mifepristone groups) on RIPC (n=10). To ensure similar conditions for the 
control and treatment groups, the no RIPC and RIPC + vehicle groups were expanded with four 
animals each (total n=13 and n=11, respectively). 
Surgical procedures
All surgical procedures were performed using standard aseptic surgical techniques. Analgesic 
(carprofen, 5 mg/kg b.w.) was administered s.c. 30’ prior to surgery. Anaesthesia was induced 
with 5% isoflurane in O
2
/N
2
O and maintained at 2-3%. Animals were placed on a sterile drape 
overlying a heating pad to maintain body temperature, which was monitored at 37.5 ± 0.5 °C. 
The incision site on the abdomen was shaved, iodized and covered with sterile surgical foil. 
Prior to the RIPC protocol, drug administration was performed i.p. or i.v. as indicated in Table 
1, Figure 1 and described under Drug dosage. In the current study, we used a fractionated 
RIPC protocol applied to both hind limbs, which was based on our previous finding that a 
fractionated protocol may be more effective than a continuous stimulus of the same duration, 
and that the effectiveness of the remote stimulus is dependent on tissue mass [37]. 
Briefly, RIPC by brief hind limb ischemia was induced by applying small blood pressure cuffs 
around the proximal thighs, which were inflated to 300 mmHg. Successful occlusion of the 
bloodstream was confirmed using a pulseoxymeter clip placed on the foot. The RIPC protocol 
consisted of three cycles of 4’ ischemia and 4’ reperfusion. In case of sham operation or renal 
ischemia only, there was a waiting period of 24’ before renal IRI induction. During the last 
12’ of the RIPC protocol, rats underwent laparotomy. Directly after completion of the RIPC 
protocol, the renal vein and artery of the right kidney were clamped for 25’. The left kidney 
was nephrectomised.
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Figure 1|Schematic overview of the study design and experimental groups. Number of animals 
per group is indicated between brackets. NAC = N-acetylcholine, hex = hexamethonium, AMG = 
aminoguanidine, mifepri = mifepristone, AM-mix = AM251+ AM630. For further abbreviations 
and details see Materials and Methods. 
One day post-op, analgesic (carprofen, 5 mg/kg b.w.) was administered s.c. and a venous 
blood sample was collected via the tail vein. On day 2 post-op, rats were anesthetized with 5% 
isoflurane in O
2
/N
2
O and sacrificed by exsanguination, followed by cervical dislocation. Blood 
samples were obtained and the right kidney was excised and divided into four quarters.
Drug dosage
Based on literature research on RIPC in other organs, we selected nine compounds for 
this study, and determined their dose and time of administration (see Table 1): opioids, 
noradrenalin, cannabinoids, glucocorticoids, iNOS, CGRP, ganglion-mediated signalling, 
HO-1 and free radicals. The selected antagonists or inhibitors for each of these compounds 
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were: naloxone (opioid receptor μ, κ and δ antagonist; Sigma-Aldrich, Zwijndrecht, The 
Netherlands), labetalol (mixed non-selective β and selective α
1
-adrenergic receptor antagonist; 
Sigma-Aldrich), AM251+ AM630 (cannabinoid receptor type 1 and 2 inverse agonists; Tocris 
Bioscience, Bristol, UK), mifepristone (glucocorticoid receptor antagonist; Tocris Bioscience), 
aminoguanidine (AMG, iNOS inhibitor; Sigma-Aldrich), CGRP
8-37
 (CGRP receptor antagonist; 
Tocris Bioscience), hexamethonium (ganglionic nicotinic acetylcholine receptor antagonist; 
Sigma-Aldrich), N-acetylcysteine (NAC, free radical scavenger; Sigma-Aldrich) and SnMP (tin-
mesoporphyrin, HO inhibitor; Enzo Life Sciences, Antwerp, Belgium). The optimal route and 
time of administration and solvent were based on compound solubility, half-life and literature 
(see Table 1 and Figure 1). Hank’s balanced salt solution (HBSS) + 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer was used as vehicle in the control group.
Tissue handling
Blood samples were collected in EDTA or heparinised tubes and centrifuged for 5 at 14000 
g to obtain plasma. Plasma and renal tissue samples were snap frozen in liquid nitrogen and 
stored at -80 °C until further use. For RNA isolation, frozen tissue was pulverized using a micro-
dismembrator (Sartorius BBI Systems GmbH, Melsungen, Germany), as described previously 
[120]. 
Histology
For damage scoring by light microscopy, the posterior quarter of the lower pole of each kidney 
was fixed in buffered formalin for at least 24 h. Tissue was then dehydrated and embedded in 
paraffin. Five μm sections were stained with periodic acid-Schiff (PAS). For each kidney, three 
sections taken at different latitudes were scored for damage and cast formation in the renal 
cortex and averaged. Damage scoring was performed on a scale from 0 to 5, with 0 signifying 
no proximal tubule damage, and 5 indicating that over 95% of tubules were damaged (Figure 
3A-F and legend). All scores were performed in triplicate by the same investigator (KW), who 
was blinded for treatment allocation.
Real-time quantitative PCR
Total RNA was isolated from pulverized kidney tissue with Trizol reagent (Invitrogen, Breda, The 
Netherlands), pelleted by centrifugation (10’ x 12000 g, 4 oC) and resuspended in DEPC-treated 
water. Reverse transcription with Mo-MLV reverse transcriptase (Invitrogen) was performed 
on 1 µg RNA. Real-time quantitative (rt-Q) PCR was performed in duplo on approximately 1 ng 
cDNA, using the ABI/PRISM 7900HT Gene Expression Micro Fluidic Card (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s instructions. cDNA amplification was 
performed in Taqman® Universal PCR Master Mix, supplemented with 20x solution of primer 
probe sets for the renal injury markers KIM-1 and the housekeeping gene β-actin (respectively 
Rn00667669_m1 and Rn00597703_m1; all from Applied Biosystems). Rt-Q PCR reactions were 
analyzed using 700 System Sequence Detection Software (version 1.2.3, Applied Biosystems).
Data analysis
Data are given as means ± SEM. Software used for statistical analysis was Graphpad Prism® 
(version 5.02 for Windows; Graphpad Software, San Diego, CA). Data were tested for 
normality using the Kolmogorov-Smirnov normality test. In part 1 of the study (screening), we 
determined which of the nine treatment groups were eligible for inclusion in part 2 of the study 
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(confirmation). The criterion for inclusion in part 2 of the study was predetermined as follows: 
a ≥20% increase in either the average plasma creatinine or plasma urea above threshold, as 
measured after 24 or 48 h of reperfusion. The threshold was set at the corresponding average 
of the RIPC + vehicle group (see also Figure 2). The renal function data of the no RIPC and 
the RIPC + vehicle group were compared using Student’s T-test. In part 2 (confirmation), 
all data were tested using a one-way ANOVA with Dunnetts multiple comparison post-test. 
Mean values were considered to be significant when p<0.05. For the Rt-Q PCR data, we first 
calculated the difference in cycle time (ΔCT) values between KIM-1 mRNA and the household 
gene β-actin. We then calculated the difference in ΔCT (ΔΔCT) by comparing each value to the 
average KIM-1 expression in the sham control group. The ΔΔCT was converted to fold change 
versus sham and plotted. 
Results
Morbidity and mortality
In total, 98 rats entered the study, all of which survived until sacrifice on day 2. The average 
weight loss of the animals from baseline to sacrifice was 2.8±0.7% for sham-operated animals 
and 6.5±2.3% for all other groups (P<0.01 versus sham). One animal in the RIPC + labetalol 
group and one animal in the mifepristone + RIPC group were excluded from the experiment 
because the kidney failed to reperfuse properly after clamp removal.
Part 1: screening of nine potential signalling molecules for their involvement in renal RIPC by 
brief hind limb ischemia.
Renal function - Renal function was evaluated by measuring plasma sodium, urea and creatinine, 
24 and 48 h after renal IRI. No difference in plasma sodium was observed between animals 
undergoing renal IRI (no RIPC group) and sham-operated animals (129±1 versus 129±1 mmol/l 
after 24 h and 146±0 versus 145±1 mmol/l after 48 h). When compared to sham-operated 
animals, plasma urea and plasma creatinine were significantly increased after renal IRI in the 
no RIPC group, both 24 and 48 h post-op (Figure 2A-D).  
An RIPC stimulus of three cycles of 4’/4’ I/R of both hind limbs improved renal function after 
24 and 48 h, as indicated by a decrease in plasma urea and creatinine in vehicle-treated rats 
undergoing RIPC and renal IRI. This difference appeared to be most pronounced after 48 h. 
RIPC reduced  the IRI-induced increase in plasma urea by 16% after 24 h and by 36% after 48 
h, as compared to the no RIPC group (respectively 34±2 versus 28±1 mmol/l, P<0.01, and 44±3 
versus 28±2 mmol/l, P<0.01). Similarly, RIPC reduced the rise in plasma creatinine by 26% after 
24 h and 41% after 48 h (respectively 256±23 versus 187±14 µmol/l, P<0.01, and 291±26 versus 
170±17 µmol/l, P<0.01). 
The plasma urea and creatinine levels of the RIPC + vehicle group were used as a threshold 
for comparison of nine groups undergoing RIPC combined with treatment with a candidate 
signalling compound antagonist or inhibitor. In four out of nine groups, urea and creatinine 
levels substantially increased when compared to vehicle-treated rats. Thus, four interventions 
(inhibition of opioid, noradrenalin, cannabinoid and glucocorticoid signalling) met the pre-
specified inclusion criterion for part 2 of the study (Figure 2). Inhibition of signalling via CGRP, 
ganglion, HO-1 or free radicals had no apparent effect on the RIPC-mediated improvement 
of renal function and did therefore not meet our inclusion criterion. For iNOS inhibition, very 
high standard deviations were observed, making it difficult to assess whether this compound 
is involved in RIPC signalling. Thus, we did not include the AMG group in the second part of 
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our study.
Figure 2|Screening of potential inhibitors of RIPC-induced renoprotection. RIPC reduces 
plasma creatinine (upper panels) and plasma urea (lower panels) 24 h and 48 h after renal 
ischemia-reperfusion injury by 16-41%. Treatment with antagonists or inhibitors of opioid-, 
noradrenalin-, cannabinoid-, glucocorticoid- and iNOS-signalling met our prespecified inclusion 
criterion, and were therefore selected for part 2 of our study. Inhibition of signalling via CGRP, 
ganglion, HO-1 or free radicals had no apparent effect on the RIPC-mediated renal protection. 
HO-1 = heme oxygenase-1, iNOS = inducible nitric oxide synthethase, CGRP = calcitonin gene-
related peptide; All groups P<0.05 versus sham, #P<0.01 from RIPC + vehicle group by Student’s 
T-test; n=7-9 for no RIPC and vehicle group, n=4 for all other groups. AM-mix = AM251+ AM630, 
AMG = aminoguanidine, CGRP = calcitonin gene-related peptide, HEX = hexamethonium, SnMP 
= tin-mesoporphyrin, NAC = N-acetylcysteine
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Part 2: involvement of opioid, noradrenalin, cannabinoid and glucocorticoid signalling in renal 
RIPC by brief hind limb ischemia
Renal function - Four compounds, namely opioids, noradrenalin, cannabinoids and 
glucocorticoids, were selected for expansion of the experimental groups to ten animals per 
group. RIPC-treatment in combination with the opioid receptor antagonist naloxone abolished 
the protective effect on renal function seen in rats treated with RIPC + vehicle (Figure 3). After 
48 h of reperfusion, serum creatinine was increased in rats treated with RIPC + naloxone, when 
compared to treatment with RIPC + vehicle (307.8±43.7 versus 169.5±16.7 µmol/l; P<0.05). 
The same effect was observed for the RIPC-mediated reduction in serum urea, which was 
also completely abolished by naloxone (42.2±4.9 versus 27.6±2.2 mmol/l; P<0.05). A similar 
trend towards decreased renal function was observed after 24 h of reperfusion, however this 
difference did not reach significance. For animals treated with antagonists of noradrenalin, 
cannabinoid or glucocorticoid receptors, no significant change in serum creatinine or urea 
was observed when compared to RIPC + vehicle, after 24 or 48 h reperfusion. Treatment with 
DMSO or peanut oil alone (vehicle for AM251+AM630 and mifepristone) had no effect on RIPC 
efficacy (data not shown). These observations indicate that RIPC by brief hind limb ischemia 
mobilizes and/or releases endogenous opioids into the circulation, which mediate protection 
against renal IRI. 
Renal histology - In line with renal function data, renal damage as assessed by histology scoring 
was absent in sham-operated animals (Figure 4F; damage score 0.0±0.1), and severe in animals 
undergoing renal IRI without RIPC (score 4.2±0.7). RIPC markedly reduced this damage (score 
2.8±0.5; P<0.01), and this protective effect was blocked by treatment with opioid receptor 
blocker naloxone (score 3.9±0.6; P<0.05), but not by inhibitors of cannabinoids, noradrenalin 
or glucocorticoids.
Renal injury markers - We observed an average cycle time of 17.8 for the household gene 
β-actin (SD 1.7), which was used to determine the relative increase of KIM-1 expression in 
the various experimental groups. In line with our previous experiments [37], we observed an 
increase in the mRNA expression of the renal damage marker KIM-1 in animals undergoing 
renal IRI and 48 hours of reperfusion (227±44 fold change versus sham; Figure 5). RIPC by 
brief hind limb ischemia effectively reduced KIM-1 expression (164±18 fold change). In line 
with our results for renal function and histological damage, the opioid inhibitor naloxone 
effectively blocked the protective effect of RIPC (304±33 fold change; P<0.05). Administration 
of mifepristone, labetalol or AM251+AM630 was without effect.
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Figure 3|Effect of preselected interventions on RIPC-induced protection. RIPC reduces plasma 
creatinine (upper panels) and plasma urea (lower panels) 24 h and 48 h after renal ischemia-
reperfusion injury. Treatment with the opioid receptor antagonist naloxone prevented the 
RIPC-mediated improvement in renal function. Inhibition of noradrenalin-, cannabinoid- and 
glucocorticoid-signalling did not affect the RIPC-mediated renal protection. #p<0.01 from RIPC 
+ vehicle group by Student’s T-test; All groups P<0.05 versus sham, *P<0.05 from RIPC + vehicle 
group by one-way ANOVA; n=11-13 for no RIPC and vehicle group, n=4 for sham group, n=9-10 
for all other groups. AM-mix = AM251+ AM630.
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Figure 4|Remote ischemic preconditioning (RIPC) reduces renal damage after ischemia-
reperfusion injury (IRI) via an opioid dependent mechanism. (A-E) Representative images 
of periodic acid-Schiff-stained kidney sections, showing five levels of proximal tubule damage 
after I/R. Subsequent images represent damage scores 0 (0% of the tubules showing damage 
and cast formation), 2 (11-30%), 3 (31-60%), 4 (61-80%) and 5 (81-100%). (F) When compared 
to sham-operated rats, 25’ of renal IRI resulted in significant renal damage after 48 h of 
reperfusion. This damage was effectively reduced by RIPC, a protective effect which could be 
blocked by the opioid inhibitor naloxone, but not by inhibitors of noradrenalin, cannabinoids 
or glucocorticoids. All groups P<0.05 versus sham, *P<0.05 versus RIPC + vehicle by one-way 
ANOVA, n = 4 for sham, n = 7-8 for all other groups. AM-mix = AM251+ AM630.
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Figure 5|Remote ischemic preconditioning-induced reduction in renal kidney injury 
molecule-1 (KIM-1) mRNA expression is blocked by the opioid inhibitor naloxone. We 
observed an increase of KIM-1 expression in renal tissue after IRI when compared to sham-
operated animals and a reduction of this increase after RIPC. This effect could be blocked by 
treatment with the opioid inhibitor naloxone. β-actin was used as household gene. All groups 
P<0.05 versus sham, *P<0.05 versus RIPC + vehicle by one-way ANOVA. n=11-13 for no RIPC 
and vehicle group, n=4 for sham group, n=9-10 for all other groups. AM-mix = AM251+ AM630. 
Discussion
The current study is the first to investigate a number of signalling molecules in renal RIPC. 
Out of the nine compounds tested, we found that the renoprotective effect of RIPC, in terms 
of renal function, histological damage and injury marker expression, could be reversed by 
treatment with the opioid receptor antagonist naloxone. Thus, our data provide evidence that 
RIPC signalling is opioid-dependent in this model.
Since the discovery of RIPC 18 years ago, we have seen a number of successful clinical trials using 
RIPC, mainly in the field of cardioprotection, but the elucidation of the signalling mechanisms 
underlying this phenomenon is far from complete. One or more humoral factors are involved 
in at least some models: supposedly small, hydrophobic compounds [125]. One of class of 
humoral factors which meets this description is the endogenous opioids: the enkephalins, 
endorphins, and dynorphins. Table 2 summarizes all studies which have investigated the role 
of opioid signalling in RIPC. The opioid receptor occurs in three subtypes: δ, κ, and µ. All three 
subtypes are found predominantly in the central and peripheral nervous system, but in rat, δ, 
κ, and µ receptors are also expressed in non-nervous tissues. The kidney expresses all three 
receptor subtypes, with the µ-receptor being the most predominant. The exact cell type(s) 
in the kidney carrying the receptors is unknown, although vascular endothelium in general 
has been found not to carry any opioid receptors [134]. Opioid receptors are also expressed 
in the spleen and on immune cells [135,134]. The latter finding is interesting, since both 
humoral and immunological mechanisms have been implicated in RIPC, and opioid signalling 
may play a role in both. Opioid receptors are known to exert their intracellular effects by 
G-protein coupled receptors. They can be inhibited by a number of selective and non-selective 
antagonists, e.g. BNTX, which selectively blocks the δ1 receptor, or naloxone: a high affinity, 
competitive antagonist of the μ receptor, which also has lower affinity antagonist action at 
Chapter 480|
κ and δ receptors. In all studies, administration of the non-selective antagonist naloxone 
reversed the protective effect of RIPC on the target organ. Inhibition of specific opioid receptor 
subtypes yielded contradictory results: blockage of the δ receptor with BTNX reversed the 
RIPC-mediated protection in heart and muscle flap [126,136]. However, another δ receptor 
antagonist, naltrindole, was without effect in a model of cardiac RIPC by hind limb ischemia. 
Instead, RIPC signalling in this study appeared to be mediated via the κ receptor, since the 
protective effect could be abolished by nor-binaltorphimine treatment [137]. 
In humans, very few studies on opioid signalling in RIPC have been conducted. One study on 
cardiac remote ischemic perconditioning (upper limb occlusion during and after percutaneous 
coronary intervention; PCI) showed an additive protective effect of morphine and RIPC [138]. In 
contrast, Wagner et al. showed that RIPC reduces cardiac IRI after CABG, but that pre-treatment 
with tramadol exacerbated cardiac damage (although this was hypothesized to be due to the 
drug’s serotoninergic effects)[139]. Thus, although the involvement of opioid receptors has 
been shown in various RIPC models, the specific receptor subtypes involved remain unclear 
and may differ depending on the remote and target organ used. Future studies using selective 
opioid receptor antagonists or opioid receptor knockout animals will elucidate which receptor 
subtypes contribute to signalling in our renal RIPC model 
Apart from the opioid antagonist, none of the other eight inhibitors tested in the current 
study significantly reversed RIPC-mediated renoprotection. Since many of the tested signalling 
pathways have previously been indicated in e.g. cardiac IRI, the current study indicates once 
more that RIPC signalling may differ depending on the target and remote organ, species and 
stimulus protocol. Interestingly, i.v. injection of the ganglion blocker hexamethonium chloride 
did not affect the renal RIPC, providing evidence against the involvement of a neurogenic 
pathway in our experimental set-up. This also suggests that opioid signalling has its main 
effects in the periphery, rather than in the central nervous system. Of note, our finding that 
the inhibitory effect of naloxone on RIPC was present during isoflurane anaesthesia facilitates 
translation of this technique to the surgical patient.  
The present data indicate that renal RIPC by brief hind limb ischemia may be the result of 
endorphin release from the hind limb after ischemia, as previously described [140]. Similar to 
findings in the heart [138,141], morphine treatment may therefore mimic or enhance renal 
RIPC, or lower its threshold. As such, the combination of morphine and RIPC poses a possible 
novel treatment strategy for patients at risk of renal IRI, especially in patient groups where RIPC 
efficacy appears to be reduced, such as the elderly and diabetic patients [111]. However, opioid 
treatment or use in patients may have either beneficial or detrimental effects on renal RIPC, 
depending on the frequency, duration and timing of the drug. Opioid administration is common 
in the peri-operative setting, which may influence the effect of endorphins released from the 
limb during RIPC. Long-term exposure to opioids may result in tolerance and altered opioid 
receptor expression (e.g. [135]). This implies that RIPC may be less effective in specific patient 
groups, e.g. those undergoing long-term morphine treatment for chronic pain or cancer, and 
those suffering from opioid addiction. However, an additive effect of morphine on cardiac RIPC 
was observed with a single dose administered shortly before RIPC, and this protocol could be 
optimized by investigating the precise threshold for potentiation in terms of dosage and timing. 
In conclusion, the involvement of opioid signalling in renal IRI holds important clues for optimal 
translation to the clinical setting. Additional studies are needed to clarify the effect of various 
opioid-related medications on RIPC. Furthermore, additional studies are needed to assess 
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whether additional signalling pathways are involved, and what down-stream intracellular 
mechanisms underlie opioid signalling in RIPC.
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Renal ischemia-reperfusion injury (IRI) frequently complicates shock, renal transplantation and cardiac and aortic surgery and has prognostic significance. The translocation of phosphatidylserines to cell surfaces is an important pro-inflammatory signal for cell-
stress after IRI. We hypothesized that shielding of exposed phosphatidylserines by the annexin 
A5 (ANXA5) homodimer Diannexin (DA5) protects against renal IRI. 
Protective effects of DA5 on the kidney were studied in a mouse model of mild renal IRI. DA5 
treatment before renal IRI decreased proximal tubule damage and leukocyte influx, decreased 
transcription and expression of renal injury markers neutrophil gelatinase associated lipocalin 
and kidney injury molecule-1 and improved renal function. A mouse model of ischemic hind 
limb exercise was used to assess DA5 biodistribution and targeting. 
When comparing its biodistribution and elimination to ANXA5, DA5 was found to have a 
distinct distribution pattern and longer blood half-life. DA5 targeted specifically to the ischemic 
muscle and its affinity exceeded that of ANXA5. Targeting of both proteins was inhibited by pre-
treatment with unlabeled ANXA5, suggesting that DA5 targets specifically to ischemic tissues 
via phosphatidylserine-binding. 
This study emphasizes the importance of phosphatidylserine translocation in the 
pathophysiology of IRI. We show for the first time that DA5 protects against renal IRI, making 
it a promising therapeutic tool to prevent IRI in a clinical setting. Our results indicate that DA5 
is a potential new imaging agent for the study of phosphatidylserine-exposing organs in vivo.
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Introduction
IRI is a major cause of cardiovascular morbidity and mortality [142]. Most sensitive to IRI are 
organs with a high energy demand and an intricate microvascular network, such as the kidney. 
Renal IRI frequently complicates shock, cardiac and aortic surgery, delays graft function after 
transplantation, and has prognostic significance [32,33]. Furthermore, renal IRI is a major cause 
of AKI, and is commonly observed in e.g. renal artery stenosis, sepsis and various types of 
renal surgery [30,31]. Even though IRI is an important and common clinical problem, effective 
strategies to reduce this condition are inadequate and novel therapies are needed.
The characteristic pathologic changes associated with IRI induced AKI are classically believed 
to be acute tubular necrosis and interstitial inflammatory cell infiltration [143]. In addition, the 
role of microvascular dysfunction in AKI has generated increasing interest [144]. The persistence 
of decreased blood flow after reperfusion (the ‘no-reflow’ phenomenon) is thought to play 
an essential role in AKI development, especially in the corticomedullary junction and outer 
medulla. The activation of endothelial cells in microcirculatory vessels plays a central role in 
the inflammatory response upon IRI. Particularly, the translocation of phosphatidylserine (PS) 
to the outer leaflet of the endothelial cell plasma membrane appears to play a central role in 
the cascades leading to end-organ damage [145,146]. 
Exposed on the endothelial cell surface, PS serve as a binding site for leukocytes, which are able 
to specifically recognize this phospholipid either through a putative PS-receptor or via bridging 
molecules [147,148]. Furthermore, PS exposition contributes to pro-thrombinase complex 
formation and is an important trigger of the complement cascade [149,150]. As a result, 
platelets and leukocytes will bind to the activated endothelium and cause an extended pro-
thrombotic  and pro-inflammatory response, consisting of T-cell recruitment and infiltration 
of monocytes and macrophages [144,151]. Overall, adhesion of immune cells will reduce 
blood flow in the renal microcirculation and cause capillary plugging, thereby aggravating the 
ischemic injury to renal tubule cells [152].
In light of the detrimental effects of PS exposition, we hypothesize that shielding of PS by 
PS-binding proteins will inhibit their pro-inflammatory effects, thereby reducing IRI. The 
endogenous protein ANXA5 binds with nanomolar affinity to PS in a calcium-dependent 
manner [153,154]. ANXA5 forms a 2D crystal structure on PS exposing cell membranes in vitro, 
thereby shielding PS from the extra-cellular environment [20]. For endothelial cells, shielding of 
PS by ANXA5 was shown to have both anti-thrombotic effects [155] and to prevent leukocytes 
adhesion [156], making this protein a promising candidate to reduce microvascular dysfunction 
after IRI. However, rapid renal clearance of ANXA5 limits its clinical utility. In contrast, the 
synthetic ANXA5 homodimer DA5 was recently claimed to have an increased half-life in the 
circulation in vivo as well as high affinity for exposed PS in vitro [157].
The aim of the present study was to investigate the protective role of DA5 in the kidney. 
We demonstrate for the first time that DA5 ameliorates renal function after IRI, reduces 
leukocyte influx and tubular damage and reduces renal injury marker expression. Secondly, we 
determined the short-term biodistribution of DA5 and show for the first time that DA5 targets 
specifically to tissues undergoing I/R, via high-affinity binding to exposed PS. We conclude that 
DA5 is a promising candidate to prevent renal IRI, and that these effects are likely mediated 
through PS-shielding.
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Materials and Methods
Chemicals
DA5 was an unrestricted gift from Alavita Pharmaceuticals Inc. (Mountain View, CA). ANXA5 
was obtained from Theseus Imaging (Boston, MA). SYBR Green®, Taqman® Universal PCR 
Master Mix and NGAL and β-actin primer probe sets (Mm01324470_a1 and 4352933E) were 
from Applied Biosystems, Zwijndrecht, The Netherlands.
Animals
All procedures involving animals were approved by the Committee for Animal Experiments 
of the Radboud University Nijmegen Medical Centre (experiment ID’s DEC2008121 and 
DEC2009006). Male FVB (Friend leukaemia virus B strain) mice were obtained from Charles 
River Germany at 5-7 weeks of age, weighing 18-22 grams on arrival. Animals were housed 
under standard specific pathogen free housing conditions at the Central Animal Facility 
Nijmegen. Up to 10 mice per cage were housed in Macrolon cages (Techniplast, Buguggiatta, 
Italy), supplied with woody bedding, shelters and treadmills. Mice had ad libitum access to 
drinking water and standard chow (RMH-TM, Hope Farms, Woerden, The Netherlands). The 
environmental temperature was regulated at 22°C, with a relative humidity of ± 45% and a 
12/12 h day/night cycle in artificial lighting with white lights on at 06:00 h. Radio sound was 
played during the day period. Air was refreshed at the rate of approximately six times per hour. 
Mice were allowed to acclimatize for at least one week before surgery.
Metabolic cages
Single mouse metabolic cages (Techniplast, Buguggiate, Italy) were used to assess renal function 
7 days pre-op and 2 or 7 days post-op. Prior to 24 h housing in metabolic cages, mice were 
weighed and 0.5 ml physiological salt solution was administered s.c. to prevent dehydration. 
To prevent hypothermia, room temperature was raised to 24 oC with a relative humidity of 53-
68%. After 24 h, body weights (b.w.) were recorded and a blood sample was collected via the 
retro-orbital sinus under isoflurane anaesthesia (5% in O2/N2O).
Surgical procedures
All experiments were performed between 08.00 and 16.00 h. Surgical procedures were 
conducted using standard aseptic surgical techniques and all microsurgical instruments were 
sterilized using a dry bead sterilizer (Inothech, Dottikon, Switzerland). Animals were placed 
on a sterile drape overlying a heating pad to maintain body temperature at 37 °C, which was 
monitored continuously using a rectal thermometer probe. Body weights were recorded prior 
to surgery. Anaesthesia was induced with 5% isoflurane in O2/N2O and maintained at 2.5-3%. 
Depth of anaesthesia was assessed by toe and tail pinch. 
DA5 and ANXA5 biodistribution and elimination
Metastable technetium-99 (99mTc)-DA5 and 99mTc-ANXA5 were prepared as described previously 
[146] at a specific activity of 5-25 µCi/µg. The radiolabeled products were purified by PD-10 
column. The radiochemical purity was found to be >90%, as determined by instant thin layer 
chromatography. PS-binding of the 99mTc-DA5 and 99mTc-ANXA5 conjugates was confirmed using 
denaturated erythrocytes in vitro as described previously [158]. 
Mice were anaesthetised and 200 µg/kg b.w. of 99mTc-DA5 or 99mTc-ANXA5 was administered 
i.v. via the tail vein. For scintigraphic imaging of whole body 99mTc biodistribution at 0, 10, 
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30, 60 and 120 min, mice (n=3 per treatment) were placed on the low-energy collimator of 
a single-headed gamma camera (Orbitor, Siemens, Hoffman Estates IL). Animals were re-
anaesthetized for measurements at 30, 60 and 120 min, after which they were euthanized 
through exsanguination. The 99mTc content of blood and various tissues was determined by 
counting tissue samples in a well-type gamma counter (Wizard, Pharmacia-LKB).
Hind limb ischemic exercise model
Anaesthesia was induced and mice (n=3-4 for 10, 30 and 120 min reperfusion and n=7-8 for 
60 min reperfusion) remained anesthetized until sacrifice. The Nervus ischiadicus of the right 
hind limb was exposed via an incision and blunt dissection through the right thigh. A 1 mm 
silicone copper wire, with a stripped section of 2-3 mm at 2 cm from its tip, served as positive 
electrode. The stripped section was placed underneath the nerve and the wire was tunnelled 
s.c. to exit at the tail base. A second length of wire with stripped ends was used as negative 
electrode, inserted through the heel of the right hind limb. Both electrodes were connected to 
the pulse generator, after which 1 test pulse was applied manually.
Approximately 20 min after the induction of anaesthesia, hind limb ischemia was induced by 
placing an orthodontic rubber band (ORB) around the proximal thigh using a McGivney ligator 
applicator. Dark pink discoloration of the ischemic toes and absence of swelling indicated 
successful occlusion of arterial and venous blood flow. After ORB application, the N. ischiadicus 
was stimulated electrically with 20 pulses at 10 sec intervals. The minimal electric current 
needed for a maximal contraction and the number of pulses needed to reach exhaustion of 
the muscle were determined in a pilot study. Stimulus parameters were controlled by an S48 
stimulator, connected to a SIU5 telefactor stimulus isolation unit and a constant current unit 
(all by Grass, Astro-Med, Rodgau, Germany). Pulses were generated at 0.1 tps train rate, 250 
ms train duration, 150 pps stimulus rate, 0.1 ms stimulus delay and 0.1 ms duration at 150 volt. 
The constant current unit was used to adjust the electric current output to 0.9 ampere.
After completion of the stimulation protocol, 99mTc-DA5 or 99mTc-ANXA5 was administered 
i.v. via the tail vein (200 µg/kg b.w.; 20 μCi per mouse). Immediately after DA5 or ANXA5 
administration, blood circulation was restored by cutting the ORB (total ischemia time was 
5 min). After the desired reperfusion time (10, 30, 60 or 120 min), mice were sacrificed by 
cervical dislocation, and the 99mTc concentration of the hind limb muscles was determined in a 
gamma counter (Wizard, Pharmacia-LKB).
The effect of a preceding injection of unlabeled ANXA5 (450 μg per mouse) was tested in two 
separate groups of mice (n=3 per treatment). The unlabeled ANXA5 was injected i.v. via the tail 
vein immediately prior to hind limb occlusion. The rest of the protocol was as described above.
Renal I/R model
For recovery experiments, ethical guidelines prescribe the use of analgesia with either 
non-steroidal anti-inflammatory drugs or opiates. Since opiates are known to influence IRI 
signalling, carprofen (5 mg/kg b.w.) was selected as analgesic in all experimental and control 
groups, even though this drug may possibly have effects on renal function and inflammatory 
cells. Carprofen was administered s.c. 30 min prior to surgery. DA5 (200 µg/kg b.w.) or 
vehicle (physiological salt solution) was administered i.v. via the tail vein [159,160]. Hereafter, 
anaesthesia was induced, the incision site was shaved, iodized and covered with sterile surgical 
foil, after which mice were laparotomized. The jejunum, ileum and cecum were temporarily 
placed outside the abdomen, wrapped in gauze and kept moist with physiological salt solution. 
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For both kidneys, the renal vein and artery were isolated and clamped for 20 min using non-
traumatic microvascular clamps (S&T, Neuhausen, Switzerland). Time between DA5 or vehicle 
administration and clamping was ± 15 min. Complete occlusion of blood flow and reperfusion 
after clamp release were confirmed visually by swift dis- and re-coloration of the kidney. After 
clamp removal, the intestine was placed back, the abdominal wall and skin were sutured and 
the animals were allowed to recover in a clean housing cage. Analgesic (carprofen, 5 mg/
kg b.w.) was administered s.c. 24 h and 48 h post-op. On day 3 or day 8 post-op, mice were 
anesthetized with 5% isoflurane in O2/N2O and sacrificed through exsanguination (8-10 mice 
per day per treatment). Sham-operated mice (n=5 per treatment) underwent all procedures 
described above, except for clamp placement and were sacrificed on day 3 post-op.
Tissue handling and renal histology 
Blood samples were collected in EDTA tubes and centrifuged for 15 min at 3000 g to obtain 
plasma. Plasma and urine aliquots were snap frozen in liquid nitrogen and stored at 80 °C 
until further use. For immunohistochemistry, tissue was embedded in Tissue-Tek Optimal 
Cutting Temperature (OCT) compound (Sakura Finetek, Zoeterwoude, The Netherlands) and 
snap frozen in liquid nitrogen. Tissues were stored at -80 °C until further use. For histological 
studies, tissue was fixed in 4% paraformaldehyde for at least 24 h.
For light microscopy of the renal cortex, ½ kidneys were dehydrated and embedded in paraffin. 
For damage scoring, sections of 5 μm were stained with periodic acid-Schiff (PAS). For each 
kidney, four sections taken at different latitudes were scored for damage of the renal cortex 
and averaged. Damage scoring was performed on a scale from 0 to 5, with 0 signifying no 
proximal tubule damaged, and 5 indicating that all tubules were damaged (see also Figure 1A-D 
and legend). For leukocyte counting, 5μm sections were stained with Leder’s esterase, which 
stains all myeloid granulocytes and mast cells. Images of 10 random fields of the renal cortex 
were obtained at 400x magnification for each kidney. Granulocytes were counted in these 10 
fields and averaged for each kidney. For both damage and granulocyte scoring, the investigator 
was blinded for the experimental group to which the mice had been assigned.
Membrane preparation and Western blotting
Total membrane fractions were obtained using a micro-dismembrator (Sartorius BBI Systems 
GmbH, Melsungen, Germany), as described previously [120]. Frozen kidneys were pulverized 
(2000 rpm, 30s) and transferred to ice-cold TS buffer (10 mM Tris-HCl, 250 mM sucrose) including 
protease inhibitors (complete Mini, Roche, Mannhein, Germany). From these suspensions, a 
supernatant containing the total protein fraction was prepared through centrifugation (30 
min x 12000 g, 4 °C). Protein concentrations were determined with a standard protein assay 
(Biorad, Veenendaal, The Netherlands).
For Western blot analysis, samples were blotted in a blinded fashion to avoid bias and were 
therefore randomly distributed over several blots. Ten μl samples corrected for protein amount 
were solubilised in Laemmli sample buffer, heated at 95 °C for 5 min, separated on a 10% 
polyacrylamide gel, and transferred to a nitrocellulose membrane using the Iblot system 
(Invitrogen, Breda, The Netherlands). Subsequently, the blot was blocked for 60 min with 5% 
non-fat dry milk powder in PBS supplemented with 0.1% Tween-20 (PBS-T), after which the 
blot was washed three times in PBS-T. The membrane was incubated overnight at 4°C with the 
primary antibodies: RbαH polyclonal KIM-1 (AbD serotec, Oxford, UK) diluted 1:1000, RαM 
monoclonal NGAL (Santa Cruz, Heidelberg, Germany) diluted 1:1000 and MαM β-actin (Sigma, 
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Zwijndrecht, The Netherlands) diluted 1:100.000. The blot was washed twice for 20 min with 
PBS-T, rinsed three times with PBS and then blocked for 30 min as described above. The blot 
was then washed three times for 20 min with PBS-T and incubated at room temperature for 
60 min with secondary antibodies alexa680-GαRb, alexa680-GαR (both Invitrogen, Breda, The 
Netherlands) or alexa800-GαM (Rockland, Gilbertsville, PA), diluted 1:5000. Finally, the blot 
was washed twice for 20 min with PBS-T and rinsed twice in PBS. Proteins were visualized using 
the Odyssey Infrared Imaging Scanner (LI-COR®, Lincoln, NE). Semi-quantitative analyses were 
performed by correcting relative fluorescence from the proteins of interest for housekeeping 
protein (ß-actin) fluorescence.
RNA isolation and cDNA reaction
RNA isolation and cDNA reaction were performed on ½ kidney from each mouse as described 
previously [120]. RTQ-PCR was performed in duplicate on approximately 1ng cDNA, using 
the ABI/PRISM 7900HT Gene Expression Micro Fluidic Card (Applied Biosystems, Foster 
City, CA) according to the manufacturer’s instructions. Primers for KIM-1 (forward 5’- 
GCTATGCTCTCCCTCACGCCA-3’ and reverse 5’- CTCTTTGATGTCACGCACGAT-3’) and β-actin 
(forward 5’-CCTCCACTCCTCCAACATCTACA-3’ and reverse 5’-ACTGTCCTTAGGGTAGGGT-3’) 
were developed using the primer express software (Applied Biosystems, Zwijndrecht, The 
Netherlands). cDNA amplification of KIM-1 and β-actin was performed in 2x SYBR Green® PCR 
Master Mix, supplemented with 1.5 μl of 10 μM forward and reverse primer in a total reaction 
volume of 25 μl. cDNA amplification of NGAL and β-actin was performed in Taqman® Universal 
PCR Master Mix, supplemented with 20x solution of each primer probe set.
The thermal cycling conditions were 2 min at 50 °C and 10 min at 95 °C, followed by 40 cycles 
of 10 s at 95 °C and 1 min at 60 °C. PCR reactions were analyzed using 700 System Sequence 
Detection Software (version 1.2.3, Applied Biosystems).
Data analysis
Data are given as means ± SEM. Number of animals used is given in the figure legends. Mean 
values were considered to be significant when P<0.05 by use of a two-way ANOVA, one-way 
ANOVA or Student’s t-test where applicable. Software used for statistical analysis was Graphpad 
Prism® (version 5.02 for Windows; Graphpad Software, San Diego, CA).
Results
DA5 reduces tubule damage and leukocyte influx after renal IRI and improves renal function. 
We investigated the effects of DA5 pretreatment on ischemic kidney damage in a mouse model 
of bilateral renal IRI. We applied a mild IRI stimulus by inducing 20 min of renal ischemia and 
either 3 or 8 days of reperfusion. Subsequently, we assessed renal damage, local inflammation 
and kidney function in mice treated with DA5 or vehicle in comparison to sham-operated mice. 
Renal proximal tubule damage was quantified by scoring of histological sections (Figure 1). 
Sham-operated mice lacked any signs of tubular damage and scored 0±0 points. Proximal 
tubule damage was significantly increased in vehicle-treated mice on day 3 and day 8 post-
I/R (P<0.001 and P<0.01, respectively). Damage scores of kidneys from DA5-treated mice did 
not differ from sham-operated mice on day 3 or day 8. Moreover, DA5 significantly reduced 
proximal tubule damage on day 3 when compared to vehicle-treated mice (P<0.05). 
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Figure 1|Diannexin (DA5) reduces proximal tubule damage after ischemia-reperfusion injury. 
(A-D) Representative images of PAS-stained kidney sections (magnification 100x), showing 
4 levels of proximal tubule damage after I/R. (A) Damage score 0: intact brush borders and 
absence of casts or destroyed tubules. Damage score 1 (image not shown) was given for 
scattered cast formation in less than 1% of tubules. (B) Damage score 2: often clustered cast 
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formation in 5-25% of the tubules. (C) Cast formation and destroyed tubules affecting 40-
60% of tubules. (D) Damage score 4: Extensive destruction and cast formation in 70-90% of 
tubules. Damage score 5 (not observed): destruction or cast formation in 100% of tubules. 
(E) When compared to sham-operated mice, renal cortex damage was significantly increased 
in vehicle-treated groups on day 3 and day 8 post-I/R. Damage in the DA5-treated groups did 
not differ significantly from sham-operated mice on day 3 or day 8 post-I/R. On day 3, DA5 
treatment significantly reduced renal damage when compared to vehicle-treated mice. Values 
are means ± SEM. *P<0.01, **P<0.001 versus sham group; #P<0.05 versus ctrl group. n=5 for 
sham-operated mice and n=10 for all other groups.
Granulocyte influx in the renal cortex was quantified by granulocyte counting in histological 
sections (Figure 2). On day 3 post-I/R, granulocyte influx in the renal cortex of vehicle-treated 
mice was significantly higher than in DA5-treated mice (P<0.01). 
We measured protein and mRNA levels of KIM-1 and NGAL, two established biomarkers for 
renal damage [22,23]. Western blot analysis showed that KIM-1 and NGAL protein expression 
was elevated 3 days after I/R in both treatment groups, when compared to sham-operated 
mice. On day 3, DA5 treatment reduced the I/R-induced KIM-1 and NGAL protein expression by 
~50%, when compared to vehicle-treated mice (P<0.001; Figure 3B-C). After 8 days of 
reperfusion, the increase in KIM-1 protein expression persisted in both treatment groups, but 
was ~35% lower in DA5-treated animals (P<0.05). NGAL protein expression on day 8 did not 
differ between treatment groups, but was increased above sham-levels only in DA5-treated 
mice. In line with the protein levels, KIM-1 mRNA levels were increased in vehicle-treated 
groups on day 3 and day 8 post-ischemia (P<0.001 and P<0.05, respectively; Figure 3D). In DA5-
treated animals, mRNA levels did not differ from sham-operated animals on day 3 or day 8, 
while KIM-1 mRNA expression on day 3 was significantly lower than in vehicle-treated mice 
(P<0.05). For NGAL, no significant increase in mRNA expression could be detected (Figure 3E), 
probably because this marker reached its maximum transcription at an earlier time-point 
[161]. 
Figure 2|Diannexin (DA5) 
reduces leukocyte influx 3 days 
after I/R. Representative pictures 
of leukocyte influx in (A) vehicle-
treated mice and (B) DA5-treated 
mice (magnification 400x). 
Granulocytes stained with Leder’s 
esterase are indicated with 
arrowheads. (C) When compared 
to vehicle-treated mice, leukocyte 
influx in renal tissue of DA5-
treated mice was decreased on 
day 3 after IRI induction. Values 
are means ± SEM. **P<0.01 
versus vehicle. n=8-10 mice per 
treatment.
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Figure 3|Diannexin (DA5) reduces expression and transcription of renal injury markers after 
IRI. (A) Representative western blot of kidney homogenate from DA5 and vehicle-treated mice 
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(ctrl), after 3 or 7 days of reperfusion, stained for KIM-1, NGAL and β-actin. Purified KIM-1 and 
NGAL protein were used as positive control. (B-D) When compared to sham operation, KIM-
1 and NGAL expression, as well as KIM-1 transcription, were increased in renal tissue 3 and 
8 days after IRI induction. DA5 treatment significantly reduced protein expression on day 3 
(KIM-1 and NGAL) and day 8 (KIM-1), when compared to vehicle-treated mice (ctrl). Also, DA5 
reduced the IRI-induced transcription of KIM-1 on day 3 and day 8. (E) NGAL mRNA expression 
was not significantly elevated on day 3 or day 8 post-IRI. CT-values for corresponding β-actin 
were 17.2±3.2 for KIM-1 and 18.5±2.9 for NGAL. Values are means ± SEM. *P<0.05, **P<0.001 
versus sham group; #P<0.05, ##P<0.001 versus ctrl group. n=5 for sham-operated mice and n=10 
for all other groups.
 
Figure 4|Diannexin (DA5) improves kidney function after renal IRI. Urine flow and urine 
glucose were measured at baseline, and 3 and 8 days after renal IRI. Twenty minutes of renal 
IRI significantly increased both parameters when compared to sham-operated mice on day 
3. On day 8, recovery of renal function was observed. (A) When compared to vehicle-treated 
mice (ctrl), DA5-treatment reduced glucosuria on day 3. (B) Urine flow was increased on day 3 
post-ischemia in vehicle-treated controls, which was normalized by DA5 treatment. Values are 
means ± SEM. *P<0.05, **P<0.01 versus sham; #P<0.05, ##P<0.001 versus DA5 group. n=5 for 
sham-operated mice and n=10 for all other groups.
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On the functional level, renal damage in mice undergoing I/R was reflected by a significant 
increase in plasma urea (sham 10.8±1.7 versus vehicle-treated 17.9±8.0 mmol/l), renal 
glucosuria and an increase in urine flow (Figure 4) on day 3 post-op, when compared to sham-
operated mice. Plasma glucose did not differ between sham-operated mice (10.0±1.0 mM) 
and vehicle- or DA5-treated mice (8.9±1.9 and 11.4±5.1 mM, respectively). Recovery of renal 
function was observed on day 8, when plasma urea (sham 10.8±1.7 versus vehicle-treated 
13.7±5.8 mmol/l), urine glucose and urine flow (Figure 4) returned to baseline levels. DA5 
treatment had beneficial effects on tubular function on day 3 after IRI: glucosuria was reduced 
when compared to vehicle-treated mice (P<0.001; Figure 4A). DA5 also prevented the increase 
in urine flow observed in vehicle-treated mice 3 days after I/R-induction (P<0.05; Figure 4B). 
Water intake after surgery was not different from baseline (3.8±0.7ml) for either DA5 or vehicle 
treated animals (2.4±1.5 and 3.2±1.6 ml, respectively, P>0.05). No effect of DA5 on plasma urea 
was observed.
Biodistribution and elimination of ANXA5 and DA5 after i.v. administration.
We compared the biodistribution and elimination of DA5 with monomer ANXA5, in order 
to clarify the pharmacokinetic properties and imaging potential of DA5. Both proteins were 
labelled with 99mTc via hydrazinonicotinamide (HYNIC) conjugation.
Ten min after i.v. injection, blood levels of 99mTc-ANXA5 were measured at 6.5% ± 0.8 of the 
injected dose per gram (% ID/g; Figure 5A). This level decreased rapidly over the next 20 min 
to 2% ID/g, and declined further during the remaining 90 min. In line with previous reports, we 
found that 99mTc-ANXA5 accumulation was most pronounced and rapid in the kidney (Figure 5B 
and supplemental figure 1A). 99mTc-ANXA5 accumulation in liver and spleen was slow and did 
not exceed 6 %ID/g. Tracer concentration in intestine, lung and heart was below 2% ID/g after 
two h. For 99mTc-DA5 (Figure 5C), blood levels after 10 min were >3 times higher than those of 
99mTc-ANXA5 (24.5±3.4% ID/g versus 6.5±0.8% ID/g; P<0.01) and declined to just below 3% ID/g 
after 1 hour. Accumulation of 99mTc-DA5 was prominent in kidney, liver and spleen (Figure 5D 
and supplemental 1B), suggesting that ANXA5 and DA5 have different routes of elimination 
and/or metabolism. Uptake in heart and lung tissue was ~10% ID/g after 10 min, but decreased 
in chorus with declining blood levels, suggesting that the 99mTc-DA5 content of these tissues 
was dependent on the concentration in the blood. 
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Figure 5|Biodistribution of Annexin A5 (ANXA5) and Diannexin (DA5) after i.v. injection, over 
a time course of 2 h. Uptake of 99mTc in vital organs is presented as % of the injected dose 
(ID) per gram. (A) Plasma levels of ANXA5 declined steeply 10 to 30 min after injection. (B) 
Accumulation was most pronounced and rapid in the kidney, while low levels of ANXA5 were 
found in liver and spleen. (C) DA5 blood levels at t=10 min were over 3 times higher than of 
ANXA5 and declined until 1 h after injection. (D) Accumulation of the probe was detected in 
kidney, liver and spleen. Values are means ± SEM. n=3 mice per treatment.
DA5 targets ischemic tissues after hind limb IRI. 
Since previously published data emphasize the high affinity of DA5 for exposed PS [157], we 
investigated whether DA5 targets to ischemic tissues and tested if DA5 and ANXA5 share 
similar binding sites, reflecting specific targeting to PS. Targeting of both 99mTc-ANXA5 and 99mTc-
DA5 was investigated in an ischemic exercise model of the mouse hind limb, mimicking our 
experimental set up used to detect ANXA5 targeting after ischemic exercise in humans in vivo 
[146]. We injected the radiolabeled annexin analogues immediately prior to reperfusion and 
measured the targeting of 99mTc-ANXA5 and 99mTc-DA5 during 2 h of reperfusion. Muscle tissue 
from the untreated contralateral limb served as negative control. 99mTc-ANXA5 targeting to the 
muscle subjected to I/R was significantly elevated at all measured time points (Figure 6A). This 
targeting appeared to decrease during the first 30 min of reperfusion, which may be due to 
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reactive hyperaemia and decreasing blood levels of 99mTc-ANXA5 (Supplemental 1A). However, 
targeting reached a steady-state between 30 and 120 min, indicating high affinity binding of 
99mTc-ANXA5 in muscle tissue after I/R. For 99mTc-DA5, targeting to the I/R muscle increased 
over time, reaching a maximum after 60 min of reperfusion (Figure 6B). Thus, 99mTc-DA5 
targeting appeared to accumulate over time, even though 99mTc-DA5 blood levels decreased. 
Furthermore, targeting of 99mTc-DA5 was significantly higher than that of 99mTc-ANXA5 after 1 
hour (1.5±0.3% ID/g versus 3.7±0.7% ID/g; P<0.05) and 2 h (1.6±0.3% ID/g versus 2.9±0.6% 
ID/g; P<0.05).
In a second set of experiments, we showed that targeting of both 99mTc-ANXA5 and 99mTc-DA5 
to the ischemic muscle was blocked by administering 450 µg of unlabelled monomer ANXA5 
prior to ischemia and the injection of labelled substrate (Figure 6C-D). This finding confirms our 
hypothesis that ANXA5 and DA5 have the same binding sites, reflecting specific targeting to PS. 
Discussion
The present study is the first to demonstrate that the ANXA5 homodimer DA5 decreases renal 
damage after IRI, in terms of kidney morphology, inflammation, gene expression and renal 
proximal tubule function. Furthermore, we show that DA5 targets specifically to exposed PS in 
ischemic tissue in vivo.  
The therapeutic effects of DA5 have been studied previously in rodent models of hepatic 
and pancreatic IRI and transplantation [160,159,162], and in an IRI model of rat cremaster 
muscle [163]. However, favourable effects on renal IRI were not yet demonstrated, even 
though its vulnerability to I/R and its impact on prognosis make the kidney an ideal candidate 
for preventive treatment against IRI. Clinical conditions that jeopardize renal perfusion 
are frequently encountered and can often be predicted, e.g. in elective major surgery and 
kidney transplantation. In such cases, an intervention that should preferably be timed at the 
moment of I/R is practical. Here, we used a murine model of renal IRI to show that a single 
i.v. administration of DA5 (200 µg/kg b.w.) 15 min before renal IRI decreases proximal tubule 
damage, nearly abolishes leukocyte influx, decreases transcription and expression of renal 
injury markers and ameliorates renal function. These effects were observed after 3, and up to 
8 days of reperfusion, indicating that the beneficial effect of DA5 outlasts the acute phase of 
I/R and lasts for several days. 
We observed beneficial effects of DA5 on renal morphology, leukocyte influx, as well as 
functional changes in urine flow and urine glucose. There is increasing evidence that PS 
externalisation on the endothelial cell membrane is an early event in IRI, giving rise to the 
adhesion and aggregation of activated leukocytes and platelets in the microcirculation. This 
in turn exacerbates injury due to e.g. ROS formation, the release of proteolytic enzymes from 
adherent or transmigrated leukocytes, and diminished microcirculatory perfusion. Our findings 
show that DA5 is able to shield exposed PS, and that leukocyte influx into the ischemic kidney 
is reduced in DA5-treated mice. Similar to monomeric ANXA5, the anti-inflammatory and anti-
thrombotic properties of DA5 are thought to originate from its ability to shield PS, thereby 
reducing leukocyte adherence and transmigration, as well as preventing the formation of the 
pro-thrombinase complex. 
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Figure 6|Diannexin (DA5) and annexin A5 (ANXA5) share the same target in the muscle after 
ischemic exercise. (A-B) Uptake of annexin A5 and Diannexin in control limbs (filled bars) and 
limbs subjected to ischemic exercise and reperfusion (open bars). (A) When compared to the 
control limb, targeting of 99mTc-ANXA5 was increased in hind limb muscle tissue subjected 
to ischemic exercise and 10, 30, 60 and 120 min of reperfusion. (B) Similarly, 99mTc-DA5 was 
increased in hind limb muscle tissue subjected to ischemic exercise and 10, 30, 60 and 120 min 
of reperfusion. Values are means ± SEM for 4-8 animals per group. *P=0.03 versus ctrl group 
(paired t-test); **P<0.001, ***P<0.0001 versus ctrl group (one-way ANOVA). n=3-4 for 10, 30 
and 120 min reperfusion and n=7-8 for 60 min reperfusion. (C-D): effect of pre-treatment with 
unlabeled ANXA5 on the targeting of labelled ANXA5 and DA5 to control muscle (filled bars) 
and ischemically exercised muscle (open bars). 99mTc-ANXA5 (C) and 99mTc-DA5 (D) target to 
the hind limb muscle after ischemic exercise and 60 min of reperfusion. This targeting was 
blocked by administration of 450 μg of unlabeled ANXA5 prior to ischemia. In the presence of 
unlabeled ANXA5, targeting to the ischemic muscle was not significantly different from control 
muscle. Values are means ± SEM. **P<0.001 versus control muscle; #P<0.05 versus ischemic 
muscle-unlabeled ANXA5. n=3 for ANXA5 pre-treated mice and n=6-7 for control mice.
Diannexin protects against renal IRI and targets phosphatidylserines in ischemic tissue|99
Prevention of leukocyte and platelet adhesion in turn leads to improved microcirculation, 
while reduced leukocyte infiltration diminishes the secondary inflammatory response. The 
precise mechanism of action is currently unknown; similar to ANXA5, DA5 may alter the 
accessibility and/or membrane expression of adhesion molecules through steric hindrance, 
and/or influence endocytosis and phagocytosis. For ANXA5, these effects are contributed to 
PS-binding and subsequent 2D-crystallisation of the protein on PS-exposing membranes. It is 
at present unknown whether DA5 exhibits 2D-crystallization. 
Lastly, we cannot exclude that the anti-inflammatory effects of DA5 could be receptor-mediated, 
or based on intracellular actions of the protein. As was recently described for annexin A1, 
receptor activation on the epithelial cells and/or leukocytes can greatly reduce leukocyte 
adhesion and infiltration [164]. Such a receptor for ANXA5 is putative at best, although ANXA5 
has been shown to be internalised by living cells [165] and influence PKC activity. For DA5 it is 
at present unknown whether these processes occur and therefore, full understanding of the 
mechanism requires further investigation.
Apart from the morphological and functional outcome measures mentioned above, we also 
assessed the renal damage markers KIM-1 and NGAL in our mouse model. The great advantage 
of these markers is that they are early, sensitive, diagnostic indicators of kidney injury when 
compared to conventional biomarkers, e.g. plasma creatinine and BUN [166,161]. Moreover, in 
mice these markers are preferred over creatinine clearance (CCr), since the impact of tubular 
creatinine excretion on CCr is even larger in mice than in humans, raising questions regarding 
the reliability of creatinine for measuring renal function in these animals [107]. Furthermore, 
these markers support our measurements of urine flow and urine glucose, which are important, 
although not standard, indicators of (proximal) tubule damage, since glucosuria indicates 
proximal tubular dysfunction, but does not directly reflect a change in GFR. We show here that 
KIM-1 and NGAL are expressed at low levels in healthy renal tissue, but increase dramatically 
in the Post-ischemic kidney. DA5 treatment reduced the expression and transcription of KIM-1 
after 3 and 8 days of reperfusion. It has been shown in vivo that the ectodomain of KIM-1 is 
shed into the urine in rodents and humans after proximal tubular kidney injury. This provides 
us with an important tool for future research to translate current findings to humans in vivo. 
We found no significant increase in NGAL mRNA expression, but this marker has been reported 
to reach its maximum transcription at an earlier time-point [161]. Decreased levels of KIM-1 
and NGAL mRNA were also observed in a pilot study of unilateral renal IRI, in which DA5 was 
administered directly upon reperfusion, rather than 15 minutes before ischemia (unpublished 
observations; Wever et al. 2009). Interestingly, KIM-1 has been described as a PS receptor 
involved in the conversion of epithelial cells to semi-professional phagocytes [167]. Thus, KIM-
1 may actually play a mechanistic role in kidney injury downstream of the initial PS exposure. 
Shielding of PS by DA5 could therefore lead to a decrease in KIM-1-mediated phagocyte 
recruitment, thereby reducing damage. 
In addition to our therapeutic findings, this study is the first to show comparative data on the 
biodistribution and elimination of ANXA5 and DA5. These data are of vital importance for future 
clinical studies, since the pharmacokinetic and imaging properties of DA5 are largely dependent 
on these parameters. In cardiovascular medicine and oncology, detection of apoptosis, which is 
accompanied by PS exposure, may provide important diagnostic and therapeutic information. 
Previous reports on the biodistribution and clearance of 99mTc-HYNIC-ANXA5 in humans and 
rodents showed rapid accumulation of ANXA5 in kidney (~50% ID) and liver (~12% ID) after 
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1-3 h. Furthermore, kinetic data for ANXA5 in the human circulation indicate a short plasma 
half-life of 24 min, while clearance occurred almost exclusively via urinary excretion [168,169]. 
Clearance of DA5 has been studied previously in rats using a 125I-DA5-conjugate. DA5 clearance 
fitted a two-compartment model, revealing a 1st and 2nd phase half life of ~12 min and ~6.5 h, 
respectively [160]. In the present study, we evaluated the 99mTc-DA5 pharmacokinetics together 
with 99mTc-ANXA5, and confirmed the longer half-life of 99mTc-DA5 as compared to 99mTc-ANXA5. 
For imaging purposes, generally a short half-life is preferred, because this allows rapid clearance 
of the tracer from the background. However, the circulatory half-life is also the driving force for 
accumulation of the tracer in the target tissue. The circulatory half-life of ANXA5 is considered 
to be too short for many imaging purposes, as discussed in e.g. [170,171]. The slightly longer 
half-life of DA5, combined with its higher affinity for PS, makes the dimer more suited to 
image PS exposure in tissues in vivo than monomer ANXA5. We found that 99mTc-DA5 shows 
physiologic uptake in liver, spleen and kidney. With respect to the imaging properties of DA5, 
this nonspecific uptake in abdominal organs may hamper visualization of apoptosis in tissues 
in the vicinity of these organs, although in most cases single photon emission computed 
tomography (SPECT) imaging will allow distinction between physiologic uptake and uptake in 
tissues nearby. Biodistribution studies using various DA5 conjugate/radionuclide combinations 
are required to optimize the imaging potential of DA5 [172].
In our experiments on DA5 and ANXA5 targeting, we found that 99mTc-DA5 accumulates in 
the hind limb muscle during the first 2 h after ischemic exercise. Targeting of DA5 increased 
over time and was significantly higher than that of ANXA5, which translates previous in vitro 
observations stating that DA5 has a higher affinity for PS than ANXA5 [157], to the in vivo 
setting. Furthermore, we showed that 99mTc-DA5 targeting to ischemic tissues is PS-specific, 
since its binding was inhibited by unlabeled ANXA5. This observation indicates that DA5 
and ANXA5 share the same binding sites in the ischemically exercised muscle and it is well 
appreciated that ANXA5 specifically binds to PS [173,153]. 
The importance of exposed PS in ischemic injury is grounded by our evidence that PS-targeting 
by DA5 attenuates IRI in the kidney. The therapeutic effects of DA5, such as those shown in 
our renal IRI model, are thought to be local rather than systemic and may be enhanced by DA5 
enrichment in ischemic tissues. The higher in vivo affinity of DA5 for PS likely results in a higher 
efficacy of this drug to prevent IRI as compared to ANXA5. The therapeutic dose and maximal 
tolerable dose of DA5 in humans have not yet been determined, but DA5 administration in 
patients in single doses up to 400 μg/kg was reported to be without serious complications 
[163]. Hemorrhagic complications in particular could, theoretically, be of concern. Of note, 
DA5 administration did not induce any notable post-operative bleeding complications in any 
of our mice (observations in > 60 mice, data not shown). Overall, effects of ANXA5 and DA5 
on systemic haemostasis have been reported to be very minimal [157,155,160]. It is likely that 
reduced inflammation, by diminished leukocyte adhesion, and consequently reduced tissue 
damage are involved in protection by DA5. This makes DA5 a promising new therapeutic agent 
to prevent IRI in a wide range of clinical settings where renal perfusion is at risk. Furthermore, 
DA5 may offer new possibilities in the field of PS-imaging in e.g. atherosclerosis, and may 
be used to provide valuable insights in the pathogenesis of disease. As a first step towards 
clinical studies on DA5, the homodimer has recently completed a Phase II clinical trial in kidney 
transplantation [162].
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Supplementary Figure 1|Whole body scintigraphy and blood elimination of i.v. 99mTc-
Annexin A5 (ANXA5; top panel) or 99mTc-Diannexin (DA5; bottom panel), over a time course 
of 2 h. (A) Accumulation of ANXA5 in kidney and loss of signal from the peripheral circulation 
occur rapidly after injection. Excretion of ANXA5 via the urine is evident 30 to 120 min after 
injection (arrows indicate bladder). (B) Accumulation of DA5 is detected in kidney, liver and 
spleen immediately after injection. Note the prolonged activity in the peripheral circulation, 
indicating the prolonged half-life of DA5. (C, D) Elimination curves of ANXA5 (C) and DA5 (D) as 
calculated from blood 99mTc activity, 10 to 120
min post-injection. n=3 mice per treatment.
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Statins are known to have cholesterol-independent pleiotropic effects, such as upregulation of the enzyme ecto-5’-nucleotidase. These effects may contribute to the protective effect of statins against ischemia and reperfusion (I/R). Interestingly, pleiotropic effects 
have been shown to differ between hydrophilic and lipophilic statins. 
Flow mediated dilation (FMD) represents a largely nitric oxide (NO)-mediated, endothelium-
dependent dilation and has been shown to decrease after exposure to I/R in humans. FMD has 
been validated to study (pharmacological) interventions in I/R-injury. We examined the effect 
of a short-term (3-7 days) statin pretreatment on brachial artery endothelial function before 
and after I/R, and whether the effect on brachial artery endothelial function differs between 
rosuvastatin (hydrophilic statin) and atorvastatin (lipophilic statin).
Our results show that I/R significantly decreases FMD, however, statin pre-treatment did not 
alter the effect of I/R on FMD (irrespective of treatment duration or type of statin used). 
This experiment suggests that the cardioprotective effects of statins (both lipophilic and 
hydrophilic) against I/R are not mediated through preservation of endothelial function. 
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Introduction
Cardiovascular disease represents the greatest burden in terms of morbidity and death in 
the Western world. Previous studies demonstrated that statins (HMG-coenzyme A reductase 
inhibitors) reduce serum LDL cholesterol, which is associated with a significant reduction in 
cardiovascular events [174–177]. Statins also have cholesterol-independent pleiotropic effects, 
such as upregulation of NT5E [178–181], activation of the phosphatidylinositol 3-kinase-Akt 
pathway [182], activation of the ERK 1/2 pathway [183] and up-regulation of NOS [184,185]. 
These pleiotropic actions may contribute to the cardioprotective effects of statins, such as 
an improved tolerance against IRI [186–189]. Indeed, we have recently demonstrated that 
rosuvastatin reduces ischemia/reperfusion (I/R) induced phosphatidylserine exposition in the 
thenar muscle in humans in vivo, involving activation of adenosine receptors [190]. In addition, 
we have reported that rosuvastatin improves formation of adenosine in the forearm and 
increases forearm post-occlusive hyperaemia via an adenosine-dependent mechanism. Finally 
we have shown in humans a 50% increase in NT5E activity on peripheral blood mononuclear 
cells after rosuvastatin treatment as compared to placebo [181]. Whether this increase is a 
resultant of a change in enzyme production, presence and/or activity remains unclear. Since 
the vasodilator response to adenosine involves endothelial release of NO, prevention of I/R-
induced endothelial dysfunction could be involved in these actions of rosuvastatin [191]. 
Currently, little is known about the potential of statins to prevent IRI of the vasculature.
Severe endothelial dysfunction is one of the consequences of IRI [192]. Ischemia activates 
arginase, which competes with NO synthase for its substrate L-arginine and results in 
subsequent decrease in endothelial NO-release [193,194]. Flow mediated dilation (FMD) 
represents a largely NO-mediated [195], endothelium-dependent dilation and has been shown 
to decrease after exposure to IRI in humans [196,192]. Recently, it was demonstrated that a 
single dose of rosuvastatin could prevent the decrease in FMD after IRI, indicating a possible 
protective effect of the pleiotropic effects of statins on endothelial function [197]. Interestingly, 
pleiotropic effects have been shown to differ between hydrophilic and lipophilic statins. 
Lipophilic statins have been reported to render endothelial and vascular smooth muscle cells 
more susceptible to apoptosis than hydrophilic statins [198]. Moreover hydrophilic statins have 
been suggested  to be superior in reducing event rate after a primary acute coronary syndrome 
in normocholesterolemic patients [199]. Thus, lipophilicity of statins may influence their ability 
to reduce IRI.
We hypothesize that short-term statin treatment prevents endothelial dysfunction after 
IRI. Therefore, the primary aim of our study is to examine the effect of a short-term statin 
pretreatment on brachial artery endothelial function before and after IRI, and secondly 
to examine whether the effect on brachial artery endothelial function differs between a 
hydrophilic statin (i.e. rosuvastatin) and a lipophilic statin (i.e. atorvastatin). Finally, we assess 
RNA expression of NT5E before and after statin therapy to further elucidate the mechanism of 
increased NT5E activity after statin therapy. 
Methods
After approval of the protocol by our local ethics committee, 48 healthy non-smoking volunteers 
(age 18-48) were included after signing informed consent. All participants underwent 
medical screening to exclude cardiovascular disease, hypertension, hypercholesterolemia, 
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impaired renal function and diabetes mellitus. Serum values of creatinine kinase and alanine 
aminotransferase were measured to exclude participants with an increased risk of adverse 
events during statin treatment. Subjects with concomitant use of medication or participation 
to other drug experiments during the past 60 days were excluded. Oral contraceptive use by 
female participants was permitted, but measurement was planned during the drug-free interval 
of the oral contraceptive to minimise the influence of the menstrual cycle on the endothelial 
function measurements [200]. 
Experimental design
In this double blind randomised controlled trial (NCT00987974), participants were allocated to 
daily treatment with either rosuvastatin (20 mg, AstraZeneca, Zoetermeer, The Netherlands), 
atorvastatin (80 mg, Pfizer, Capelle a/d IJssel, The Netherlands) or placebo (Department of 
Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands). 
Both rosuvastatin and atorvastatin were capsuled according to GMP standards to match 
placebo by the Department of Clinical Pharmacy (Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands). Participants were equally divided across a 3- or 7-day 
pretreatment, since the duration of pretreatment may influence the impact of statins on 
IRI. On the first day, drug intake was performed under medical supervision. On subsequent 
days, capsules were taken individually before breakfast. At the end of the treatment, subjects 
returned to our laboratory to examine right brachial artery endothelial function before and 
after IRI. The latter was induced using 15 minutes of ischemia, followed by 15 minutes of 
reperfusion of the right arm.
Measurements
In the 24 hours prior to the test, participants were instructed to refrain from caffeine. 
Participants were instructed to take the last capsule 3 hours before the test and to fast for 4 
hours prior to the test. Before the test, venous blood was taken from the antecubital vein to 
assess lipid profile, caffeine level and RNA-expression of NT5E in mononuclear cells. 
Flow mediated dilation
Endothelium-dependent, largely NO-mediated, vasodilator function was assessed using 
FMD [195,201]. Participants rested in the supine position in a temperature controlled room 
(22 oC) for at least 15 minutes to facilitate baseline assessment of heart rate and blood flow. 
To examine brachial artery FMD, the right arm was extended and positioned at an angle of 
~80o from the torso. A rapid inflation and deflation pneumatic cuff (D.E. Hokanson, Bellevue, 
WA) was positioned on the forearm immediately distal to the olecranon process to enable 
induction of forearm ischemia [202]. A 10-MHz multi-frequency linear array probe attached to 
a high resolution ultrasound machine (T3000; Terason, Burlington, MA) was used to image the 
brachial arteries in the distal ⅓rd of the upper arm. When an optimal image was obtained, the 
probe was held stable and the ultrasound parameters were set to optimize the longitudinal, 
B-mode images of lumen-arterial wall interface. Continuous Doppler velocity assessment was 
simultaneously obtained using the ultrasound machine, and was collected using the lowest 
possible insonation angle (always <60o), which did not vary during each study. Baseline images 
were recorded for 1 minute. The forearm cuff was then inflated (>200 mmHg) for 5 minutes. 
Diameter and blood flow recordings resumed 30 seconds prior to cuff deflation and continued 
for 3 minutes thereafter.  
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The baseline FMD measurement was followed by the experimental IRI. The pneumatic cuff 
was placed proximally around the upper arm and inflated to 200 mmHg to apply 15 minutes of 
ischemia followed by cuff deflation. After 15 minutes of reperfusion, the procedures for FMD 
assessment as described above were repeated by the same experienced sonographer.  
FMD analysis
Analysis of brachial artery diameters and shear rate were performed using edge-detection and 
wall-tracking software which is largely independent of investigator bias [203]. Recent papers 
contain detailed descriptions of our analysis approach [204]. From synchronised diameter and 
velocity data, blood flow (the product of lumen cross-sectional area and Doppler velocity (n) 
was calculated at 30 Hz. Shear rate (an estimate of shear stress without viscosity) was calculated 
as 4 times mean blood velocity/vessel diameter [205]. Reproducibility of the FMD using this 
semi-automated software possesses a within subject coefficient of variance of 6.7-10.5% [206]. 
Baseline diameter, blood flow and shear rate were calculated as the mean of data acquired 
across the 1 minute preceding the cuff inflation period. Peak diameter following cuff deflation 
was automatically detected using an algorithm which identified the maximum bracket of data 
subsequent to performance of a moving window smoothing function. FMD was calculated 
as the percentage rise of this peak diameter from the preceding baseline diameter and was 
calculated based on standardised algorithms applied to data which had undergone automated 
edge-detection and wall-tracking, and were therefore observer-independent [204]. In 
accordance with recent findings [204,207], we calculated the shear rate stimulus responsible 
for endothelium-dependent FMD following cuff deflation.
Blood analysis
In all volunteers blood was collected to determine fasting serum lipid profile (HDL-, LDL-, and 
total cholesterol and triglycerides) with a commercially available kit (Aeroset, Abbott). Plasma 
caffeine concentrations were determined by use of reversed-phase HPLC with UV detection set 
at 273 nm [208]. 
RTQ-PCR procedures
All procedures were carried out according to the manufacturers’ instructions. Whole blood was 
collected in PAXgene blood RNA tubes and stored at -80 oC., after which RNA was isolated using 
the PAXgene Blood RNA Kit (both from Qiagen, Venlo, The Netherlands). Total intact RNA was 
reverse transcribed using pd(N)6 random hexamer primers and M-MLV reverse transcriptase 
(Invitrogen). RTQ-PCR was performed using the ABI/PRISM 7900HT Gene Expression Micro 
Fluidic Card (Applied Biosystems). cDNA amplification was performed in Taqman® Universal 
PCR Master Mix, supplemented with 20x solution of primer probe sets for NT5E (Hs01573922_
m1), and β-actin (Hs4333762F; all from Applied Biosystems). PCR reactions were analyzed 
using 700 System Sequence Detection Software (version 1.2.3, Applied Biosystems).
Sample size and statistical analysis
Using the observed difference in FMD after I/R between treatment and control, standard 
deviation and group size reported by Liuni et al. [197], we calculated that the standard deviation 
of the observed difference in FMD before and after I/R was 3.85%. Thus, with 48 volunteers in 
the present study, and based on the predicted SD of 3.85%, 80% power and a significance level 
of 5% we expected to detect  a treatment effect of 4% in FMD response after I/R.
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All data are presented as mean ± standard error, unless stated otherwise. To avoid multiple 
testing we used ANOVA for repeated measures with interaction terms to analyse the effect 
of different treatments on cholesterol and FMD. Paired T-test was used to test the effect of 
ischemia on FMD within the placebo group. Statistical analyses were performed using SPSS 
16.0. For NT5E expression data, 3 measurements were found to have a deviation from the 
group average of >4 times the SD. This was related to very high β-actin CT values of these 
measurements: >5 CTs above average. Since this suggests that the quality of these RNA samples 
was compromised, these measurements were excluded from the analysis.  
Results
Before deblinding, one volunteer (placebo) was excluded because of caffeine intake (caffeine 
level of 1.5 mg/L). Baseline characteristics and cholesterol data of all groups are presented in 
table 1.
LDL and total cholesterol were not affected by placebo treatment. Statin treatment significantly 
reduced LDL and total cholesterol in all groups (ANOVA p<0.05). We found no differences in the 
effect of treatment on LDL and total cholesterol between rosuvastatin and atorvastatin (ANOVA 
p=0.98 and 0.86 respectively). Statin pretreatment had no effect on the RNA expression of 
NT5E in peripheral blood mononuclear cells (Figure 1) (ANOVA p=0.38).
Table 1|Baseline characteristics and cholesterol values before and after treatment with 
placebo, rosuvastatin or atorvastatin. Data represent mean (SD).
Placebo
(n=15)
Rosuvastatin
(n=16)
Atorvastatin
(n=16)
At baseline
 Age (years) 21.8 (1.5) 24.4 (7.1) 22.2 (1.3)
 Female (%) 60 75 62.5
 BMI (kg/m2) 22.1 (1.7) 22.7 (2.2) 22.3 (2.2)
 Systolic blood pressure (mmHg) 119 (9) 122 (10) 122 (7)
 Diastolic blood pressure (mmHg) 73 (8) 75 (7) 76 (7)
 Heart rate (bpm) 68 (10) 63 (10) 66 (11)
 Glucose (mmol/l) 4.7 (0.5) 5.0 (0.8) 5.0 (0.6)
 Total cholesterol (mmol/l) 4.6 (0.7) 4.3 (0.7) 4.7 (0.8)
 LDL(mmol/l) 2.8 (0.6) 2.5 (0.6) 2.7 (0.8)
After treatment
 Total cholesterol(mmol/l) 4.6 (0.7) 3.4 (0.7) 3.8 (1.2)
 LDL(mmol/l) 2.7 (0.6) 1.7 (0.6) 1.9 (0.9)
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Figure 1|Ecto-5’-nucleotidase mRNA expression (percentage change from baseline 
measurement before treatment) before treatment (closed bars) and after treatment (open 
bars). Error bars represent standard errors.
Endothelial function and I/R
An overview of the FMD measurements is presented in table 2. No differences were observed 
in baseline diameter or in the shear rate stimulus between the FMD-response before and after 
IRI. 
In the placebo group, I/R significantly decreased FMD (paired t-test p<0.05). Treatment duration 
(3 versus 7 days) did not affect the results. Therefore, for each statin, data of 3 and 7 day 
treatment are pooled. Statin pre-treatment did not alter the effect of I/R on FMD, irrespective 
of the type of statin used (see Figure 2). Figure 3 shows the reduction in FMD (FMD before I/R 
minus FMD after I/R) for all individual participants in all treatment groups.
Table 2|FMD measurements before and after ischemia and reperfusion. Data represent 
mean (SD).
Placebo (n=15) Rosuvastatin (n=16) Atorvastatin (n=16)
Before IRI
  Baseline diameter(mm) 0.34 (0.07) 0.36 (0.07) 0.35 (0.06)
  FMD (mm) 0.37 (0.07) 0.39 (0.07) 0.38 (0.06)
  FMD (%) 7.7 (3.9) 6.9 (3.4) 8.3 (4.7)
  Shear rate(s-1) 27211 (14614) 28609 (11349) 27693 (8409)
  Time to peak (s) 63 (24) 56 (23) 50 (16)
After IRI
  Baseline diameter 0.34 (0.07) 0.37 (0.06) 0.34 (0.06)
  FMD (mm) 0.36 (0.07) 0.39 (0.06) 0.36 (0.05)
  FMD (%) 5.1 (2.4) 5.8 (3.0) 5.7 (3.4)
  Shear rate (s-1) 26817 (11661) 27150 (10755) 27553 (9676)
  Time to peak (s) 44 (25) 48 (24) 46 (20)
  reduction FMD (%) 34 16 31
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Figure 2|Brachial artery flow mediated dilation (presented as percentage change from 
baseline) in all pooled treatment groups before I/R (open bars) and after I/R (closed bars). 
Error bars represent standard errors.
 
Figure 3|Individual results of reduction in FMD after I/R (FMD before I/R minus FMD after 
I/R) for all treatment groups. Lines represent means.
Discussion
Using a double-blind, randomised design we examined the effect of a short-term pretreatment 
(3 to 7 days) of a lipophilic (i.e. atorvastatin) and a hydrophilic (i.e. rosuvastatin) statin to prevent 
the I/R-induced attenuation in endothelial function in humans. First, we confirmed previous 
observations of a brachial artery endothelial dysfunction after IRI in healthy volunteers. 
However, in this relatively large sample size, the observed effect of I/R on brachial FMD was 
smaller (34%) than reported previously  (40-80%) [196,209–214]. In contrast to Liuni et al., 
we observed a persistent reduction in FMD by I/R in statin treated individuals, irrespective of 
the type of statin used. This suggests that the protective effects of statins against IRI are not 
mediated through preservation of NO-mediated endothelial function.
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We found that I/R resulted in endothelial dysfunction in the control group, which confirms 
observations in previous studies [192,197,209,215,216]. However, the 34% decrease in 
endothelial function seen in the current study is less than typically observed in most studies 
[192,197,215,216].  A potential explanation for this finding is that our ischemic stimulus was 
relatively mild compared to previous studies. Indeed, using an ischemic stimulus of 20 minutes, 
MacAllister’s group repeatedly demonstrated a reduction of the brachial artery endothelial 
function of 50% to 70% [196,210,211]. Since we adopted a methodological design comparable 
to MacAllister’s group, our findings suggest that the duration of ischemia to induce IRI 
importantly determines the magnitude of decrease in FMD after I/R injury. In addition, the site 
of FMD assessment may play a role in the magnitude of endothelial dysfunction after artificial 
IRI. Liuni et al. found a remarkable reduction of 83% in radial artery FMD after a 15-minute 
ischemic stimulus [197]. Recent reports have demonstrated heterogeneity in responsiveness to 
physiological stimuli between the brachial and radial artery, which may contribute to variation 
in FMD decrease after a 15-minute ischemic stimulus between studies. For example, a 6% 
constriction in radial artery was found when exposed to 5 minutes ‘low flow’ [217], whilst a 
similar stimulus in the brachial artery has no impact on resting diameter [218,219] or even leads 
to a slight dilation [219]. Also, the degree of dilation to a 5-minute ischemic stimulus differs 
between both arteries when examined simultaneously within subjects [220]. Taken together, 
these observations suggest that methodological aspects (e.g. site of measurement, ischemia-
stimulus for IRI) must be considered when comparing studies that examine the impact of I/R 
on endothelial function. 
The site of measurement of endothelial (dys)function in relation to I/R is of special interest 
to ultimately extrapolate the results to more clinically relevant vascular beds, such as the 
coronary arteries. In the brachial artery a diminished FMD can predict future cardiovascular 
events [221,222], whilst such prognostic value is less clear for the radial artery. In addition, 
a correlation was found between coronary artery endothelial function and brachial as well 
as radial artery endothelial function [223,224]. Combining the correlation of the coronary 
circulation with the strong predictive value of the FMD for clinical relevant end-points (future 
cardiovascular events), the brachial artery seems a logical measurement site for human in vivo 
models studying IRI.
It is important to realise that experiments on endothelial dysfunction after IRI are almost 
exclusively carried out in healthy volunteers. At present it is not known to what extent these 
findings can be extrapolated to patients with ischemic heart disease. Furthermore, given the 
current discrepancies between studies adopting a different methodological design, we strongly 
recommend harmonization of the methodological approach for future studies of the effects of 
I/R on endothelial dysfunction. To further support this process we are currently performing a 
study to directly compare the brachial and radial artery with respect to the effect of 15 minutes 
of ischemia and reperfusion on FMD.
An important finding of our study is the persistent reduction in FMD after short statin 
pretreatment on brachial artery endothelial function after IRI in a relatively large study 
population. The effect of statins was independent of the duration of the pretreatment (3 versus 
7 days), whilst also compound lipophilicity did not alter the ability to protect the endothelium 
against IRI. Our findings suggest that statins do not protect the brachial artery against I/R 
induced endothelial dysfunction, which is in contrast to a previous study that demonstrated that 
a single dose of 40 mg rosuvastatin completely prevents I/R-induced endothelial dysfunction 
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in the radial artery [197]. As discussed above, methodological differences between studies 
relating to the site of measurement (brachial versus radial) may contribute to these conflicting 
findings. In addition, differences in the dose (40 versus 20 mg) and duration of pretreatment 
(3-7 days versus single dose) between our study and that of Liuni et al. [197] may contribute to 
the distinct findings of these studies. However, based on the pharmacokinetics of rosuvastatin, 
the estimated serum levels of rosuvastatin at the time of FMD measurement in the experiment 
by Liuni et al. should be comparable to those in the present study prior to I/R, due to some 
accumulation of rosuvastatin after repeated dosing. Therefore, the protective effect of statins 
against endothelial dysfunction after I/R may occur in the radial artery but not in the brachial 
artery. However, future studies should further examine this potentially clinically important 
topic.
Recently, we found that short-term treatment with rosuvastatin reduces ischemia-induced 
phosphatidylserine exposition in the thenar muscle as quantified with ANXA5 targeting 
[190]. This finding indicates that rosuvastatin pretreatment increases tissue tolerance against 
ischemia-induced cellular apoptosis and subsequent injury. The results of our present 
experiment add the novel knowledge that the attenuating effect of rosuvastatin on I/R induced 
phosphatidylserine exposition is not related to endothelial dysfunction after IRI.
 
We have previously observed a 50% increase in NT5E activity on peripheral blood mononuclear 
cells of volunteers who received a 8 day rosuvastatin pretreatment (20 mg daily) [181]. In 
this study we show that RNA-expression of NT5E on peripheral blood mononuclear cells was 
not increased after short-term statin treatment. Although we did not measure NT5E activity, 
combining our findings with previous observations suggests the presence of a non-genomic 
effect of rosuvastatin on NT5E activity, such as changes in post-translational modification or 
localization of the enzyme. In accordance with this interpretation, others have demonstrated in 
endothelial cell culture that lovastatin increases NT5E activity by reducing enzyme endocytosis 
[179]. In the dog heart, the PI3-kinase/Akt pathway has been involved in the up-regulation 
of NT5E by statins [180]. The exact mechanism of up-regulation in humans needs further 
exploration.
Conclusion
In the present study we show a moderate effect of ischemia and reperfusion on brachial artery 
endothelial function, which persisted after adequate short-term hydrophilic or lipophilic statin 
treatment. Since brachial FMD predicts cardiac events, this suggests that the cardioprotective 
effects of statins are not mediated through preservation of endothelial function after I/R. 
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Adenosine modulates inflammation and prevents associated organ injury by activation of its receptors. During sepsis, the extracellular adenosine concentration increases rapidly, but the underlying mechanism in humans is unknown. We aimed to determine 
the changes of adenosine metabolism and signalling both in vivo during experimental human 
endotoxemia and in vitro. 
We studied subjects participating in three different randomized double-blind placebo-controlled 
trials. In order to prevent confounding by the different pharmacological interventions in these 
trials, analyses were performed on data of placebo-treated subjects only. Setting of this study 
was the intensive care research unit at the Radboud University Nijmegen Medical Center. In 
total we used material of twenty-four healthy male subjects. Subjects received 2 ng/kg E. Coli 
endotoxin (LPS) intravenously. 
Following experimental endotoxemia, endogenous adenosine concentrations increased. 
Expression of 5’ectonucleotidase (5NT) mRNA was upregulated (p=0.01), while adenosine 
deaminase (ADA) mRNA was downregulated (p=0.02). Furthermore, both ADA and adenosine 
kinase (AK) activity was significantly diminished (both p<0.0001). A
2a
 and A
2b
 receptor mRNA 
expression was elevated (p=0.02 and p=0.04, respectively), whereas mRNA expression of A
1
 
and A
3
 receptors was reduced (both, p=0.03). In vitro, LPS dose-dependently attenuated the 
activity of both ADA and AK (both p<0.0001).
Adenosine metabolism and signaling undergo adaptive changes during human experimental 
endotoxemia promoting higher levels of adenosine thereby facilitating its inflammatory 
signaling.
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Introduction
The purine nucleoside adenosine is an important signalling molecule involved in tissue 
protection and repair in situations of impending tissue danger. After decades of pharmacological 
studies it was the genetic in vivo approach that allowed to uncover the unique role of A
2a
 
adenosine receptors. The A
2a
 adenosine receptor plays a critical and non-redundant role 
in the regulation of inflammation and subsequent tissue damage [225]. During hypoxia, 
ischemia, and inflammation, the extracellular adenosine concentration rapidly increases, and 
subsequent stimulation of membrane-bound adenosine receptors induces various effects 
aimed to protect the affected tissue. This is accomplished by vasodilation, inhibition of 
thrombocyte aggregation, increased intrinsic tolerance against ischemia and reperfusion, and 
modulation of the inflammatory response [226]. The extracellular adenosine concentration is 
determined by the formation, the transmembrane transport, and degradation of adenosine 
[227] (Figure 1).  Under physiological conditions, adenosine is formed by dephosphorylation 
of adenosine monophosphate (AMP) by ecto-, and endo-5’-nucleotidase  (5NT) and through 
hydrolysis of S-adenylhomocysteine. Adenosine degradation is confined to the intracellular 
compartment in which ADA and AK are responsible for the degradation of adenosine. The ENT 
controls the facilitated diffusion between extra- and intracellular adenosine depending on the 
concentration gradient [228].
Figure 1|Schematic representation of adenosine metabolism. 5’-nucleotidase (5NT) catalyzed 
the dephosphorylation of adenosine monophosphate (AMP), S-adenylhomocysteine hydrolase 
(SH) accounts for the hydrolysis of S-adenylhomocysteine (SAH); adenosine deaminase (ADA) 
and adenosine kinase (AK) are responsible for the degradation of adenosine, which mainly occurs 
intracellularly. The equilibrative nucleoside transporter (ENT) facilitates transmembranous 
adenosine transport. ADP = adenosine diphosphate; AMP = adenosine monophosphate.
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It has been well-established in vitro that, during hypoxia, the rise in the extracellular adenosine 
concentration results from an activation of ecto-5NT, a reduced activity of AK and ADA, 
and a reduction in ENT capacity [229,230]. During systemic inflammation, the extracellular 
adenosine concentration increases rapidly as well [231,232,24], with concentrations increasing 
up to tenfold in septic shock patients [231]. How inflammation affects these enzyme activities 
in humans is unknown. Unravelling these mechanisms may be important, because it allows 
for the development of pharmacological strategies to potentiate the increase in extracellular 
adenosine, which could limit tissue damage during inflammation. 
The aim of the current study was to investigate the inflammation-induced changes in 
adenosine metabolism during systemic inflammation in humans in vivo, and in isolated human 
lymphocytes and  peripheral blood mononuclear cells (PBMC) in vitro. 
We hypothesized that, during inflammation, the adenosine metabolism is altered, resulting in 
an increased extracellular adenosine concentration. Furthermore, we hypothesized that the 
adenosine receptor expression changes during systemic inflammation, thereby potentiating 
the anti-inflammatory potential of adenosine. We studied the gene expression and protein 
activities of ecto-5NT, ADA, AK, and the ENT, as well as gene expression of the adenosine 
A
1
, A
2a
, and A
3
 receptors during systemic inflammation evoked by experimental human 
endotoxemia (administration of lipopolysaccharide [LPS] in healthy volunteers). Furthermore, 
in vitro studies were performed to confirm the adaptive changes in adenosine metabolism and 
rule out potential confounding by changes in circulating cell numbers and types during human 
endotoxemia.
Methods
Healthy volunteers 
To investigate the effects of systemic inflammation on adenosine metabolism, blood samples 
were collected during three different human endotoxemia trials. These trials are registered 
at the Clinical Trial Register (NCT00513110, NCT00783068 and NCT01091571) [24,233]. In 
order to prevent confounding by the different pharmacological interventions in these trials, 
analyses were performed on data of placebo-treated subjects only. After approval by the local 
ethics committee of the Radboud University Nijmegen Medical Centre, a total of 55 healthy 
volunteers signed written informed consent. All volunteers had a normal physical examination, 
electrocardiography and routine laboratory values before the start of the experiment. 
Volunteers were asked not to take any prescription drugs and they refrained from caffeine 
intake 48 hours prior to the LPS administration. The subjects were admitted to our clinical 
research unit on the day of the experiment and were kept under close observation during 10 
hours. In total 24 healthy subjects received placebo treatment.
 
Experimental protocol 
A cannula was inserted in a deep forearm vein for administration of 2.5% glucose/0.45% 
saline solution to ensure an optimal hydration status [234]. Subjects received 1.5 l in one hour 
immediately before LPS infusion (prehydration), followed by 150 ml/h until 6 hours after LPS 
infusion and 75 ml/h until the end of the experiment. LPS was injected at t=0 hours and blood 
was collected at various time points thereafter. 
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Endotoxin 
U.S. reference E. coli endotoxin (Escherichia coli O:113, Clinical Centre Reference Endotoxin, 
National Institute of Health, Bethesda, MD) was used. Ec-5 endotoxin, supplied as a lyophilized 
powder, was reconstituted in 5 ml 0.9% NaCl for injection and vortex-mixed for at least 10 
minutes after reconstitution. The endotoxin solution was administered as an intravenous bolus 
injection at a dose of 2 ng/kg of body weight. 
Cell isolation
Since neutrophils do not express 5NT [235], and previous animal studies demonstrated 
profound changes in adenosine metabolism in lymphocytes, we focused on changes in the 
lymphocyte population. PBMCs were collected at different time points (T=0, 2, 4, 6 and 24 
hours) after LPS administration using Mononuclear Cell Preparation Tubes (BD Vacutainer CPT; 
Becton Dickinson and Company, Franklin Lakes, NJ). After centrifugation at 1800 g at room 
temperature for 20 minutes, mononuclear cells were harvested and washed twice with PBS.
For the separation of lymphocytes from the PBMC fraction, the magnetic-activated cell sorting 
separation (MACS) technique was used (Miltenyi Biotec, Leiden, The Netherlands), according 
to manufacturer’s instructions. In brief, cells were labelled with a magnetic CD14 antibody and 
separated using miniMACS columns placed in a magnetic field. Monocytes were retained on 
the column, while unlabeled lymphocytes passed through. Lymphocyte purity was evaluated 
using flow cytometry (FC500, Beckman Coulter, Woerden, The Netherlands). 
In vitro experiments
PBMCs were collected from 6 healthy male volunteers who did not participate in the 
endotoxemia studies using commercially available Mononuclear Cell Preparation Tubes (BD 
Vacutainer CPT) as described before. PBMCs  were washed three times in sterile PBS and 
resuspended in culture medium (RPMI 1640 Dutch modification, Flow Labs, Irvine, UK), 
supplemented with l-glutamine 2 mM, pyruvate 1 mM, gentamicin 50 mg/ml and fetal calf 
serum 10%. Cells were seeded in 96-well culture plates at a density of 5 X 105 cells/well in 
200 μl, and incubated with increasing concentrations of LPS (0, 1, 10 and 100 ng/ml, LPS 
Ultrapure E. coli, 0111:B4; Invivogen, Toulouse, France) for 24 h at 37 °C, 95% O
2
 and 5% CO
2
. 
All experiments were performed in duplicate. After incubation, culture plates were centrifuged 
(1400 rpm, 10 min) and the supernatant was stored at −20 °C until further analysis. 
In addition, lithium-heparin anticoagulated (Vacutainer, BD Biosciences) blood was collected 
from 3 healthy male volunteers and diluted 1:5 in culture medium for experiments in whole 
blood. Diluted blood was incubated in 24-well culture plates (at a volume of 1 ml) with 
increasing concentrations of LPS (0, 1, 10 and 100 ng/ml) for 24 h at 37 °C, 95% O
2
 and 5% 
CO
2
. All experiments were performed in duplicate. After incubation, blood cultures were 
centrifuged (14000 rpm, 5 min) and supernatants were collected and stored at -80 °C until 
further analysis. Erythrocytes were dissolved in 3-(N-morpholino)propanesulfonic acid (MOPS) 
buffer at a concentration of 20% and stored at 4 °C until analysis of uridine transport. A small 
fraction of the samples was used to determine hematocrit levels.
Cytokine measurements
Plasma concentrations of tumor necrosis factor (TNF)-α and interleukin (IL)-6 were determined 
using a simultaneous Luminex Assay (Bio-Plex cytokine assay, Bio-Rad, Hercules, CA) according 
to the manufacturer’s instructions. TNF-α and IL-6 concentrations in cell culture supernatants 
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were determined by ELISA (TNF-α: R&D duoset, R&D systems, Minneapolis, MN; IL-6: Pelikine 
Compact, Sanquin, Amsterdam, The Netherlands) according to the manufacturer’s instructions.
Enzyme activity assays (ADA, AK and 5NT)
Enzyme activity assays for ADA, AK, and ecto-5NT were performed as previously described 
[181;236]. In summary, PBMCs were washed three times in sterile PBS. Cell pellets were 
resuspended and lysed using mammalian protein extraction reagent (MPER) in combination 
with the protease inhibitor HALT. For nucleotidase activity 350 μL of incubation buffer (100 
mM Tris/HCL pH 8, 20 mM β-glycerolphosphate and 0.2% Triton X-100) was added to 150 μl 
suspension. For the measurement of adenosine deaminase and kinase activity the suspension 
was centrifuged and 400 μl TRIS-Buffer was added to 150 μl supernatant. Samples were stored 
at -80 °C until analysis.
For the determination of ADA activity, adenosine was added to erythrocyte lysate in Tris-buffer 
(0.35% erythrocytes) in a final concentration of 25, 50, 100, 200, and 300 µmol/l at 37°C. After 
15 min, HClO
4
 was added to a final concentration of 0.3M, and the solution was placed on ice. 
After centrifugation, 0.5 M trioctylamine in chloroform was added to the supernatant in equal 
volumes. Finally, after centrifugation, the neutralized supernatant was used for the detection 
of inosine and hypoxanthine with reversed-phase HPLC using tetrabutylammonium hydrogen 
sulphate (10 mM) as the ion-pair forming agent (pH 6.0) with UV detection set at 254 nm. The 
sum of inosine and hypoxanthine was used for the calculation of V
max
 and K
m
 for adenosine 
deaminase. 
For the determination of AK activity, adenosine was added to 10 µl lysate in 43 µl distilled 
water, 2 µl 50 mM MgCl, 2 µl 100 mM DTT, 2 µl 50 mM GTP, 0.7 µl 3 mM erythro-9-(2-
hydroxynon-3-yl)-adenine (EHNA), and 100 µl Tris-buffer in a final concentration of 0.1, 0.2, 
0.5, 1, and 2 µmol/l at 37°C. After 3.5 min, 50 µl 1.5 M HClO
4
 was added, and the solution was 
placed on ice. After centrifugation, 100 µL 0.5 M trioctylamine in chloroform was added to 150 
µl supernatant. Finally, after centrifugation, the AMP concentration in the supernatant was 
measured with reversed-phase HPLC using tetrabutylammonium hydrogen sulphate (10 mM) 
as the ion-pair forming agent (pH 7.7) with UV detection set at 260 nm. The increase in AMP 
was used to calculate V
max
 and K
m
 values. 
We determined the activity of 5NT exposed on the surface of PBMCs by quantifying the 
conversion of 1,N6-ethenoadenosine 5’-monophosphate to 1,N6-ethenoadenosine in the 
presence and absence of the CD73-specific inhibitor α,ß-methyleneadenosine 5′-diphosphate. 
The difference in these 2 activities reflects CD73 activity. To eliminate the influence of 
nonspecific dephosphorylation of 1,N6-ethenoadenosine 5′-monophosphate to 1,N6-
ethenoadenosine and 1,N6-ethenoadenosine transport, CD73 activity was measured in the 
presence of ß-glycerophosphate. ß-Glycerophosphate forms a competitive substrate for 
nonspecific phosphatases eliminating the contribution of nonspecific dephosphorylation of 
AMP. 
ENT determination by uridine transport measurements
We used uridine to reliably obtain the transport characteristics of the ENT, since erythrocytes 
lack uridine kinases and phosphorylases. Contrary to uridine, adenosine is rapidly deaminated 
and rephosphorylated after uptake into the cell, a characteristic that will affect proper ENT 
measurement with the use of adenosine. For uridine transport measurements, a 50-µl uridine 
solution was added to 100 µL of 10% erythrocytes in 3-(N-morpholino)propanesulfonic acid 
Chapter 7122|
buffer to obtain final concentrations of 1000 µmol/l. After 3 seconds, uridine uptake was 
completely blocked by 100 µl of 25-µmol/l dipyridamole, and erythrocytes were isolated by 
immediate centrifugation through a dibutylphthalate layer. After removal and washing of the 
upper layer, erythrocytes were lysed with Triton X-100 (Sigma-Aldrich BV, Zwijndrecht, The 
Netherlands) and proteins were precipitated using perchloric acid. After centrifugation, uridine 
concentrations in the supernatants were determined by HPLC.
RTQ-PCR procedures
All procedures were carried out according to the manufacturers’ instructions. Using Trizol 
reagent (Invitrogen, Breda, The Netherlands), total intact RNA was isolated from isolated 
lymphocytes stored in RNAlater. RNA was pelleted by centrifugation (10 minutes at 12000 g 
and 4 °C), resuspended in diethylpyrocarbonate-treated water and reverse transcribed using 
pd(N)6 random hexamer primers and M-MLV reverse transcriptase (Invitrogen). RTQ-PCR 
was performed using the ABI/PRISM 7900HT Gene Expression Micro Fluidic Card (Applied 
Biosystems). cDNA amplification was performed in Taqman® Universal PCR Master Mix, 
supplemented with 20x solution of the primer probe sets listed in Table 1 (all from Applied 
Biosystems). PCR reactions were analyzed using 700 System Sequence Detection Software 
(version 1.2.3, Applied Biosystems).
Table 1|Taqman primer probe assays.
Gene Number
5NT Hs01573922_m1
ADA Hs01110945_m1
AK Hs00417071_m1
ENT Hs01085706_m1
A
1
Hs00379752_m1
A
2a
Hs00169123_m1
A
2b
Hs00386497_ml
A
3
Hs01560269_m1
GAPDH Hs99999905_m1
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE), blotting and antibodies
For Western blot, a fraction of the isolated lymphocytes was stored in RIPA-buffer until analysis. 
Standard wet blot procedures were used, and proteins were visualized as described previously 
[237]. Ten μl samples, corrected for protein amount, were solubilised in Laemmli sample 
buffer, heated at 95 °C for 5 min, separated on a 10% polyacrylamide gel, and transferred to 
a nitrocellulose membrane using standard wet blot procedures. Subsequently, the blot was 
blocked for 60 min with 5% non-fat dry milk powder in PBS supplemented with 0.1% Tween 20 
(PBS-T), after which the blot was washed three times in PBS-T. The membrane was incubated 
overnight at 4 °C with the primary antibodies: mouse-anti-human CD73 (AbD Serotec Dusseldorf, 
Germany) and mouse-anti-β-actin (Sigma-Aldrich). The blot was washed twice for 20 min with 
PBS-T, rinsed three times with PBS and then blocked for 30 min as described above. The blot 
was then washed three times for 20 min with PBS-T and incubated at room temperature for 
60 min with secondary antibodies donkey-anti-mouse alexa dye 680 (Invitrogen, Breda, The 
Netherlands). Finally, the blot was washed twice for 20 min with PBS-T and rinsed twice in 
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PBS. Proteins were visualized using the Odyssey Infrared Imaging Scanner (LI-COR®, Lincoln, 
NE). Semi-quantitative analysis was performed by correcting relative fluorescence of 5NT for 
housekeeping protein (ß-actin) fluorescence.
Statistical analysis
LPS-induced changes in time were analyzed using repeated measures ANOVA, with post-hoc 
tests for specific time points (Bonferroni). Nonparametric analyses were performed using the 
Friedman test followed by Dunn’s multiple comparison test. Since all gene expression levels of 
the enzymes, transporter and adenosine receptor subtypes had a non-Gaussian distribution, 
data were log transformed before analyses with one-way ANOVA, followed by Dunnett’s 
multiple comparisons post-test. For reasons of clarity, all data are presented as median 
[interquartile range (IQR)] in the Figures. Demographic characteristics are presented as mean 
± SD. A P value <0.05 was considered statistically significant.
Results
The demographic characteristics of the healthy volunteers are presented in Table 2. 
Table 2|Demographic characteristics of the 25 
healthy volunteers that participated in the in 
vivo endotoxemia experiments (Mean ± SD). 
Age (yr) 22 ± 2
Height (m) 1.84 ± 0.06
Weight (kg) 79 ± 10
Body mass index (kg/m2) 23 ± 3
Heart Rate (bpm) 71 ± 7
Mean arterial pressure  (mmHg) 92 ± 6
In vivo experiments: LPS-induced changes in endogenous adenosine levels
During human endotoxemia, the endogenous plasma adenosine concentration increased 
from 9.5 [8.0-14.3] ng/ml at baseline to a peak level of 13.7 [10.9-17.7] ng/ml (an increase of 
41±16%) two hours after LPS administration (p=0.043). In comparison, in sepsis patients who 
were admitted to our intensive care unit, we found a median (IQR) adenosine concentration of 
29 [22 to 43] ng/ml (n=31).
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In vivo experiments: LPS-induced changes in enzyme and transporter activity
Human experimental endotoxemia resulted in a profound increase in plasma concentrations of 
the pro-inflammatory cytokines TNF-α and IL-6 (both, p<0.0001, Figure 2). During the peak of 
the innate immune response, 5NT activity on PBMC, responsible for the formation of adenosine, 
did not increase, while it was significantly decreased 4 hours after LPS administration (52±7%, 
p<0.0001; Figure 3A). The degradation of adenosine was also attenuated: PBMC ADA activity, 
responsible for the deamination of adenosine, was reduced with a maximum of 59±3% 4 hours 
after LPS administration (p<0.0001; Figure 3B), and AK activity, responsible for adenosine 
phosphorylation, decreased with a maximum of 41±4% (p<0.0001; Figure 3C) 4 hours after 
LPS administration. ENT activity, measured in circulating erythrocytes, did not change after LPS 
administration (p=0.27; Figure 3D).
In vivo experiments: LPS-induced changes in enzyme and transporter gene expression on 
purified lymphocytes
The purity of the lymphocyte isolation averaged 88±2% (n=10). The expression of 5NT mRNA 
was significantly enhanced 2 hours after LPS administration and returned to normal within 
24 hours (p=0.010; Figure 4A). The protein expression of 5NT, which was determined in 
isolated lymphocytes from 5 volunteers, showed a trend towards an increase 2 hours after 
LPS administration, and this increase tended to persist up to 24 hours after LPS (p=0.099; 
Supplemental Figure 1). The gene expression of ADA decreased in the first hours after LPS 
administration, but returned to normal within 24 hours (p=0.024; Figure 4B), whereas AK 
mRNA expression did not change significantly during endotoxemia (p=0.52; Figure 4C). Gene 
expression levels of ENT were enhanced 4 hours after LPS administration (p=0.034; Figure 4D).
Figure 2|The inflammatory response to LPS. Human experimental endotoxemia resulted 
in a transient increase in TNF-α and IL-6 levels (n=23). Data are presented as median [IQR]. 
Probability values refer to LPS-induced increases of cytokines, analyzed by the Friedman test.
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Figure 3|Changes in enzyme/transporter activity during human experimental endotoxemia. 
Following the administration of 2 ng/kg E. Coli LPS, the activity of 5NT (A), ADA (B) and AK 
(C) was significantly reduced. ENT activity did not change following LPS administration (D). 
Data are presented as median [IQR]. The probability values refer to changes in enzyme activity, 
analyzed by Friedman test (n=10). The increase in transporter activity was analyzed by RM 
ANOVA (n=4). *P<0.05.
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Figure 4|Enzyme/transporter mRNA expression levels in isolated lymphocytes. Following 
the administration of LPS, the mRNA expression of ADA (B) significantly decreased. Expression 
levels of both 5NT (A) as well as ENT (D) were significantly elevated following LPS administration. 
AK expression (C) did not change during endotoxemia. Data are presented as median [IQR]. 
Probability values refer to changes in mRNA expression, analyzed by RM ANOVA after log 
transformation of the data (n=8). *P<0.05 versus t=0.
In vivo experiments: LPS-induced changes in gene expression of adenosine receptor subtypes
In isolated lymphocytes, the A
2a
 receptor mRNA expression was up-regulated during 
experimental human endotoxemia (p=0.022; Figure 5C), whereas mRNA expression of the 
adenosine A
1
 and A
3
 receptors was attenuated (p=0.029 and p=0.026 respectively; Figure 5A- 
B). A
2b
 receptor mRNA expression was significantly altered following endotoxemia (p=0.043, 
Figure 5D).  
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Figure 5|mRNA expression levels of three different adenosine receptor subtypes. 
Endotoxemia-induced changes in mRNA expression levels of the four different adenosine 
receptor subtypes in isolated lymphocytes, during endotoxemia. Data are presented as median 
[IQR]. Probability values refer to changes in mRNA expression, analyzed by RM ANOVA after log 
transformation of the data (n=4-8). *P<0.05.
In vitro experiments
During experimental endotoxemia the circulating cell population changed rapidly, therefore, 
we also studied changes in adenosine metabolism in isolated PBMC’s and erythrocytes 
stimulated with LPS. In general, during human experimental endotoxemia the total leukocyte 
count decreases in the first hour after LPS administration, followed by leukocytosis, with a peak 
leukocyte count eight hours after LPS administration. As depicted in Figure 6, incubation of 
both PBMC’s (Figure 6A) and whole blood (Figure 6B; both harvested from healthy volunteers 
not participating in the endotoxemia experiments) with increasing doses of LPS resulted in a 
significant and dose-dependent increase in TNF-α levels (p<0.0001 and p=0.017 respectively). 
In vitro stimulation of PBMC’s with LPS during 24 hours did not change ecto-5NT activity 
(p=0.195; Figure 7A). ADA activity on the other hand was significantly decreased by LPS in a 
dose-dependent fashion, with a maximum reduction of 59±7% after incubation with 100 ng/ml 
LPS (p<0.0001; Figure 7B). The rephosphorylation of adenosine by AK was also attenuated with 
increasing doses of LPS; AK activity decreased with a maximum of 67±3% (p<0.0001; Figure 
7C). Incubation of whole blood with increasing doses of LPS tended to increase ENT activity, 
with a maximum effect observed at 10 ng/ml LPS of 68±29% (p=0.075; Figure 7D).
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Figure 6|The inflammatory response to LPS. In vitro incubation of PBMCs (A; n=6) and whole 
blood (B; n=3) in the presence of increasing doses of LPS, resulted in a significant increase in 
TNF-α. Data are presented as median [IQR]. Probability values refer to LPS-induced increases 
of cytokines, analyzed by the Friedman test.
Figure 7| In vitro changes in enzyme/ transporter activity following increasing doses of LPS.
Incubation of PBMCs with increasing doses of LPS did not change the activity of 5NT (A), 
whereas it significantly reduced the activity of ADA (B) and AK (C; n=12). Incubation of whole 
blood with increasing doses of LPS, resulted in a dose-dependent increase in transporter 
activity (D; n=3). Data are expressed as median [IQR]. The probability values refer to changes 
in enzyme activity, as analyzed by RM ANOVA (n=12). Transporter activity was analyzed by 
Friedman test (n=3). *P<0.05 versus t=0.
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Discussion
The main finding of our study is that during experimental human endotoxemia, the circulating 
endogenous adenosine concentration increases within 2 hours after LPS administration, and 
that this rise appears to be caused by an inhibition of intracellular adenosine degradation 
rather than augmentation of adenosine formation. Concomitantly, the gene expression of the 
adenosine A
2a
 receptor subtype, which upon activation has potent anti-inflammatory effects 
[238,239], is increased, whereas the gene expression of the adenosine A
1
 and A
3
 receptor is 
decreased. 
Knowledge of the effect of inflammation on adenosine metabolism is of great importance, since 
endogenous adenosine can act as a potent negative feedback signalling molecule aimed to limit 
tissue damage in situations of hypoxia, ischemia, and inflammation. As such, (pharmacological) 
potentiation of this feedback mechanism, e.g. with ENT inhibitors, could be a promising 
strategy to limit tissue injury during inflammation [240,241]. For this approach, however, 
thorough knowledge of the mechanism mediating the increase in endogenous adenosine is 
essential. We showed that the rise in the extracellular adenosine concentration is initiated 
by a reduced intracellular degradation of adenosine. Consequently, the transmembrane 
adenosine concentration gradient will be reduced, and the uptake of extracellular adenosine 
via the ENT transporter is attenuated. Based on our findings, ENT inhibitors may increase the 
baseline adenosine concentration before initiation of inflammation, but will not potentiate 
the inflammation-induced increase in the extracellular adenosine concentration because the 
transmembrane adenosine concentration gradient is reduced. This fits into our observation 
that seven day treatment with dipyridamole increases the baseline adenosine concentration, 
but does not potentiate the inflammation induced rise in adenosine formation [242]. Our 
results suggest that the use of pharmacological activators of ecto-5NT may be more successful, 
as this will further increase the extracellular adenosine concentration, particularly since 
adenosine degradation is reduced. Only recently, Haskó and co-workers demonstrated that 
ecto-5NT decreases mortality and organ injury during murine sepsis [243]. Interestingly, recent 
studies in animals and in humans in vivo have shown that statins cause an activation of ecto-
5NT activity [181,180,190]. Furthermore, it was recently demonstrated that the use of statins 
during ICU stay reduces hospital mortality [244], but whether an increase in extracellular 
adenosine accounts for the survival benefit needs to be further explored. 
During human experimental endotoxemia the enzymatic activities of ADA and AK were inhibited 
already 1.5 hours after LPS administration. In addition, 4 hours after LPS administration, ecto-
5NT activity was modestly reduced. Interestingly, these changes in activity levels were not 
caused by an alteration in gene transcription: ADA gene transcription was reduced, but only 
6 hours after LPS administration, transcription of AK was not affected, and transcription of 
ecto-5NT was even increased. Therefore, the changes in enzymatic activities of ADA, AK, and 
ecto-5NT are likely to be due to an effect on protein translation or due to a direct effect of 
inflammation on protein activity. The latter mechanism is most probable, given the findings 
that protein expression of ecto-5NT followed the change in its gene transcription (Figures 4 
and 5). 
In parallel with the adaptive changes in adenosine metabolism, we demonstrated that the 
expression levels of the adenosine receptor subtypes also change during systemic inflammation. 
Expression of the predominantly anti-inflammatory adenosine A
2a
 receptor [245,225] 
increases in the first two hours after LPS administration. Recent studies also demonstrate anti-
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inflammatory properties of the A2b receptor [246,247]. Herein we demonstrate significant 
changes in A2b receptor expression following endotoxemia. In contrast, both the adenosine A
1
 
and the A
3
 receptor are downregulated during human endotoxemia. Whether these changes 
in expression levels are functional remains to be determined [21]. Nonetheless, the changes in 
adenosine receptor gene transcription levels are in accordance with previous in vitro studies 
demonstrating that in LPS-stimulated macrophages, the gene transcription of the A
2a
 and A
2b
 
receptor is augmented, whereas A
1
 and A
3
 receptor expression is reduced. Furthermore, this 
increase in the number of A
2a
 receptors correlated with an increase in the potency of a specific 
A
2a
 receptor agonist to reduce TNF-α release [248]. In accordance, in septic patients, the 
expression of the adenosine A
2a
 receptor on circulating granulocytes is increased 26. However, 
receptor function appeared to be impaired because of reduced ligand-binding affinity, thereby 
diminishing the anti-inflammatory potential of adenosine [249].
Our results show that the effects of inflammation on adenosine metabolism differ to 
some extent from the reported effects of hypoxia/ischemia. Hypoxia results in a profound 
upregulation of ecto-5NT expression and function [229]. Also, hypoxia reduces expression of 
hENT1. In contrast, during human experimental endotoxemia, the activities of these proteins 
do not explain the rise in extracellular adenosine. With regard to the degradation of adenosine, 
similarities between hypoxia and inflammation exist. In cultured pheochromocytoma cells, 
hypoxia decreased the gene expression of ADA and AK, but only after 24 hours. In addition, 
hypoxia also induces an immediate inhibition of AK [250]. In our study, we observed a reduction 
in ADA and AK activity already 1.5 hours following LPS administration. As such, this reduced 
adenosine breakdown could well explain the rise in extracellular adenosine concentration 
observed 2 hours after LPS administration. 
Moreover, our findings are in accordance with the recent finding that during murine 
peritonitis, the extracellular adenosine concentration increases rapidly due to changes in the 
adenosine metabolism. The expression levels of 5NT mRNA were enhanced 6 hours after E. 
coli administration, followed by a peak 5NT protein concentration 24 hours after induction of 
peritonitis. ADA and AK mRNA levels were reduced 12 hours after induction of peritonitis, and 
the activity of ADA was significantly decreased 12 hours after induction of peritonitis [251]. 
Our findings are also supported by the only previous human in vivo study that demonstrated 
that in patients with chronic pulmonary inflammation, adenosine metabolism changes rapidly 
[252], resulting in an increase in 5NT expression, reduction in ADA activity and increased A
2b
 
receptor expression levels in pulmonary tissue. These data illustrate that in humans both local 
(pulmonary) and systemic (endotoxemia) inflammation results in similar changes in adenosine 
metabolism.
During experimental human endotoxemia, a shift in circulating cell populations occurs [253]. It 
is characterized by relative leucopenia in the first hour following LPS administration presumably 
due to sequestration, followed by leucocytosis in the hours thereafter. During leucocytosis the 
cellular population almost exclusively consists of neutrophils. At the same time, the PBMC 
fraction is diminished and merely consists of lymphocytes the first 6 hours after induction 
of endotoxemia. Shifts in lymphocyte populations, both the total lymphocyte count as well 
as possible functional changes, could have influenced the in vivo measurements of enzymes 
involved in adenosine formation and metabolism. To further characterize the intrinsic effects 
of inflammation on adenosine metabolism, we therefore also performed in vitro experiments 
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in which PBMCs were stimulated with LPS. Our in vitro results demonstrate that 24 hour 
incubation with LPS causes a dose-dependent inhibition of ADA and AK enzymatic activity, 
whereas ecto-5NT and ENT activities were not significantly affected. Moreover these results 
demonstrate that the effects observed in vivo are not attributed to systemic changes in cell 
populations, at least for ADA, AK and ENT, but are a direct consequence of alterations at the 
cellular level. 
In conclusion, the elevation in plasma adenosine during systemic inflammation evoked by 
experimental human endotoxemia is caused by reduced intracellular clearance of adenosine, 
not by enhanced formation. At the same time, the adenosine A
2a
 receptor mRNA expression 
is up-regulated which may further reinforce the anti-inflammatory effects of adenosine. 
Pharmacological modulation of these alterations in adenosine metabolism may potentiate the 
protective properties of adenosine.
Supplemental Figure 1|Relative 5NT protein expression levels. Western Blot of the 
endotoxemia-induced changes in protein expression compared to β-actin expression following 
the administration of LPS. The presented Western blot is representative for 4 separate 
experiments (n=4). 5NT protein expression tended to increase following endotoxemia. 
Probability values refer to changes in protein expression, analyzed by one-way ANOVA after 
baseline correction of the data.
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8.1 Lost in translation?
The average life expectancy of a twenty-one year old in a developed country has risen 
from forty-three additional years in medieval times to sixty additional years at present day. 
Undoubtedly, medical science has made an important contribution to this seventeen years 
increase, warding off health hazards to successfully postpone the inevitable: living causes 
death. Many of the complex pathologies which currently head the list of causes of death 
in developed countries are closely linked to IRI (e.g. cardiovascular disease, ischemic heart 
disease and cerebrovascular disease). Thus, overcoming IRI remains a major challenge for 21st 
century experimental medicine.
This thesis attempts to navigate what is arguably the most important and complicated phase 
of medical research: the translation from bench to bedside. In the case of IRI, translational 
medicine is especially complicated due to the heterogeneity of the patients at whom our 
treatments are aimed: they are often elderly and suffer from diabetes, obesity and other 
cardiovascular co-morbidities. For any given patient there are many factors which may 
influence the working mechanism of a new treatment, making it difficult to assess its efficacy. 
Therefore, experimental models are needed in which these variables can be controlled, which 
is why scientists have relied on models using e.g. cells or animals to unravel the mechanistics 
of IRI and potential treatments. Compared to genetically and microbiologically standardized 
rats and mice, patients seem unfavourable subjects for such mechanistic studies. On the other 
hand, how valuable are results from standardized animal experiments for the design of human 
trials with the intention to treat?  And when clinical translation appears to stagnate (e.g. in the 
case of RIPC against IRI), how do we optimize this process?
8.1.1 The value of models
Research in animal models, as presented in chapters 2-5 of this thesis, is often a necessary 
if not a mandatory (in terms of safety and regulatory aspects) step before a new treatment 
is tested in humans. Using our renal IRI model in rats and mice, we were able to investigate 
aspects of renal IRI, DA5 and RIPC signalling that are too invasive to study in humans (e.g. 
sampling renal tissue for histology and the administration of various drugs). These experiments 
provided valuable information about the pathophysiology of IRI and subsequent inflammation, 
the pharmacology of DA5 and the mechanism underlying RIPC. For DA5, our findings have 
contributed to the first steps towards clinical application: DA5 was judged safe and well 
tolerated in healthy adult subjects in a phase I trial, and promising results have been obtained 
in a Phase II study on DA5 in renal transplantation [254].  
Concerning the translation of RIPC, single experiments in healthy animals, such as those 
described in chapters 3 and 4, have unfortunately not paved the road to clinical practice. 
As illustrated in chapter 2, we propose that, prior to performing any additional experiments 
in animals or humans, systematic review and meta-analysis should be carried out to assure 
optimal design of new studies. At present, we have performed such an analysis on data from 
animal experiments on IPC in renal IRI, from which we attempted to derive leads for clinical 
trials. However, the resulting recommendations are based on the assumption that there is a 
certain degree to which we can extrapolate results from animals to humans. This may hold true 
for many physiological phenomena, but not necessarily for all, and whether this holds true for 
RIPC is currently under debate. In any type of meta-analysis of animal studies, this ‘black box’ 
hampers the process of translation. Therefore, we propose that meta-analysis may prove even 
more powerful when data from human studies (if available) are retrospectively compared with 
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data from animal studies. Such a strategy may provide important information on the degree to 
which we can actually extrapolate results from both species, which is presently only guessed at 
but not empirically studied. The retrospective comparison is presently not common practice in 
systematic reviews, but may prove fruitful in the future.
Thus, extrapolation of results from animals to humans is not always straightforward. It has 
been proposed that preclinical testing of RIPC in animal models of disease (e.g. diabetes or 
hypertension) is needed to determine the influence of these co-morbidities. However, the 
combination of risk factors normally present in a cardiovascular patient is difficult to replicate 
in a single animal model. Therefore, translational models in human cells and tissues ex vivo or 
in humans in vivo are vital to further evaluate the possibilities of preconditioning. For instance, 
the experimental endotoxemia model in human volunteers enables us to investigate many 
aspects of this complex disease in detail, and is therefore very valuable in the study of sepsis 
and inflammation. For IRI in humans in vivo, a validated and well-tolerated model has not 
yet been established. As described in chapter 6, measurement of FMD to assess endothelial 
dysfunction after IRI of the forearm is a promising method to investigate this aspect of IRI. 
However, the FMD model requires optimization in terms of the duration of ischemia and 
reperfusion, the ischemic area and the time and site of measurement. 
A second promising technique to quantify IRI in humans is the use of ANXA5 scintigraphy, 
in which the phosphatidylserine-binding properties of this protein are employed to image 
phosphatidylserine exposition in the forearm [181,22]. In view of our results as described in 
chapter 5, we propose that DA5 scintigraphy may be equally effective to ANXA5 and perhaps 
more suitable for the detection phosphatidylserine exposition in the human forearm. A phase 
I study indicated that DA5 in doses up to 400 µg/kg has no adverse events in humans, and 
forearm scintigraphy may well be possible using lower doses. Unfortunately, both ANXA5 and 
DA5 are presently no longer commercially available for human use, which hampers further 
development of this technique.
8.2 RIPC: how does it work?
Explaining the phenomenon of RIPC to a layman or fellow researcher is apt to raise a few 
eyebrows and even more likely to be followed by the question “how does that work?”. This 
thesis provides a proof-of-principle for the protective effect of RIPC on renal IRI, and sheds light 
on the role of opioids in the underlying mechanism. However, our knowledge on RIPC signalling 
is far from complete. Each of the three signalling routes identified so far (Introduction, Figure 2) 
will be initiated by the release of some substance from cells in the remote organ, the question 
is: which? 
The most elegant method to answer this would be to measure the signalling compound(s) 
directly in the preconditioned tissue or blood, and timely i.e. during the RIPC stimulus. 
This method, however, is almost never achieved in current literature. For the neurogenic 
pathway, only tiny amounts of signalling compound may be adequate to induce signalling, 
and the substances released are probably very short-lived, which makes them extremely 
hard to detect. For the humoral and immunologic pathway, substances may be released in 
larger amounts, but still, measuring them can be challenging due to their short half-life, or 
simply the due to lack of an assay to quantify them. This is why most studies turn to the use of 
inhibitors or antagonists of the proposed signalling compounds to determine their role in RIPC 
signalling. This pharmacological approach has yielded nearly all of our current knowledge on 
RIPC signalling, yet has some major downfalls. Firstly, the half-life of the inhibitor may exceed 
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the duration of the RIPC stimulus, thereby interfering with physiological processes past the 
therapeutic intervention. Secondly, the effect of the signalling compound of interest may only 
occur locally, while the antagonistic drug is nearly always administered systemically. Thirdly, if 
the receptor specificity of the antagonist is low, the drug may influence not only the signalling 
route of interest, but others as well. Any of these three properties of the antagonist mat cause 
side effects which perturb the study results. 
Importantly, we also assume here that we have a notion of which compounds we are looking 
for. While it is possible (based on previous studies on IPC and IRI) to make an educated guess 
as to which signalling molecules are good candidates, there is an infinite range of compounds 
which could be involved, but have never been implicated in RIPC. Identifying these is not unlike 
looking for a needle in a haystack. This brings us to the final, important gap in current research 
on RIPC signalling. There is a plethora of RIPC studies using various remote and target organs, 
different drugs and various RIPC stimuli, and most of them report the involvement of a single 
signalling compound. There appears to be a certain threshold in RIPC signalling which must 
be reached for the protective effect to occur, and non-significant results (e.g. antagonists that 
were without effect) are seldom published. This may give the impression that the slightest 
change in experimental design may lead to the activation an entirely different RIPC signalling 
route. However, we may also draw almost the opposite conclusion, namely that RIPC signalling 
is multi-factorial and that not one, but a palette of factors is released from the remote organ 
which confers protection. The problem is that it is impossible to discern these two hypotheses 
by conducting experiments using single-factor antagonists. On the other hand, using a cocktail 
of antagonists is also unfavourable, since this may lead to drug-drug interactions that can 
perturb the experimental results (added on top of the downfalls of antagonists in general).
So far, it has proven difficult to find an alternative approach in identifying RIPC signalling 
factors. Two attempts were made to directly characterize a humoral factor: Serejo et al. [124] 
used reversed phase liquid chromatography to identify temperature-sensitive hydrophobic 
substances with molecular weights >3.5 kDa in the effluent from preconditioned rat hearts, 
which conferred cardioprotection through the activation of protein kinase C (PKC). Using 
a proteomic method, Lang et al. [255] concluded that either a humoral factor >8 kDa, or a 
neurogenic pathway was responsible for signalling after a remote renal preconditioning 
stimulus. Although these groups were not yet able to pinpoint which factors were present, 
advanced –omics approaches (e.g. NMR spectrometry and metabolomics) seem promising to 
further characterize the differences between naive and preconditioned serum and/or tissue. 
Since sample collection for these approaches is fairly non-invasive, they can be applied to study 
humoral factors not only in animals, but also in humans. 
8.3 The role of adenosine
In chapters 6 and 7, we show that adenosine is an important molecule in two experimental 
models of disease in humans: sepsis and IRI of the muscular bed. Inflammation and ischemia 
play a major role in both of these pathologies (see chapter 1), and adenosine is involved in 
both processes. In chapter 7, we show that changes of the adenosine metabolism of blood 
borne cells can occur as a rapid response to cell stress, which is perhaps not surprising in view 
of adenosine’s short half-life. Indeed, adenosine has been shown to be involved in the early 
window of cardiac preconditioning. In the ischemic phase of renal IRI, adenosine is thought 
to be generated from AMP by NT5E. Recently, Grenz and colleagues [256] showed that 30 
minutes of renal ischemia and reperfusion causes an increase in endogenous adenosine. Upon 
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reperfusion, the formed adenosine is quickly taken up via ENT transporters on the proximal 
tubule cell. Treatment with the ENT-inhibitor dipyridamole allows for higher interstitial 
adenosine levels, and thereby reduces inflammation and improves renal function after renal 
IRI. Furthermore, deletion of the ENT transporter yielded selective protection against renal IRI 
in ENT -/- mice. Thus, there appears to be a role for adenosine in IRI and related pathologies, 
and several drugs allow us to modulate the adenosine metabolism. Since we show in chapter 3 
that RIPC-mediated protection against renal IRI is not adenosine dependent in our model and 
RIPC protocol, we propose that pharmacological support of the adenosine pathway may have 
an additive effect on RIPC. 
8.4 Future perspectives
8.4.1  Clinical application of RIPC
Will the gaps in our understanding of the mechanism underlying RIPC stand in the way of its 
implementation in clinical practice? Not necessarily, since a number of clinical trials on RIPC are 
already in progress. Perhaps the non-invasive, inexpensive and safe character of RIPC makes 
it easier to perform clinical trials on this protective strategy, as compared to e.g. novel drugs. 
However, clinical trials are costly and extending our knowledge of the mechanism underlying 
RIPC will reduce the risk of performing a sub-optimal trial. It may enable us to predict RIPC 
efficiency and optimize its application in various patient groups, and to effectively boost RIPC-
mediated protection with specific medication. Meanwhile, the first steps in the translation of 
RIPC to clinical practice are in progress in several important fields.
One such field is renal transplantation, where preconditioning of the donor may transfer 
protection of the transplanted kidney. There are 28.000 kidney patients in the Netherlands 
alone, 879 of which are on the waiting list for renal transplantation (as of May 2012; www.
transplantatiestichting.nl). In 2010, a total of approximately 93.000 patients were registered 
on the kidney transplant waiting list in the United States. This number is expected to rise in the 
coming years because of the increased incidence of obesity, diabetes and hypertension, which 
are important risk factors for renal failure. The mortality rate among patients waiting for a 
kidney transplant is 20%. In 2011, 833 patients in The Netherlands received a renal transplant, 
436 of which were from a living donor. Long-term function and survival of a renal graft largely 
depend on the occurrence of acute rejection and DGF, as a consequence of renal damage. IRI 
is a major determinant of DGF, which occurs in 20-40% in grafts from heart-beating donors and 
approximately 5% of patients receiving a graft from a living donor. Therefore, RIPC-mediated 
protection against IRI in the transplanted kidney can improve graft function and survival and 
reduce the chance of rejection. Studies of the effect of RIPC on kidney function in adults and 
children undergoing cardiovascular surgery have shown conflicting results [40,39,41,257]. The 
first phase III trial on RIPC in renal transplantation has recently been started in London (the 
REPAIR trial, see also http://repair.lshtm.ac.uk/).
A second group of patients at whom we wish to aim our future research on RIPC are those 
at risk for contrast-induced nephropathy. The damage caused by radiologic contrast agents is 
thought to result from vasoconstriction and subsequent renal ischemia, combined with toxicity 
on vascular endothelial cells and tubular epithelial cells. This complication continues to be a 
common form of hospital-acquired acute renal failure, since contrast media are used often, 
also in vulnerable patients. Although the incidence of contrast-induced nephropathy is low 
in patients with normal renal function, it can be much higher in e.g. the elderly, diabetics and 
patients with severe renal insufficiency. Patients may even need renal replacement therapy, 
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e.g. dialysis as a result of contrast imaging. Mortality rates can increase from 1% in patients 
with no contrast-induced nephropathy to up to 35% for those who develop nephropathy 
requiring dialysis. Current strategies to prevent contrast-induced nephropathy are effective 
but insufficient, and many candidate measures failed to show benefits in randomized double-
blinded trials. Given the role of ischemia in this disease, RIPC may be a new tool to prevent 
contrast-induced nephropathy, as recently indicated by a retrospective observational cohort 
study [258]. Future studies are needed to clarify whether RIPC can be a successful strategy in 
this field.
Even though the kidney had received much attention in this thesis, the heart (birth place of 
RIPC [14]) is still the main organ of interest for clinical application of this technique. A number 
of clinical trials have investigated the protective effects of RIPC on e.g. CABG, valve replacement 
and ventricular septal defect surgery (recently summarized in [259]). Systematic review and 
meta-analysis of these trials indicates that RIPC reduces myocardial damage markers after 
vascular surgery, but does not influence mortality or perioperative infarction rate [260]. 
However, as we show in chapter 2, clinical trial designs may be improved if the major findings of 
the laboratory studies are taken into account. For the heart, animal studies on (R)IPC protocols 
are overflowing, but no meta-analysis of these data has been performed to date. A systematic 
review of animal studies on IPC in myocardial IRI is in progress in our laboratory, which will shed 
light on the factors influencing IPC efficacy in this field. Furthermore, the list of interventions in 
which RIPC may reduce ischemic damage goes on: animal studies have implicated its usefulness 
in transplantation (renal, but also e.g. liver and pancreas), plastic surgery, perinatal asphyxia, 
stroke and other ischemic conditions. However, the aforementioned considerations regarding 
the clinical translation of RIPC also apply to these fields, and evidence in humans is currently 
very scarce. 
8.4.2 Clinical application of DA5
The therapeutic effect of DA5 on IRI suggests a mechanistic role for PS exposition in this 
condition. Animal studies have shown a protective effect of DA5 in liver IRI, renal IRI, myocardial 
ischemia and pancreatic isle transplantation, which gives this protein a wide range of possible 
clinical applications. As mentioned above, the first results in humans have been obtained in a 
Phase II study on DA5 in renal transplantation (NCT00615966). The incidence of delayed graft 
function and days on dialysis were significantly reduced in recipients of marginal deceased 
donor kidneys who were treated with 400 μg/kg DA5, compared with control subjects treated 
with placebo. Importantly, 400 μg/kg DA5 did not increase the frequency or severity of 
adverse events. At one month post-transplantation, trends for higher 24-hour urine output and 
estimated glomerular filtration rates were observed among DA5-treated recipients. Further 
investigations with this intervention are planned, but depend on the future availability of 
clinical grade DA5.
8.4.3 Renal Ischemic Per- and Postconditioning
There is one key prerequisite for RIPC which limits its therapeutic implementation: the 
occurrence of IRI needs to be known beforehand. This restricts the application of preconditioning 
to planned interventions, such as elective surgery, contrast administration and living-donor 
renal transplantation. However, this approach fails when the IRI occurs unexpectedly, e.g. in 
myocardial infarction and in grafts obtained from a non-heartbeating donor. 
Recently, it has been found that this problem can be overcome by applying the ischemic 
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conditioning stimulus during or after index ischemia, two approached respectively known 
as perconditioning and postconditioning. Kadkhodaee et al. recently reported that remote 
ischemic per- and postconditioning significantly reduced renal IRI in a rat model of renal IRI 
[261]. In line with these results, we recently reported the first data on the combined effect of 
local and remote ischemic postconditioning (LIPostC and RIPostC, respectively) on renal IRI. In 
our rat model, renal IRI caused a decline in renal function, as reflected by an increase in plasma 
creatinine, plasma urea and FENa. These detrimental effects were only partially reduced by 
RIPostC or LIPostC alone. However, the combined application of RIPostC + LIPostC significantly 
reduced the IRI-induced decrease in renal function. Furthermore, a similar synergistic effect of 
RIPostC + LIPostC was observed for renal histological damage, as assessed by scoring periodic 
acid Schiff-stained sections of renal cortex on a 0-5 scale by an investigator blinded to treatment 
allocation [37]. Thus, we showed that RIPostC and LIPostC have synergistic protective effects 
on IRI of the kidney. 
Although both strategies have been shown to influence the status of the MPTP, it has been 
postulated that LIPostC does so by delaying the normalisation of the intracellular pH [262], 
while RIPostC is thought to cause the release of various signalling molecules, such as adenosine, 
opioids and cytokines, which act on the MPTP through  the activation of the cGMP/PKG, RISK 
and/or SAFE pathway [263]. Our present finding supports the theory that the mechanisms of 
action could be different for LIPostC versus RIPostC. Our data suggest that the combination 
of local and remote ischemic postconditioning is a highly interesting approach for further 
preclinical studies. However, the concept of RIPostC is relatively new, and further studies are 
needed to investigate possibilities for clinical implementation of ischemic postconditioning in 
renal kidney transplantation and other fields.
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Summary
As described in detail in chapter 1, ischemia-reperfusion Injury (IRI) is the damage that occurs 
when an organ or tissue is temporarily occluded from the bloodstream. Due to its high energy 
demand and intricate vascular network, the kidney is especially vulnerable to IRI. Renal IRI 
occurs in many clinical conditions, such as sepsis, shock, renal artery stenosis, contrast 
administration, cardiac and aortic surgery and transplantation. Current methods to reduce 
IRI are inadequate and novel therapies are needed, not only for the kidney, but also for the 
heart and other vital organs. This thesis sheds light on a number of promising approaches to 
reduce IRI: ischemic preconditioning, modulation of adenosine and opiate metabolism and 
modulation of the immune response with Diannexin (DA5).
IPC, a method in which a brief ischemic stimulus is applied locally (LIPC), or to a remote 
organ (RIPC), is a potent strategy to reduce IRI in many organs. However, this method has not 
yet been translated successfully into clinical practice, in spite of promising results in animal 
studies. Meta-analysis of animal studies can provide clues to improve the design of clinical 
trials on (R)IPC. In chapter 2, we report the results of a systematic review and meta-analysis of 
animal studies, in which we aimed to identify factors modifying IPC efficacy in renal IRI. Meta-
analysis of data from fifty-eight papers showed that IPC improves renal function and reduces 
renal damage after IRI, as compared to controls. Local and remote IPC were equally effective 
in reducing renal IRI. We observed a large gap in study data concerning the optimal window 
of protection, but IPC appeared to be more effective when applied >24 hours before ischemia 
(late window of protection). Furthermore, IPC efficacy may be species dependent, since the 
protective effect differed between animal species (rat versus mouse). These results can be 
used to enhance the design of future (clinical) studies, since current clinical trials on RIPC may 
not be optimally designed. Our findings also identify a need for further standardization of 
animal experiments.
RIPC using the limb as remote organ poses a safe, non-invasive, low-cost method to reduce IRI, 
and has been shown to be effective for heart and liver. Therefore, in chapter 3, we used a rat 
model to investigate whether RIPC by brief hind limb occlusion protects against renal IRI, and 
whether this protection is adenosine dependent. Rats underwent either no RIPC, unilateral 
RIPC or bilateral RIPC. The preconditioning stimulus was either continuous (12’/12’ I/R) or 
fractionated (three times 4’/4’ I/R). After the last reperfusion period, we induced 25’ ischemia 
in the right kidney. After 24 h of reperfusion, renal function was improved by 30-60% in both 
bilateral RIPC groups and in the fractionated unilateral group. Renal tubule damage and kidney 
injury molecule-1 expression were reduced in three of four RIPC groups. Treatment with the 
adenosine receptor blocker 8-(p-sulfophenyl)theophylline had no effect on fractionated or 
continuous RIPC. Thus, brief hind limb ischemia induces protection against renal IRI, which 
makes this a promising strategy to prevent renal IRI in a clinical setting. Bilateral RIPC was 
more effective than unilateral RIPC, and this protection occurs via an adenosine-independent 
mechanism.
Since we found that adenosine did not appear to play a major role in our model, we went on to 
further address the gap in understanding of renal RIPC signalling in chapter 4. Using the renal 
IRI model as described previously, we investigated the involvement of candidate signalling 
molecules and enzymes in RIPC. Inhibitors and antagonists of noradrenalin, cannabinoids, 
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glucocorticoids, inducible nitric oxide synthase, calcitonin gene-related peptide, ganglion-
mediated signalling, heme oxygenase and free radicals were without effect. However, pre-
treatment with the opioid receptor antagonist naloxone completely blocked the protective 
effect of RIPC after renal IRI in terms of renal function and renal damage. Thus, renal RIPC by 
brief hind limb ischemia may be the result of endorphin release, e.g. from the brain, the hind 
limb or the kidney itself. The importance of opioid signalling in renal RIPC provides vital clues 
for its successful translation to the clinical setting.
In chapter 5, we studied a different target for the reduction or prevention of IRI, namely 
phosphatidylserine exposition. The exposition of phosphatidylserines on the outer leaflet of 
the cell membrane is a pro-inflammatory signal for cell-stress, and an important event in the 
pathophysiology of IRI. We hypothesized that shielding of exposed phosphatidylserines by 
the ANXA5 homodimer DA5 protects against renal IRI, and studied this hypothesis in a mouse 
model of mild renal IRI. DA5 treatment before renal IRI decreased proximal tubule damage 
and leukocyte influx, decreased transcription and expression of renal injury markers NGAL and 
KIM-1 and improved renal function. Furthermore, we used a mouse model of ischemic hind 
limb exercise to assess DA5 biodistribution and targeting, in which DA5 was found to have a 
distinct distribution pattern and longer blood half-life. DA5 targeted specifically to the ischemic 
muscle and its affinity exceeded that of ANXA5. Our findings indicate that DA5 is a promising 
therapeutic tool to prevent IRI in a clinical setting, and a potential new imaging agent for the 
study of phosphatidylserine-exposing organs in vivo.
Next to the kidney, the heart has been the first and most important target organ for studies 
on IPC and IRI. IRI occurs not only in cardiac, but also in skeletal muscle of the arm, which 
is easily accessible for experimental studies in humans. In chapter 6, we used an IRI model 
of skeletal muscle in healthy human volunteers, which enables us to study in vivo effects of 
IRI non-invasively. Given the fact that many aspects of IRI are similar in various organs, this 
model may allow us to extrapolate our results to the cardiac muscle and other organs. In this 
model, we studied endothelial function after IRI by measuring the flow-mediated dilatation 
(FMD) of the forearm muscle. Furthermore, we hypothesized that treatment with statins 
would have a protective effect on endothelial function after IRI, since these drugs upregulate 
the adenosine producing enzyme ecto-5’nucleotidase (NT5E). Our results show that I/R 
significantly decreases FMD; however, statin pretreatment did not alter the effect of I/R on 
FMD (irrespective of treatment duration or type of statin used). This experiment suggests 
that the cardioprotective effects of statins (both lipophilic and hydrophilic) against I/R are not 
mediated through preservation of endothelial function.
Apart from its protective effects on IRI, adenosine also appears to play a role during sepsis, when 
the extracellular adenosine concentration increases rapidly. Since the underlying mechanism 
of this increase in humans is unknown, in chapter 7 we used a model of experimental 
endotoxemia in healthy volunteers to study the role of adenosine signaling and metabolism in 
sepsis. Following experimental endotoxemia, endogenous adenosine concentrations increased. 
Expression of NT5E mRNA was upregulated, while adenosine deaminase (ADA) mRNA was 
downregulated. Furthermore, both ADA and adenosine kinase (AK) activity were significantly 
diminished. A2a receptor mRNA expression was elevated, whereas mRNA expression of A1 
and A3 receptors was reduced. In human leukocytes in vitro, LPS dose-dependently attenuated 
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the activity of both ADA and AK. We conclude that adenosine metabolism and signaling 
undergo adaptive changes during human experimental endotoxemia, promoting higher levels 
of adenosine thereby facilitating its signaling.
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Samenvatting
Ischemie-reperfusieschade (IRS) treedt op wanneer een orgaan of weefsel tijdelijk wordt 
afgesloten van de bloedsomloop. Zoals uitgebreid is beschreven in hoofdstuk 1, is de nier 
buitengewoon gevoelig voor deze schade, hetgeen voortkomt uit de hoge energiebehoefte 
van dit orgaan en haar verfijnde netwerk van capillaire bloedvaatjes. Renale IRS komt vaak 
voor en speelt in veel klinische situaties een rol, onder andere bij sepsis, shock, stenose van 
de nierarterie, toediening van contrastvloeistof, hart- en aortachirurgie en transplantatie. 
De huidige behandelingsmogelijkheden om IRS te verminderen zijn ontoereikend en er is 
behoefte aan nieuwe therapieën, niet alleen voor de nier, maar ook voor het hart en andere 
vitale organen. Dit proefschrift beschrijft een aantal veelbelovende nieuwe strategieën om IRS 
tegen te gaan: ischemische preconditionering (IPC), het beïnvloeden van het adenosine- en 
opioïdmetabolisme en het aanpassen van de immuunrespons met Diannexine. 
IPC is een methode waarbij een korte ischemische stimulus wordt gegeven aan het doelorgaan 
zelf (lokale ischemische preconditionering; LIPC), of aan een orgaan op afstand (‘remote’ 
ischemische preconditionering; RIPC). Deze techniek blijkt voor veel organen een goede 
methode om IRS te verminderen, maar heeft desondanks de vertaalslag naar de kliniek nog niet 
gemaakt. Door meta-analyse van gepubliceerde dierstudies kunnen belangrijke aanwijzingen 
worden verkregen om de opzet van klinische trials naar de effecten van IPC in mensen te 
verbeteren. In hoofdstuk 2 rapporteren we de resultaten van een systematische review en 
meta-analyse van dierstudies, waarin we hebben geprobeerd factoren te onderscheiden die de 
effectiviteit van IPC op renale IRS beïnvloeden. Meta-analyse van data uit achtenvijftig studies 
wijst uit dat IPC de nierfunctie na IRS verbetert en nierschade vermindert, vergeleken met 
onbehandelde controledieren. LIPC en RIPC zijn hierbij even effectief. IPC bleek effectiever 
te zijn wanneer er een interval van meer dan 24 uur was tussen de IPC-stimulus en het 
induceren van de nierschade, ook wel het ‘late window of protection’ genoemd. Daarnaast 
kan de effectiviteit van IPC diersoortafhankelijk zijn, aangezien deze beschermende techniek in 
muizen effectiever is dan in ratten. Onze analyse impliceert dat de opzet van lopende klinische 
studies naar IPC van de nier niet optimaal is en de resultaten kunnen gebruikt worden om het 
ontwerp van toekomstige studies te verbeteren. Onze kwaliteitsanalyse van de artikelen in 
deze review geeft aan dat er op het gebied van standaardisering en rapportage van dierstudies 
nog veel verbetering nodig is.
RIPC waarbij een arm of been als ‘remote’ orgaan wordt gebruikt, lijkt een veilige, niet-
invasieve en goedkope methode om IRS te verminderen en deze strategie is in dierstudies 
effectief gebleken voor het hart en de lever. Daarom gebruiken we in hoofdstuk 3 een 
nierschademodel in ratten om te onderzoeken of RIPC, door middel van het kort afklemmen 
van een been, ook de nier kan beschermen tegen IRS. Daarnaast hebben we onderzocht of dit 
beschermende effect afhankelijk is van de signaalstof adenosine. Bij de ratten werden ofwel 
géén (controlegroep), één (unilateraal), danwel beide (bilateraal) achterpootjes kortdurend 
ischemisch gemaakt. Deze ischemische stimulus vond  continue (12 minuten ischemie / 12 
minuten reperfusie) danwel gefractioneerd (drie cycli van 4 minuten ischemie / 4 minuten 
reperfusie) plaats. Na de laatste reperfusieperiode van de pootjes werd de rechternier 
gedurende 25’ ischemisch gemaakt. Na 24 uur was er een verbetering in nierfunctie van 30-
60% zichtbaar in de bilaterale RIPC-groepen én de gefractioneerde unilaterale RIPC groep in 
vergelijking tot de controlegroep. Nierschade was verlaagd in drie van de vier RIPC groepen, 
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zoals vastgesteld aan de hand van histologie en de expressie van de schademarker KIM-1. 
Toediening van de adenosinereceptorantagonist 8-(p-sulfophenyl) theophylline had geen effect 
op het beschermende effect van RIPC. We concluderen dat RIPC door het kort afklemmen van 
een ledemaat beschermt tegen ischemische nierschade, wat het een veelbelovende strategie 
maakt om IRS in de klinische setting tegen te gaan. Bilaterale RIPC is hierbij effectiever dan 
unilaterale RIPC en het effect is niet afhankelijk van adenosine.
Gezien onze bevinding dat adenosine in ons model geen belangrijke rol speelt in de 
signaalroute van RIPC, bestuderen we in hoofdstuk 4 welke signaalstoffen wél betrokken 
zijn bij het beschermende effect van RIPC op IRS van de nier. Een aantal signaalmoleculen en 
enzymen werd geselecteerd en onderzocht in het voorgenoemde nierschademodel in de rat. 
Remmers en antagonisten van noradrenaline, cannabinoïden, glucocorticoïden, iNOS, CGRP, 
neurale ganglia, heemoxygenase en vrije radicalen beïnvloedden het beschermende effect van 
RIPC op renale IRS niet. Echter, voorbehandeling met naloxon, een opioïdreceptor antagonist, 
blokkeerde het beschermende effect van RIPC volledig, zowel wat betreft nierfunctie als voor 
nierschade. De afgifte van endorfines in bijvoorbeeld de achterpoot, de nier, of het brein lijkt 
dus ten grondslag te liggen aan de bescherming van de nier door het kort afklemmen van 
deze ledemaat. Kennis met betrekking tot de rol van opioïden als signaalstof in RIPC biedt 
belangrijke aanwijzingen om deze techniek succesvol te kunnen implementeren in de kliniek.
In hoofdstuk 5 richten we onze aandacht op de rol van fosfatidylserine expositie in de preventie 
van renale IRS. De expositie van fosfatidylserines in de buitenste laag van de celmembraan is 
een vroeg pro-inflammatoir signaal dat optreedt bij celstress en is een belangrijke stap in de 
pathofysiologie van IRS. We veronderstelden dat het afschermen van fosfatidylserines door 
middel van Diannexine (een annexine A5 dimeer; Introductie Figuur 3) zou beschermen tegen 
IRS van de nier en we hebben deze hypothese getest in een nierschademodel in muizen. 
Voorbehandeling met Diannexine leidde tot verminderde proximale tubulusschade en leukocyt 
influx, verminderde expressie van de schademarkers NGAL en KIM-1 en een verbeterde 
nierfunctie. Tevens hebben we een model voor ischemische inspanning in muizen gebruikt om 
de biodistributie en targeting van Diannexine te bestuderen. In vergelijking tot annexine A5 
heeft Diannexine een langere halfwaardetijd en een specifiek distributiepatroon. Diannexine 
bindt specifiek aan ischemisch spierweefsel en heeft hierbij een hogere affiniteit dan annexine 
A5. Onze resultaten geven aan dat Diannexine een veelbelovend middel is om IRS in de kliniek 
te voorkomen en dat deze stof gebruikt kan worden als imaging tool om de fosfatidylserine 
expositie in organen in vivo te bestuderen.
Het hart is, naast de nier, het eerste en belangrijkste orgaan in studies naar IPC en IRS. IRS komt 
nier alleen voor in de hartspier, maar ook in skeletspier en andere organen, en er zijn veel 
overeenkomsten in de pathofysiologie van IRS in deze verschillende organen. In hoofdstuk 6 
zetten we in gezonde vrijwilligers een niet-invasief model van IRS in spierweefsel op, omdat 
we hierin de effecten van IRS in de mens in vivo kunnen onderzoeken en onze resultaten 
kunnen vertalen naar de hartspier. In dit model hebben we vóór en na IRS van de onderarm 
de flow mediated diliatation (FMD) in de onderarm gemeten, die als maat dient voor de 
endotheelfunctie in dit spiervaatbed. We veronderstelden eveneens dat behandeling met 
statines een beschermend effect zou kunnen hebben op de endotheelfunctie, omdat deze 
medicijnen het adenosine producerende enzym ecto-5’-nucleotidase (NT5E) activeren. Onze 
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resultaten geven aan dat de FMD na IRS afneemt en de endotheelfunctie dus verminderd is. 
Echter, behandeling met statines beïnvloedde dit effect niet, ongeacht het type statine en de 
duur van de behandeling. We concluderen dat de gunstige effecten van statines, zoals die 
bekend zijn voor het hart, niet voortkomen uit een beschermend effect op de endotheelfunctie.
Naast de beschermende effecten van adenosine in IRS speelt deze purine ook een rol tijdens 
sepsis, gezien het feit dat de extracellulaire adenosineconcentratie in mensen met sepsis 
snel toeneemt. Het mechanisme dat aan deze toename ten grondslag ligt is onbekend, 
en in hoofdstuk 7 gebruiken we een model van experimentele endotoxemie in gezonde 
vrijwilligers om de rol van adenosine en haar metabolisme tijdens sepsis te bestuderen. Na 
experimenteel opgewekte endotoxemie nam de concentratie van endogeen adenosine toe. 
Ook de expressie van het enzym NT5E nam toe, terwijl die van adenosinedeaminase juist 
afnam. Ook de activiteit van de enzymen adenosinedeaminase en adenosinekinase nam af. 
De expressie van de adenosine-2a-receptor was verhoogd, terwijl de A1- en A3-receptoren 
juist in expressie afnamen. In humane leukocyten in vitro remde LPS dosisafhankelijk de 
activiteit van adenosinedeaminase en adenosinekinase. We concluderen dat het metabolisme 
en de signaalroutes van adenosine tijdens experimentele endotoxemie zó veranderen dat de 
adenosineconcentratie wordt verhoogd, waardoor de signaalroutes van deze stof kunnen 
worden versterkt.
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Abbreviations
5NT 5’-nucleotidase
8-SPT 8-(p- sulfophenyl) theophylline
99mTc Metastable technetium-99
ADA Adenosine deaminase
ADO Adenosine
ADP Adenosine diphosphate
AK Adenosine kinase
AKI Acute kidney injury 
AMP Adenosine monophosphate
ANXA5 Annexin A5
ATP Adenosine triphosphate
b.w. Body weight
bilat Bilateral
BP Blood pressure
BUN Blood urea nitrogen 
CABG Coronary artery bypass grafting 
Ccr Creatinine clearance
CI Confidence interval 
DA5 Diannexin
DGF Delayed graft function
EDTA Ethylenediaminetetraacetic acid
ENT Equilibriative nucleoside transporter
FENa Fractional excretion of sodium
FMD Flow mediated dilatation
GaM Goat anti mouse
GaR Goat anti rat
GFR Glomerular filtration rate
HPLC High-performance liquid chromatography
HR Heart rate
I/R Ischemia and reperfusion
ID Injected dose
IL Interleukin
IPC Ischemic preconditioning
IRI Ischemia-reperfusion injury
KIM-1 Kidney injury molecule-1
LIPC Local ischemic preconditioning
MaM Mouse anti mouse
MAO Mesenteric artery occlusion
MPTP Mitochondrial permeability transition pore
NAD Nicotinamide adenine dinucleotide
NGAL Neutrophil gelatinase-associated lipocalin
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NO Nitric oxide
NT5E Ecto-5’-nucleotidase
OCT Optimal cutting temperature
ORB Orthodontic rubber band
PAS Periodic acid Schiff
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PBS-T PBS-tween
PCI Percutaneous coronary intervention
PCR Polymerase chain reaction
PS Phosphatidylserine
RbaH Rabbit anti human
RIPC Remote ischemic preconditioning
ROS Reactive oxygen species
RTQ Real-time quantitative
SBP Systolic blood pressure
SD Standard deviation
SEM Standard error of the mean
SMD Standardized mean difference
SPECT Single-photon emission computed tomography
TNF Tumor necrosis factor
Unilat Unilateral
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jullie hierbij allemaal voor alle gezelligheid, luisterende oren, gedeelde frustraties, pep-talks, 
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graag je dag voor je (hij draagt dan zijn mintgroene broek en roze overhemd en sneakt het 
huis uit zonder dat Cecilia hem gezien heeft). Frank heeft àltijd minstens tien ideeën over 
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nieuwe stagiaire van Kees? Janny weet het! Janny, ik ben vaak jaloers op de wijsheid die je hebt 
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belangstelling over wat mij en anderen bezig houdt buiten het lab, bedankt voor alle gezellige 
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H·O-groep (de; m,v)
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in dit gezelschap, waarvan de harde kern bestaat uit één post-doc (Al·win! Na een 
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één analist (Bas, bedankt voor de gezelligheid in U1 en je hulp aan mij en mijn stagiares bij 
allerhande celkweken, kleuringen en andere experimenten) en één creatieve explosie (zie 
Wagener, Frank).
Big Wil·mer (de; m)
Pseudoniem van de vrolijke zuiderling Mar·tijn Wil·mer, fesitvalkenner en aanvoerder van het 
front ‘CiPTEc’s 4 president”. Komt van pas bij ronde 7 en is de soepelste man op de dansvloer 
bij 90’s Now!
Greup (De; m)
Ook bekend als Rick Greu·pink, een stabiele, vriendelijke, farmacologisch connaisseur met 
goed haar en een brede interesse in o.a. microchirurgie en kwarktaart. Tevens liefhebber van 
kantinebroodjes en archaïsche woorden.
Plof·kop (de; m)
Oftewel Rick Mut·saers, afdelingsheraut met persoonlijke haarstijl en mede-piraat. Na een 
gewenningsperiode van een paar weken vol droogijsbommetjes, dropbombardementen en 
uitspraken als “What arè you smiling aboút?!’” “Yarrr!” en “Eddíííe”, ga je vanzelf van hem 
houden ;)
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Per·tijs, Jean·ne (v)
Histologie-expert met engelengeduld, vaak te herkennen aan knalroze vingers en vierkante 
ogen, i.v.m. alle gesneden coupes en PAS-kleuringen. Je hulp bij de rat RIPC studies en expertise 
op histologiegebied was onontbeerlijk, waar voor zeer veel dank!
Van der Vliet, Daan (m)
Gedreven vaatchirurg die met veel enthousiasme het vaatchirurgisch onderzoek aanstuurt. 
Motiveert, zorgt voor feedback en ruggespraak m.b.t. manuscripten, abstracts en 
subsidieaanvragen en daarnaast ook voor vermaak d.m.v. zijn wijnkennis en sterke (reis-)
verhalen.
Men·ting, Theo (m)
Bracht samen met ondergetekende heel wat uurtjes in het CDL door en later achter RevMan 
(zie hoofdstuk 2), wat altijd gezellig was. Is eigenlijk altijd enthousiast en vrolijk, ook al moeten 
er eindeloos ratjes gewogen worden of komt er geen eind aan de lijst met referenties. Op naar 
die mooie Cochrane review!
Anes·the·sio·lo·gie (de; v)  
Afdeling met een aantal gezellige en bevlogen onderzoekers, zoals Mi·chiel Va·ne·ker, Je·roen 
van Hees en Mat·thijs Kox, die altijd klaar stonden om onderzoeksperikelen met een gezonde 
dosis humor (of een statistische goocheldoos) te lijf te gaan. Maar bovenal twee fantastische 
biotechnici: I·lo·na en Fran·cien. Laatstgenoemden hebben ook een plaatsje verdiend op de 
lijst-der-onmisbaren. Zij leerden mij o.a. hanteren, prikken, hechten, opereren en reanimeren, 
lieten mij steeds allerlei spullen lenen / gebruiken, serveerden talloze koppen thee / 
soep / drinkyoghurt en waren altijd geïnteresseerd in mijn huis / liefdesleven / weekend / 
cocktailavondjes. Kortom: jullie waren van onschatbare waarde! 
In·ten·sive care (de; m)
Afdeling die wordt bevolkt door onder andere professor Pe·ter Pick·kers en Bart Ra·ma·kers, de 
onbetwiste goeroes van het humaan endotoxemiemodel dat de data opleverde voor hoofdstuk 
7. Bedankt voor de mooie samenwerking! Het schijnbaar eindeloze aantal bloedbuizen en 
epjes met lymfo’s en mono’s, de vele PCRs en blotjes en de nodige uurtjes graven in de -80 
vriezer op zoek naar nog meer samples, hebben uiteindelijk tot het prachtig CCM paper geleid! 
Nu·cle·ai·re ge·nees·kun·de (de; v)
Afdeling die de thuisbasis is van onder andere professor Ot·to Boer·man en biotechnicus 
Ca·the·lij·ne Frie·link. Zonder inbreng van Otto zou hoofdstuk 5 waarschijnlijk niet hebben 
bestaan, zowel tijdens het ontwerpen van de experimenten als het interpreteren en beschrijven 
van de resultaten was zijn input onmisbaar. Otto, bedankt voor je interesse, positieve blik en 
geduldige uitleg (dat ik aanvankelijk vrijwel niets van nucleaire imaging wist stond ons overleg 
nooit in de weg) en het steeds snel en nauwkeurig becommentariëren van mijn manuscript. 
Ca·the·lij·ne, het lijkt al weer een tijdje geleden, maar wij hebben samen toch flink wat 
manuurtjes gedraaid op de RNU! We hadden het geluk dat onze experimenten eigenlijk heel 
goed verliepen: er bleef zelfs tijd over om het genrè van de korte film, de belevenissen van 
Marieke en Constantijn en het houden van konijnen en cavia’s onder de aandacht te brengen! 
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Claas·sen, Ka·ri·na (v)
Wahrst meine ersten Stagiaire, was bedeutet dass wir extra viel von einander gelernt haben. 
Zeichnete sich in der Zählung von Nieren-Coupes (ohne jemals dieser langweiligen Job zu 
beschweren) und Ihre Westerns und PCRs erklärten ein großes Teil der Nierestudiendaten. Für 
dieses möchte Ich Ihnen danken, und wie immer wird vermutlich Ihre Antwort sein: “Graag!”.
Riet, Luuk te (m)
Vrolijke, gezellige Twentse bioloog met krullenbol en onvolprezen zangkwaliteiten. Daarnaast 
als stagiair zeer bedreven als OK-assistent, westernblotter, PCR-master, waarvan acte in 
hoofdstuk 3. Woont altijd trouw werkbesprekingen bij om 9 uur ’s ochtends en ’s middags na 5 
uur. Tegenwoordig aanwinst als AIO voor het Erasmus MC.
Cen·traal Die·ren La·bo·ra·to·ri·um (het; o)
Alle CDL biotechnici, met name Daph·ne en Bi·an·ca, en alle CDL dierverzorgers, met name 
Hel·ma en Nan·cy, wil ik hartelijk bedanken voor al hun hulp, advies en goede zorgen tijdens 
mijn dierexperimenten.
Hooij·mans, Car·lijn (v)
Paranimf die pas in de laatste fase van mijn promotie in beeld kwam in de rol van sprankelende 
dierstudie review-expert. Opende mijn ogen voor de wereld van SR’s en MA’s (nu bijna 
dagelijkse kost bij heelkunde!), hetgeen leidde tot het prachtige tweede hoofdstuk van dit 
proefschrift. Carlijn, over samenwerkingsprojecten met jou maak ik me nooit zorgen: ook al 
bevatten ze 5731 referenties, gezellig wordt het toch wel! Bedankt dat je mijn paranimf wilt zijn 
als vertegenwoordigster van onze gezamelijke passie voor dierexperimentele reviews.
Wou·ters, Con·stan·tijn (m)
Zelfbenoemde blije doos in de gedaante van cardioloog in opleiding en ge-upgrade van collega 
tot vriend en paranimf. Belangrijkste bijdragen aan mijn promotie zijn (naast hoofdstuk 6): het 
leuten van veel thee en cola, het sturen van zinnige en onzinnige mails over wetenschap, ijs 
en grappige YouTube-filmpjes, tochtjes naar de kinderboerderij of speeltuin met Hugo en Tijl, 
het samen tillen van de laatste loodjes op heidagen, talrijke feestjes en etentjes met Malaika 
en het opfleuren van Hartstichtingscursussen op Papendal. Ben superblij dat je naast me wilt 
staan!
Vriend (de; m,v; meervoud: vrienden)
Persoon waarmee men door gevoelens van genegenheid is verbonden, bij uitstek geschikt om 
leuke dingen mee te ondernemen en de zinnen te verzetten. Van mijn oud-huidgenootjes en 
oud-biologen (er verandert véél in 5 jaar) tot mijn nieuwe stalgenootjes, bedankt allemaal! Een 
speciaal woord van dank aan Mo·ji·bi·o, een bron van veel vermaak, cocktails en toeristische 
uitjes in eigen land en Weurt Up!, al jaren lang het vaste pubquiz-team dat garant staat 
voor een dinsdagavond vol hersenactiviteit op andere vlakken dan IRS. Rik, Mar·ta, Gui·do, 
Lin·da, Je·roen, Ar·jan, Sas·ki·a en Fin·cent en Bar·ba·ra en Gijs, bedankt voor jullie steun en 
gezelligheid bij de eerste en laatste loodjes. Het is wel tijd voor een feestje!
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Fa·mi·lie (de; v; meervoud: families)
Je bloedverwanten, je gezin, de plek waar je vandaan komt en waar thuis is. Alle lieve ooms 
en tantes die steeds weer benieuwd waren naar de vorderingen van mijn promotie: dank jullie 
wel! 
Han en Wil·ma, ik heb vaak gebruik mogen maken van jullie luisterende oren en jullie advies bij 
strubbelingen, als ik er doorheen zat of als het allemaal weer veel te langzaam vorderde naar 
mijn zin. Daarnaast zorgden jullie, met papa en mama natuurlijk, voor vele leuke verjaardagen, 
warme maaltijden, hulp bij het ophalen van spullen en natuurlijk de algehele gezelligheid. 
Ook als steunpilaar voor paps en mams zijn jullie onmisbaar en daarvoor wil ik jullie heel erg 
bedanken.
Mijn lieve zussen E·rin en Me·gan, wat ben ik blij met jullie! Jarenlang heb ik onderschat hoe 
goed jullie mij eigenlijk kennen (misschien een valkuil van de oudste?), maar nu weet ik dat ik 
altijd bij jullie terecht kan. We hebben veel meegemaakt en waren daarin soms erg op onszelf, 
maar uiteindelijk heeft het ons dichter bij elkaar gebracht. Gelukkig kunnen we ook als de 
besten kletsen, lachen en feesten! Natuurlijk gesteund door Le·on en Thier·ry, de leukste, 
handigste en gezelligste schoonbroers, aan wie dank voor vele gezellige etentjes, feestjes en 
dagjes klussen!
Pa·pa, ik weet wel dat je het jammer vindt dat je niet hebt kunnen promoveren op je onderzoek 
als Neerlandicus, maar dat weerhield ons er niet van om (soms urenlang, sorry andere 
aanwezigen!) te discussiëren over mijn onderzoek en de wereld van de wetenschap. Ik denk 
dat ik mijn nieuwsgierigheid, de primaire beweegreden van elke wetenschapper, van je geërfd 
heb, evenals je liefde voor talen, die ook zeer goed van pas komt. Ik hoop dat mijn promotie 
een beetje op jou af kan stralen, zodat je nu dus een klein beetje mee-promoveert met mij (en 
dat bespaart je dan een boel stress!).
Ma·ma, als jij mij niet zulke goede organisatorische kwaliteiten had meegegeven, had 
deze promotie nog vele malen langer kunnen duren! Over ons gedeelde, buitengewone 
verantwoordelijkheidsgevoel kan ik geen uitspraak doen, zoals je waarschijnlijk wel weet werkt 
dat soms mee en soms tegen, maar het hoort bij ons. Ook al luisterde je altijd aandachtig naar 
mijn ervaringen op het werk (en het was heerlijk om soms even uit te kunnen razen), ik wist wel 
dat je ondertussen altijd probeerde te ontcijferen hoe het met me ging en dat heeft me enorm 
gesteund. Fijn hè, dat het boekje af is?
Blik·sem (de; m; meervoud: Bliksems!)
Donderstraal met evenveel loop- als eetlust. Brengt leven in de brouwerij en een grote, lieve 
snuit in je jaszak. 
Caer·te·ling, San·der (m)
The last mile is the longest one... ik ben zo blij dat jij er was om met me mee te lopen. Je leerde 
me dat het niet erg is om er totaal doorheen te zitten, of zelfs de finish niet te halen. Maar 
met jouw steun en zorg kon ik gelukkig uiteindelijk de race uitlopen. Je schier onverwoestbare 
positieve instelling i.c.m. je zelfgemaakte liedjes zorgden ervoor dat je mij elke keer weer aan 
het lachen kreeg. “Het komt allemaal goed!”, ik ga het bijna geloven! Laten we lekker gaan 
genieten van ons nieuwe huisje en samen gelukkig zijn.
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Curriculum vitae
Kim Wever werd op 11 juni 1982 geboren in het Universitair Medisch Centrum St. Radboud 
te Nijmegen, op ongeveer 250 meter van haar huidige werkplek. In 2000 behaalde zij haar 
VWO diploma aan het Stedelijk Gymnasium Nijmegen en werd uitgeloot voor de studie 
diergeneeskunde. Zij startte daarom met de studie van haar tweede keuze: biologie aan de 
Katholieke Universiteit Nijmegen en heeft daarna niet meer meegeloot. Kim maakte deel uit 
van de laatste jaargang Biologie ‘oude stijl’ en liep voor haar doctoraalfase twee stages in haar 
favoriete disciplines: één aan het Donders Institute for Brain, Cognition and Behaviour, onder 
begeleiding van dr. M. van Turenout en één bij de afdeling Organismale Dierfysiologie, onder 
begeleiding van prof. dr. G. Flik. Tijdens haar studie was zij zeer actief in de studievereniging 
BeeVee en als student-assistent in het biologieonderwijs. In oktober 2006 legde zij het 
doctoraal examen cum laude af. Gedurende haar hele studie bracht zij met plezier post rond 
als zaterdagpostbode bij achtereenvolgens PTT, TPG en TNT Post.
In april 2007 begon Kim aan haar promotietraject aan de afdeling Farmacologie-Toxicologie 
van het Universitair Medisch Centrum St. Radboud. Het project stond hoofdzakelijk onder 
begeleiding van prof. dr. G.A. Rongen en dr. R. Masereeuw en werd gesubsidieerd door de 
Nederlandse Hartstichting. Het onderzoek was gericht op het voorkomen van ischemie 
reperfusie schade, met name na niertransplantatie. De resultaten hiervan staan beschreven 
in dit proefschrift. 
Sinds 1 december is Kim in het voorgenoemde ziekenhuis werkzaam als post-doc op de 
afdeling Heelkunde, waar zij onder supervisie van dr. J.A. Van der Vliet en dr. M.C. Warlé het 
onderzoek naar ischemie reperfusie schade zal voortzetten, onder meer met behulp van de in 
dit proefschrift beschreven modellen.
176|
